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Chapter 1 
General introduction and outline 
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Background 
Otitis Media with Effusion (OME) is a common ear condition in childhood that is 
characterised by the accumulation of fluid in the middle ear behind an intact tympanic 
membrane, in the absence of signs and symptoms of an acute infection.1 Peak prevalences 
have been reported in the first and fourth years of life2'1 but at least 8 0 % of infants will 
have experienced one or more episodes of OME before their fourth birthday.1 OME is a 
self-limiting condition, with a high rate of spontaneous recovery.3 However, OME also has 
a high rate of recurrence: within seven months after treatment with tympanostomy tubes 
for chronic OME, recurrence rates in young children vary from 50% to 70%, including a 
large proportion of children who develop recurrent bilateral OME. 0 7 
As the presence of OME is associated with an average hearing loss of 25 dB ' B ' n and the 
occurrence of OME coincides with a period of rapid language acquisition," there is a risk 
of language impairment in children with recurrent or persistent OME. Although the 
literature is far from consistent1 2, there is some evidence that sequelae of persistent 
hearing loss may delay or impair speech, language 1 ' 1 3 14 and cognition, which may affect 
school performance. J Additionally, tympanic membrane abnormalities (such as 
atelectasis and attic retract ion) 8 1 6 1 ' and middle ear changes may also result from the 
presence of fluid and/or treatment with tympanostomy tubes. 1 8 As the adverse effects of 
OME mainly occur in the group of children with a history of recurrent or chronic OME, it 
would be useful to be able to distinguish these children from the total group of OME 
children early in the course of the disease, in order to instigate some type of early 
intervention before any serious sequelae can arise.1 9 
It seems reasonable to assume that predisposing factors for the recurrence of OME are 
related to its aetiology. Infections of the upper respiratory tract, the development and 
functioning of the Eustachian lube and the response of the maturing immunological 
system are generally considered to contribute to both the development and duration of 
OME. In general, the presence of viruses or bacteria in the nasopharynx is considered to 
play an essential role in the aeliopathogenesis of OME. The most common otitis media 
pathogens are Streptococcus pneumoniae, Haemophilus influenza and Moraxella 
catarrhalis. l· urthennore, several respiratory viruses, in particular human rhinoviruses 
(HRV), respiratory syncytial virus (RSV) and corona viruses (RSV), have been 
demonstrated in middle ear effusions and nasopharyngeal aspirates.2 0 Recently, several 
studies have suggested that these respiratory viruses may promote bacterial colonisation 
of the nasopharynx and the adherence of bacteria to epithelial cells. In this way, viruses 
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may enhance or predispose to bacterial infections of the middle ear.21 Both viruses and 
bacteria can contribute to the development of OME by either migrating directly into the 
middle ear via the ET and subsequently initiating immune reactions in the middle ear, or 
indirectly by inhibiting ET function. The ET has three important functions with respect to 
the middle ear (ME): ventilation, protection against nasopharyngeal pressure variations, 
ascending secretions and micro-organisms, and clearance of middle ear secretions. 
Deterioration of one or more of these functions can contribute to the development of 
effusion in the middle ear. Eustachian tube dysfunction and the inflammatory response to 
viruses and bacteria entering the upper airway are considered to be two core elements in 
the development of OME.23·24 
The immunoglobulins IgA, IgG and IgG subclasses202 ' and impaired ET ventilation and 
protection function28"30 are believed to be associated with recurrent acute otitis media or 
OME. Internal and external risk factors, such as day care attendance, exposure lo 
smoking at home, autumn season, birth weight, history of acute otitis media, history of 
upper respiratory tract infections, short period of breast-feeding, presence of siblings, 
family history of otitis media and sniffing habit, have also been mentioned in association 
with chronic OME.31"33 Most of these risk factors contribute to the development of OME, 
because they are related to ET dysfunction or the immune system. High-risk infants who 
required neonatal intensive care seemed to have a higher incidence of OME between six 
months and two years of age than infants who had a normal birth weight.14 However, it is 
not yet clear whether high-risk infants are more likely to develop chronic or recurrent 
OME. 
Several surgical and non-surgical strategies are currently being used in clinical practice 
to treat persistent or recurrent OME. These include antibiotic treatment, adenoidectomy 
and/or myringotomy with and without the insertion of tympanostomy tubes. 1 ' , 0 Once we 
are able to distinguish children who are more likely to develop recurrent OME from the 
group of children who are more likely to have transient OME, the next question will be: 
Which is the most appropriate treatment to prevent the recurrence of OME? In the group 
of children who are more likely to develop recurrent OME, a preventive treatment strategy 
might be needed. For example, vaccination could be one of those causative treatment 
strategies that may generate a protective immune response to middle ear pathogens. 
Streptococcus pneumoniae is an important bacterial cause of OME, thus pneumococcal 
vaccination may be an adequate treatment strategy by improving the immune response to 
the polysaccharide capsules of this bacteria.17 Pneumococcal vaccines contain the most 
common pathogenic serotypes known to cause the majority of pneumococcal infections.38 
13 
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Multivalent pneumococcal conjugate vaccines enhance the immune response to 
pneumococcal serotypes. The induction of a T-helper-cell-dependent immune response 
leads to the induction of immune responses. Repeated immunisations induce 
immunological memory, which leads to higher IgG anti-pneumococcal antibody t i ters. 3 9 4 0 
Several trials have assessed the preventive effect of pneumococcal vaccines and 
pneumococcal conjugate vaccines in acute otitis media.4 1 However, no studies have been 
published on the preventive effect of pneumococcal vaccination in recurrent OME. 
Objective and study design 
The main objective of this thesis was to gain further insight into the separate and 
combined roles of Eustachian tube function and the immune system in the development of 
recurrent OME in children. 
Specific research objectives were: 
1. to develop an aetiological model for the development of OME, 
2. to study the role of Eustachian lube function in the aetiopathogenesis of OME 
recurrence, 
3. to study the role of the immune system in the aetiopathogenesis of OME recurrence, 
4. to study the association between birth characteristics and OME (recurrence) and 
5. to study the combined roles of Eustachian tube function and the immune system in 
predicting OME recurrence. 
In the pursuance of these objectives, we conducted a prospective cohort study on a group 
of children aged between two and seven years, whose first clinical episode of OME had 
persisted for at least three months. Several parameters of the immune system, such as 
immunoglobulin levels, are influenced by age, antigenic exposure and the infection status 
of the patient. Therefore, these aspects have to be taken into account when immune status 
is investigated in relation with OME recurrence. A prospective study design on children 
who were homogenous with respect to OME status at the start of the study enabled us to 
examine the roles of immune status and ET function in their subsequent probability of 
developing recurrent OME. 
At study entry all children received bilateral tympanostomy tubes for OME under general 
anaesthesia. During this surgical intervention, blood samples were collected, serum was 
14 
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isolated and stored at —20° C until required for analysis. To assess tympanostomy lube 
extrusion and recurrence of OME an otologist examined the ear status once every three 
months. In ears with patent tympanostomy tubes, ET function tests were performed. 
The date of the first check-up in which tube extrusion was observed (per ear) was taken as 
the start of the follow-up period for recurrence of OME. The outcome of interest was OME 
recurrence within the first six months of follow-up. Figure 1 shows the time flow of our 
study design. 
"•"star, + x months 
(3 monthly) 
4 tube extrusion 
Study entry 
^ insertion ventilation tubes 
collection blood samples 
Post-operative check-up 
» patent tube: ET function test 
Check-up visits 
» patent tube. ET function test 
T,, (6 months) ' ' 
Start follow-up for OME recurrence 
> tympanometry + otoscopy 
- • • tympanometry + otoscopy 
Maximum follow-up 
» tympanometry + otoscopy 
Figure I.Time flow of our study design 
Outline of the thesis 
The layout of this thesis adheres fairly closely to the order of the specific objectives 
formulated above. Chapter 2 presents an aetiological model for the development of OME 
that formed the basis of our study design. Ventilatory ET function and protective ET 
function in relation with subsequent OME recurrence are described in Chapter 3. Chapter 
4 investigates the roles of several aspects of the immune system in the development of 
recurrent OME {Chapter 4.1), the preventive effect of pneumococcal vaccination against 
otitis media (Chapter 4.2) and against OME (Chapter 4.3). Birth factors in relation to the 
recurrence of OME (Chapter 5.1) or the point prevalence of OME (Chapter 5.2) are 
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described in Chapter 5. Chapter 6 focuses on the results of the combined effect of ET 
function and the immune system on the recurrence of OME. Chapter 7 discusses the 
information obtained from all the studies reported in Chapters 2 to 6, in the context of the 
core objective of this thesis: to gain more insight into the development of recurrent OME. 
In addition, recommendations are made for further research and the potential implications 
are discussed for clinical practice. 
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Summary 
Otitis Media with Effusion is highly prevalent among young children. Adverse effects of 
this disorder are mainly restricted to the group of children with a history of recurrent or 
persistent Otitis Media with Effusion. Early identification, assessment and intervention 
might prevent these adverse effects. Up to now it is not possible to distinguish these 
children from those with transient Otitis Media with Effusion. This article piesents a 
comprehensive model for the aetiology of Otitis Media with Effusion. Eustachian tube 
functioning and the immunological response to environmental pathogens are the two core 
elements. This model can be used to formulate specific hypotheses about the interaction 
of several factors that may lead to the early identification of children who are likely to 
develop persistent or recurrent Otitis Media with Effusion. 
20 
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Introduction 
Otitis Media with Effusion (OME) is defined as inflammation of the middle ear (ME) in 
which a collection of liquid is present in the middle ear space.1 Signs and symptoms of 
acute infection, such as otalgia and fever, are absent and the tympanic membrane is 
intact.2 OME is highly prevalent among young children, with peak prevalences at around 
two and five years of age.3 At least 80% of children will have experienced one or more 
episodes of OME by the age of four years.4 OME is characterised by a high rate of 
spontaneous recovery. The natural course of OME shows a constant improvement rate of 
about 50% every three months. However, OME is also characterised by a high rate of 
recurrence, with a cumulative recurrence rale in natural course of 50% within 24 
months.' 
The presence of middle ear effusion (MEE) impedes sound transmission and causes an 
average hearing loss of 25-30 dB in most children with OME. Hearing usually returns to 
normal when the MEE resolves.2 Hearing loss caused by persistent or recurrent MEE may 
be associated with delayed or impaired development of speech language, and cognition in 
young children, which might affect school performance.6 Long-term adverse effects of 
OME on hearing chiefly occur in children with a history of persistent OME.' Persistent 
OME at pre-school age was found to have a small but significant effect on speech-in-noise 
performance at school age." 
In view of the adverse effects in the group of children with a history of recurrent or 
persistent OME, it is necessary to discriminate these children from the total group of 
OME children early in the course of the disease to enable early intervention. 
Unfortunately, up to now no parameters have been found for the early identification of this 
group of high-risk children. As it is likely that predictive factors for the sequelae of OME 
are related to its aetiology, the aim of this paper is to present a comprehensive model of 
the multifactorial processes that can result in OME. 
A model based on the available evidence about contributing factors and their mutual 
interaction may improve our understanding of the development of OME and enable 
specific hypotheses to be formulated for further research. It is well-known that internal 
and external determinants (e.g. age, sex, prematurity, cleft palate, Down's syndrome and 
upper respiratory tract infections) contribute to the occurrence of OME, because they are 
related to Eustachian tube (ET) dysfunction or the immune system.9"14 Our model is based 
on these two core elements: ET function and the immunological response to 
environmental pathogens. 
21 
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Firstly, the history of changing viewpoints on OME aetiology is presented. Secondly, the 
morphology, function and pathology of the ET and ME are described. Thirdly, the 
immunological response to bacteria is discussed. Finally, a comprehensive model for 
OME aetiology is presented and discussed with special focus on the development of 
specific hypotheses and consequences for future research. 
Historical view 
The first description of OME is generally attributed to Adam Politzer (1867) who 
described 'Das Vorkommen von sichtbaren Schleimblasen in der Trommelhöhle'.'1 
Several theories on the aetiology of OME have appeared since. One of the first was the 
transudation theory (hydrops ex vacuo theory), which states that gas enclosed in the ME is 
continuously absorbed by the mucosal lining. Transient opening of the ET, allowing 
airflow into the ME, compensates for this gas absorption. If ET ventilation is insufficient, 
negative pressure develops, which leads to retraction of the tympanic membrane, mucosal 
oedema and transudation of fluid into the ME cavity.'124 Since 1980 it has become clear 
that gas exchange in the ME is a bi-directional process instead of the presumed 
unidirectional process postulated in the transudation theory. 0" Transudation as the sole 
mechanism responsible for the development of fluid in the ME cavity has gradually been 
overruled by evidence of bacteria and bacterial products in MEEs. Prior to 1958, it was 
assumed that persistent MEEs were sterile; this argument was used to support the 
transudation theory. Senturia et al (1958) were the first, followed by others, to 
demonstrate positive ME fluid cultures in up to 40% of effusions obtained from OME 
patients with persistent MEE.28"36 Especially Haemophilus influenza. Streptococcus 
pneumoniae and Moraxella catarrhalis are highly prevalent. Recently, the use of 
microbiological and molecular biological techniques has made it possible to detect the 
presence of pathogens even in negative MEE cultures.11'32 Thus, although a substantial 
proportion (up to 50%) of MEEs remain negative for the presence of bacteria or bacterial 
products, a negative finding does not exclude the possibility of involvement of bacteria. 
Secretory products from the ME epithelium contain antibacterial factors, such as locally 
produced immunoglobulins and lysosomal enzymes.37 In addition, apparently sterile ME 
fluids from children with OME may contain viruses, in particular Respiratory Syncytial 
Virus (RSV), Adenovirus, Human Respiratory Virus (HRV) or Human Coronavirus 
(HCV).38"10 It can therefore be postulated that a bacterial or viral infection in the upper 
respiratory tract is a prerequisite for the development of effusion in the ME. 
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Middle ear and Eustachian tube 
The ear has three major parts: the outer ear (OE), the middle ear (ME) with ET and the 
inner ear (IE). The anatomy of the ear is shown in figure 1. Both the ET and ME are 
important in relation with the accumulation of fluid behind the tympanic membrane (TM). 
Below, the morphology, physiology, dysfunction and immunology of these structures are 
discussed. 
Figure 1. Anatomy of the ear: outer ear (OE); middle ear (ME); inner ear (IE); tympanic membrane 
(TM); Eustachian tube (ET); nasopharynx (NP) 
Morphology of the Eustachian tube and middle ear 
The ME is an air-filled chamber which contains the auditory ossicles. The ET connects 
the ME with the nasopharynx. Total ET length in adults is 31-38 mm. In children the ET 
is shorter, wider and runs more horizontally.41'43 The nasopharyngeal two thirds of the 
tube is cartilaginous, while the tympanic one third is bony and blends into the ME 
cavity. The mucosal lining of the ET consists of epithelium and subepithelial 
connective tissue, which contains numerous blood capillaries, lymph capillaries and 
nerve fibres.4D The nasopharyngeal end of the ET has a squamous epithelial lining. This 
lining is mucociliary and continuous with two strands of ciliated cells on the floor of the 
ME cavity. The mucociliary epithelium is covered with a mucus blanket. This provides 
the basis for tubotympanic mucociliary transport, which clears the ME cavity.4;';47;48 
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Physiology of the Eustachian tube and middle ear 
The ET has three important functions with respect to the ME: ventilation, protection and 
clearance.1 9 M Ventilation of the ME is established through opening of the ET by muscle 
contraction. The tensor veli palatini muscle (TVPM) is the main dilator of the tube.1 
Active opening of the ET during swallowing and yawning equalises nasopharyngeal and 
ME pressure, resulting in atmospheric pressure. Surfactants in the ET help to lower the 
surface tension, thereby facilitating normal opening of the lube.3 0 
The ME is protected by the functional anatomy of the ET and by immunological and 
mucociliary defence of the mucosal lining. Al resi, the ET is closed, which protects the 
ME from nasopharyngeal secretions, sounds and pressure variations. When the lube is 
open, its anatomical design prevents secretions from entering the ME. 4 9 
Clearance of the ME is achieved by mucociliary transport in the ET. Ciliary movement is 
directed towards the nasopharynx and transports ME secretions via a mucus blanket on 
top of the cilia.1' The mucociliary system is the primary defence of the tubotympanum to 
keep the ME sterile. The immune system is also an important defence mechanism against 
viral and bacterial antigens that may enter the ET and ME (see below). 
Impairment of Eustachian tube function 
ET dysfunction is considered to be an aetiological factor in the development of OME. 1 2 
Studies on different populations of children indicate thai ET function is impaired in 
children with OME or otitis-prone children compared to heallhy children.1 2"1 1 Impairment 
of ventilation may result from anatomical obstruction of the ET or from a defective 
opening mechanism. Anatomical obstruction may be the result of oedema of the mucosal 
lining (in consequence of inflammation secondary to infection or allergy) or an enlarged 
adenoid.4 9 A defective opening mechanism of the ET may be the result of increased tubal 
compliance (a lack of stiffness), inadequate muscular function or an inflamed mucosa.1 9 
Inflammation of the mucosa may reduce the activity of the substance in the mucus 
blanket that lowers the surface lension. In children, opening failure of the tube is very 
common. This might be caused by a lower density of elastin in the cartilage, the higher 
cartilage cell density and the greater number of folds in the mucosal lumen of children 
compared to adults . 1 9 1 3 A loss of protective function of the ET can be the consequence of 
abnormal patency (too open), a relatively short ET or a negative pressure at the tympanic 
end of the lube.4 9 Nasopharyngeal secretions and micro-organisms may reflux into the ME 
as a consequence of these tubal impairments.4 9 Impairment of clearance funclion can 
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result from epithelial damage by viral or bacterial infection originating in the 
nasopharynx, e.g. nontypable Haemophilus influenza and influenza A virus.16"19 Impaired 
mucociliary clearance can contribute to the accumulation of secretions in the ME.47'60 In 
children with OME, the mucociliary function was found to be reduced or totally absent 
and the mucociliary clearance relumed to normal after the ear had clinically fully 
recovered.'2-60 
As a consequence of ET dysfunction, pathogens can enter the normally sterile ME cavity. 
The presence of bacteria and viruses in the ME initiates an inflammatory response, which 
subsequently may change the gas composition and also the tissue characteristics (see 
below). 
Immunological response of the middle ear and gas exchange 
Despite multiple defence systems in the upper respiratory tract, pathogens sometimes 
enter the ME and evoke a local immune response. Under normal conditions, the defence 
systems are sufficient to eliminate invading pathogens.11'f'' ω Polymorphonuclear 
leukocytes (PMNLs) accumulate in ME tissue as a result of Chemotaxis. The primary 
function of PMNLs is phagocytosis and intracellular killing of invading micro-organisms. 
There are also indications thai PMNLs conlribute to chronic ME inflammation by 
producing different types of mediator/'1 In in vitro experiments impaired peripheral 
PMNLs Chemotaxis activily was found in children with recurrent OM.6 4 Developmenl of 
lymphatic tissue in ihe middle ear mucosa of children with persislenl OME was shown 
and could be regarded as a reaction upon repeated local challenge with anligen.0 ' The 
presence of bacteria or baclerial products in the ET or ME also stimulates the synthesis of 
cytokines, which are well-known potent mediators of inflammation and regulators of ihe 
immune response.6 0 The acute inflammatory response as well as long-term inflammation 
usually induce mucosal cell differentiation in the ME, which leads to the increased 
formation of mucus synthesizing cells. Mucus glands and subepithelial mucus-secreting 
cysls may appear.6 7 These changes bring about an increase in mucus secretion. In ihis 
way, mucus may fill the entire ME. To conclude, a general consequence of inflammation 
is a vast increase in the number of blood vessels in the mucosa. This may affect gas 
exchange between the ME cavity and venous blood and cause an increase in negative ME 
pressure.6 7 
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Immunology of the upper respiratory tract 
Viral infections frequently disturb the homeostasis of the upper respiratory tract of 
otherwise healthy children. These viral infections may lead to an inflamed ME, negative 
ME pressure, accumulation of cellular and mucus debris in the lumen and epithelial 
damage that results in destruction of the mucociliary system.'*19 '6869 Viruses are also 
known to facilitate bacterial penetration from the nasopharynx into the ME.08 Both 
systemic and local immunological responses to upper respiratory tract infection might be 
important in the complex aetiology and prognosis of OME. 
Systemic immune response 
Much research into immunological defence against ME infections, has focused on 
Streptococcus pneumoniae, one of the main pathogens for otitis media. Effective defence 
by means of phagocytosis against infections with pneumococci depends on opsonisation 
by specific antibodies and complement.'0 Specific antibodies directed towards the 
polysaccharide capsule of these bacteria protect children from upper respiratory tract 
infections, including otitis media. The anli-pneumococeal activity predominantly belongs 
to the IgG! and IgG2 subclasses. 
Local immune response 
The upper respiratory tract is the site of initial exposure to ingested and inhaled antigens. 
The nasopharynx is part of the upper respiratory tract and is closely related to the ME and 
ET. Waldeyer's ring (predominantly represented by the adenoid) belongs to the mucosa-
associated lymphoid tissue (MALT), which forms the primary defence against pathogens 
at the port of entry of the upper respiratory tract. The lymphoid cells of the ring are able 
to sample, recognise and destroy any inhaled pathogens. In addition, effector and memory 
lymphocytes are produced here which may migrate to neighbouring mucosal sites (i.e. the 
ME) to reinforce the local immune capacity.'1 Another defence mechanism against 
infection in the upper respiratory tract is the production of secretory IgA (SIgA) antibody 
by the mucosal lining and lymphoid ring, e.g. the adenoid. Secretory IgA in 
nasopharyngeal secretions inhibits bacterial adherence and reduces nasopharyngeal 
bacterial colonisation, both important factors in the protection against otitis media.72 
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Impaired immune response 
When local and systemic defence mechanisms are impaired, pathogens will multiply and 
predispose a child to recurrent ME infection.71 '7 Several studies suggested that the 
adenoids of children with OME are more susceptible to infections than those of children 
without OME. Lower levels of SIgA were demonstrated in children with OME and this 
may facilitate the multiplication of pathogens in the nasophai-ynx.7""'10 The migration of 
pathogens into the ET may be facilitated by poor mucociliary clearance of the adenoids in 
these children due to hyperplasia, squamous epithelialization and a decreased number of 
ciliated cells.'2 The exact mechanism of nasopharyngeal pathogen migration is not clear 
yet, but it is shown that pathogens in the ME arise from the nasopharynx.10 
Previous investigations have shown that otitis-prone children or children with recurrent 
AOM have lower levels of IgG2 than non-otitis-prone children.708182 Such lower 
concentrations of anli-polysaccharide antibodies could be due to immaturity of the 
immune response (e.g. due to premature birth). The biological activity of these antibodies 
also depends on interaction with Fc receptors. Phagocytosis is mediated by immune 
effector cells that express receptors for the Fc-part of these immunoglobulins and 
receptors for complement. Three major classes of human Fc receptors for IgG are 
currently recognized. Structural and functional polymorphisms for several of these 
receptor classes have been described.81 Recently, it has become evident that some of 
these genetically determined, functional polymorphisms may contribute to susceptibility 
to infections.M Besides IgG, IgA is important in the defence against viral and bacterial 
infections, particularly on the mucosal levels. Fc receptors for IgA have also been 
described.B, However, little is known about the actual role of IgA and its Fc receptors on 
phagocytic cells. 
Even after the successful elimination of viable bacteria by either host defence or 
antibiotic treatment, bacterial products may remain in the ME, particularly when tubal 
function is affected and clearance is disturbed. This may trigger the development of 
OME.86-"9 
Theoretical model of the aetiology of OME 
The previous section describes the anatomy, physiology and immunology of the upper 
respiratory tract, with emphasis on the ME and ET in the development of OME. It is clear 
that the development of OME is multifactorial. Several mechanisms are involved either in 
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succession or through inleraction. A diagram of a hypothetical aetiological model for OME 
is presented in figure 2. 
bacteria/viruses in nasopharynx 
adenoid migration to ET migration to ME 
Eustachian tube dysfunction 
middle ear 
status OME 
Figure 2. Hypothetical aetiological model for OME 
The presence of bacteria or viruses in the nasopharynx (including the adenoid) is 
considered to be the first essential step in the aetiology of OME. They can contribute to 
the development of OME by migrating into the ME via the ET (—¥ migration to ME) and 
subsequently initialing immune reactions in the ME, or by disturbing ET function (—> 
migration to ET). 
Viruses in the nasopharynx facilitate nasopharyngeal bacterial colonibation and 
subsequent entiy into the ET, due to viral destructive interference in the mucociliary 
system. 38,39.68.60 A vicious circle may occur, because mucus accumulation inables the 
replicalion of invaded micro-organisms, such as Slreplococciis pneumoniae and nontypable 
Haemophilus influenza, more micro-organisms induce more mucus, mucus stasis 
increases blockage of the ET which affects the ventilation function and the circle repeats 
itself. An obstructed ET, e.g. by mucus, can lead to the transudation of fluid because 
reduced ventilation causes negative pressure in the ME (—> ME status ). Another 
consequence of prolonged negative pressure is mucosal transformation that leads lo more 
mucus-producing cells in the ME. 
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ET dysfunction also facilitates the migration of pathogens via this tube into the ME (—> 
+ ). Pathogens in the ME induce mucosal immune reactions. The subsequent metaplastic 
changes lead to more mucus-producing cells. If the immune system fails to eliminate the 
bacteria (although there has been an effective reduction in bacterial growth sufficient to 
prevent an acute middle ear infection) and the other defence mechanisms fail to clear the 
mucus, then the ME will fill with fluid. If in addition, the ET is not functioning properly, 
the fluid produced in the ME will not drain through the ET, so the effusion remains in the 
ME (-> OME). 
Conclusion 
The purpose of this article was to develop a model for the aetiology of OME as a basis for 
formulating hypotheses about the interaction of factors that can lead to the development of 
OME. We have no reason to believe that the development of persistent OME, or recurrent 
episodes, follows other principal pathways than the one described in this paper. 
Spontaneous resolution of the problem may eventually follow maturation of the immune 
system by recurrent infections and anatomical development with increasing age. The core 
hypothesis is that children with recurrent/persistent OME have reduced local and/or 
systemic immune response in combination with/or inadequate ET function than children 
without OME or with transient OME. It is not yet clear whether one of these aetiological 
factors causes recurrent/persistent OME or whether both factors have to be present. Some 
support for the notion that proper ET function protects against the development of 
otological complications after viral upper respiratory tract infection was found in an 
experiment on adults.90 Below, four specific hypotheses are given to distinguish children 
with recurrent or persistent OME from cases those that resolve spontaneously. 
• Children with recurrent/persistent OME have quantitative and/or qualitative defects in 
anti-polysaccharide antibodies compared to children with transient OME; 
• There is a difference in the frequency of certain polymorphisms (e.g. Fc receptors) 
between children who predispose to recurrent/persistent OME and children with 
transient OME; 
• Children with recurrent/persistent OME have an impaired local immune response, 
especially of the adenoid, compared to children with transient OME; 
• Children with recurrent/persistent OME have an impaired ET function compared to 
children with transient OME. 
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There is an urgent need to study and lest these hypotheses and the core hypothesis in 
general, because in a small but substantial proportion of children, persistent or recurrent 
OME has unfavourable consequences on the development of communicative skills. Up to 
now it is not possible to distinguish these children from those with a benign course at an 
early enough stage to provide treatment and prevent the occurrence of adverse 
developmental effects. Future aeliologieal studies on OME in children should include 
dysfunction of the ET as well as deficient immune response. Epidemiological studies, 
clinical trials and laboratory studies are needed. Recently, we have started a 
comprehensive programme of studies that aim to add empirical evidence to the theory 
discussed in this paper (KN00P4). These and other studies will eventually answer the 
intriguing question of why many children recover from OME without receiving medical 
treatment, while others do not. 
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Abstract 
Objective To study the role of Eustachian tube function in the development of recurrent 
otitis media with effusion (OME) in children treated with tympanostomy tubes for OME. 
Design Cohort study. 
Setting Academic and general hospital. 
Patients Children aged between two and seven years with a first clinical episode of OME 
that persisted for at least three months; 136 of the 186 eligible children (73%) 
participated. All children received tympanostomy tubes for bilateral OME at study entry. 
Main outcome measure Recurrence of OME within six months after tube extrusion. 
Results No statistically significant differences were present in ET function test results 
between ears that did develop recurrent OME and those that did not. Differences in 
passive ventilation function between ears with and without OME recurrence were 10 daPa 
(95% CI: -24 to 43 daPa) for the opening pressure, and - 3 daPa (95% CI: -18 to 11 
daPa) for the closing pressure. Overall difference in the proportion of ears with and 
without OME recurrence that were unable to equilibrate both positive and negative 
applied pressures was 12% (95% CI: - 2 % to 26%). The proportions of ears with and 
without OME recurrence that were able to induce a negative pressure in the middle ear by 
forcefully sniffing were 22% and 3 1 % , respectively (p > 0.75). 
Conclusion Measurement of ventilatory and protective ET function with the forced 
response test, the pressure equilibration test and the sniff lest has no value in predicting 
whether children have an increased risk of OME recurrence. 
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Background 
Otitis media with effusion (OME) is highly prevalent in young children; at least 80% of 
children experience one or more episodes of OME by the age of four years. :2 OME is 
characterised by a high rate of spontaneous recovery, but also by a high rate of 
recurrence. At present, it is not possible to distinguish children who will develop 
persistent or recurrent OME from those who will develop transient OME. Predisposing 
factors for recurrence are probably related to aetiology. OME is a multifactorial-generated 
condition in which Eustachian tube (ET) function is believed to play a crucial role.3 The 
ET has three important functions with respect to the middle ear (ME): ventilation, 
protection (i.e. against nasopharyngeal pressure variations, ascending secretions and 
micro-organisms) and clearance of secretions.3 Studies involving different populations of 
children have indicated thai ET function is impaired in children with OME. " These 
cross-sectional studies however, have not clarified whether ET dysfunction is a cause or a 
result of middle ear effusion. We hypothesised that differences in ET function between 
children will determine why some develop recurrent or chronic OME, while others have 
transient OME. The aim of this study was to test this hypothesis in a group of children 
treated with tympanostomy lubes for OME. These children performed the forced response 
test (passive ventilatory ET function), ihe pressure equilibration test (active ventilatory 
ET function) and the sniff test (protective ET function). By comparing ihe results of ears 
thai did develop OME recurrence after spontaneous tympanostomy lube extrusion to those 
that did not, we aimed to establish whether ET function predisposes children with OME to 
recurrence of this condition. 
Patients and Methods 
In the Netherlands, health insurance companies require referral by a general practitioner 
(GP) before refunding specialist care. Therefore, nearly all patients with OME are first 
seen by their GP. According to the guidelines of the Dutch College of General 
Practitioners, children with chronic OME should only be referred to an otologist after 
repeated observations of middle ear effusion during a period of at least three months. 
Children were eligible for the study if they were aged between two and seven years, and 
had a first clinical episode of bilateral OME persisting for at least three months as 
documented by their GP and they had been referred for the first time to the Departments 
of Otorhinolaryngology of one of the three participating hospitals in Nijmegen or 
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Winterswijk (the Netherlands) between December 1999 and March 2002. Children with 
Down's syndrome, cleft palate, cystic fibrosis or daily treatment with inhalation or topical 
corticosteroids for at least one month per year were excluded from our study, as were 
children with documented immunodeficiency or previous adenoidectomy. The Medical 
Ethical Commitlees of the three participating hospitals approved the study protocol. 
Signed informed consent was obtained from the parents or legal guardians. 
At study entry, all the children received bilateral tympanostomy tubes for OME under 
general anaesthesia. Check-up visits were planned one week after tube insertion and once 
every three months thereafter. At each check-up ET function lests were performed on ears 
with patenl tympanostomy tubes. The risk period for the developmenl of OME dated from 
the first check-up in which spontaneous tube extrusion was observed (per ear). The end of 
follow-up was reached al the check-up when OME had been diagnosed, or when six 
months had elapsed after ihe observation of spontaneous tube extrusion. OME was 
defined according to an algorithm based on tympanometry and otoscopy.10 The 
tympanograms were classified in accordance with Jerger." OME was considered to be 
present when lympanomelry resulted in a type Β tympanogram, or a type C2 tympanogram 
in combination with otoscopie findingb that suggested ihe presence of effusion in the 
middle ear and no signs of acute ear infeclion. If tympanometry could not be performed, 
otoscopie findings that suggested effusion in the middle ear were used to diagnose OME. 
We refer to ears that developed recurrent OME within the maximum follow-up period of 
six months after spontaneous tube extrusion as rOME-|- ears, whereas ears that did not 
develop OME within the follow-up period are referred to as rOME- ears. ET function tests 
and tympanometry were performed using the TYMP 87 middle ear analyser (Rexton 
Danplex A/S Copenhagen, Denmark). Pressure applied by the pump ranged from 600 to -
600 daPa, at a pump rate of 50 daPa/s. 
E T function tests 
Procedure 
First, presence and permeability of the tympanostomy tubes were confirmed otoscopically. 
Each child was seated comfortably and given instructions. The external ear canal was 
then sealed airtight with the probe of the middle ear analyser. Both ears were measured, 
starting with the right ear. 
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Forced response test 
The forced response test was used to assess ventilation function of the ET with opening 
pressure (Po) and closing pressure (Pc) as the outcome variables. Passive ET ventilatory 
function was assessed by gradually increasing the pressure in the middle ear using the 
pressure pump until the ET opened, as indicated by a sudden decrease in the pressure 
(Figure 1). The maximum pressure was recorded as the opening pressure. After the ET 
had opened, the pressure pump was turned off so that the ET could close, as indicated by 
stabilization of the pressure. This residual pressure was recorded as the closing pressure. 
To reduce measurement errors, Po and Pc were recorded three times in each session of 
three minutes or less, and the means of the three measurements were used for further 
analysis.12 The difference between Po and Pc was calculated (Pdif). When the ET did not 
open before the maximum pressure of 600 daPa was applied, Po was arbitrary recorded as 
700 daPa. The corresponding Pc could not be assigned in these cases, because no reliable 
estimate of Pc could be made. Po reflects the resistance to tubal opening and 
consequently reflects the total closing forces, i.e. the luminal forces (mucosal factors, 
surface tension, viscosity of secretions, etc.) and extraiuminal forces (elasticity of 
cartilage, pressure of surrounding tissues) of the ET. Pc reflects the extraluminal forces of 
the ET, i.e. the forces that keep the ET closed in rest. When the ET is opened actively, 
these forces must be overcome. J Extremely high Po and Pc values thus indicate poor ET 
ventilation function. Very low Po and Pc values however, do not automatically indicate 
good ET function, because they may be associated with impaired protective function. 
Pressure equilibration test 
The pressure equilibration test is a qualitative method to measure active ET ventilatory 
function. The results reflect the ability to equilibrate positive and negative pressures. 
Positive and negative pressures ( + 100 and -100 daPa) were applied to the middle ear 
and the residual pressure (Pr) recorded after several déglutitions (the children were asked 
to swallow a small amount of water) (Figure 1). Based on the Pr, each ear was classified 
into one of four tubal function groups according to Einer et al.14 Group 1: ears were able to 
equilibrate positive and negative pressures completely (Pr<10 daPa and >-10 daPa, 
respectively). Group II: ears could equilibrate positive and negative pressures partially 
(Pr > 10 daPa and < -10 daPa, respectively). Group III: ears could equilibrate positive 
pressure completely or partially, but were unable to equilibrate negative pressures. Group 
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IV: ears could not equilibrate positive and negative pressure. We considered a single 
measurement sufficient to obtain reliable results.1 
Sniff test 
The sniff test is a measure of the capacity of the ET to protect the middle ear cavity 
against extreme nasopharyngeal pressure variations. ' 0 1 6 Children were asked to sniff 
forcefully five times. When the negative nasopharyngeal pressure exceeds the closing 
forces of the ET, there is a pressure breakthrough and the middle ear space is evacuated. 
Subsequently, the ET closes and a negative pressure is established in the middle ear 
(Figure l). 1 ' ' As the ET should remain closed to protect the middle ear against negative 
pressures created in the nasopharynx, opening of the lube implies poor protective 
function. If the middle ear pressure decreases once or more after sniffing, ihis is regarded 
as poor protective ET function. 
pressure 
Forced response test 
Po 
Pressure equilibration test 
deglutition 
deglutition Sniff test 
Figure 1 . Examples of recordings of the forced response test w i t h opening (Po) and closing (Pc) 
pressure, the pressure equilibration test w i t h starting (Pst) and residual pressure (Pr) and the sniff 
test 
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Statistical analyses 
All analyses were performed with the Statistical Analysis Systems (SAS version 8.0). A 
linear mixed model (SAS procedure MIXED) was fitted to calculate the differences in Po, 
Pc and Pdif, between rOME+ and rOME- ears, based on all ET measurements from both 
ears, excluding those obtained during the first check-up which took place approximately 
one week after lube insertion. These data were excluded because the middle ear status 
could nol have been stabilized and surgery may have short-term effects on the mucoid 
layer and epithelium of the middle ear and ET. Therefore, the results of the forced 
response test may not adequately represent ET function in a physiological condition. 
Data from the children with missing values at one of the check-ups, due to obstruction of 
the tympanostomy tube, otorrhoea, poor co-operation of the child, or absenteeism, were 
included in the analyses, because the occurrence of these missing values was assumed to 
be random. A variance components covariance structure was used with random intercepts 
for left and right ears. The mean structure of the model employed to calculate the 
differences between rOME+ and rOME— ears contained the main effect of OME adjusted 
for time and side. 
To study the development of the active ET function over time, the ears belonging to tubal 
function group I and II were pooled with ears in tubal function group III, as there were 
only few ears that appeared to belong to the two former categories. Generalized estimation 
equation (GEE) with exchangeable correlation structure (SAS procedure GENMOD) did 
not show any difference in test results of both the dichotomized pressure equilibration test 
and the sniff test obtained at the longitudinal check-ups. Subsequently, a summary 
measure was defined for the most frequent test outcome per ear. The influence of tubal 
function group and the sniff test on the recurrence of OME that accounted for dependency 
of ears within a child, was tested with the Likelihood ratio test. GEE models including the 
main effect of the specific ET function test plus adjustment for side, were compared to the 
GEE model excluding the main effect of ET function. 
Furthermore, additional analyses were performed. GEE, based on the longitudinal 
measurements, was used to study the possible interaction effect of the sniff test with either 
the pressure equilibration test or the forced response test on the risk of OME recurrence. 
The timing of OME recurrence in relation to pressure equilibration test and the sniff test 
were tested with Fisher's exact test. 
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Results 
A total of 168 children met the criteria for inclusion in the study; 136 of them (73%) 
participated. Median age at study entry was 5.3 years (range: 2.1 to 7.5 years) and 50% 
were male (Table 1). 
Table 1 . Characteristics of 136 children treated with tympanostomy tubes 
for OME 
Gender (% boys) 
Median (range) age at study entry in years 
Low birth weight (< 2500 g) (%) 
Premature birth (< 37 weeks) (%) 
Breast-feeding (> 4 months) (%) 
Diagnosis of OM in first year of life (%) 
Diagnosis of OM in year before study entry (%) 
Otorrhoea in year before study entry (%) 
Children aged between 2-4 years at study entry (%) 
Attending day care at study entry (%) 
Children aged 2-4 years and attending day care 
Siblings present (%) 
Family members with a history of OM (%) 
Exposure to passive smoking at home (%) 
study entry (%) 
% cohort 
50 
5 3 (2.1-7.5) 
6 
9 
63 
8 
43 
31 
41 
21 
18 
93 
61 
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Tympanostomy tubes were inserted bilaterally in 135 children and unilaterally in one 
child. Thus, 271 ears had tympanostomy tubes in situ at study entry. Figure 2 shows the 
profile of the check-ups at which ET function was measured (patent tympanostomy tubes) 
and the check-ups when ears were at nsk of OME recurrence (after spontaneous extrusion 
of the tubes). 
Tympanostomy tubes appeared to be extruded a median of 9 months after insertion. The 
documentation data of tube extrusion ranged from 3 months to 30 months and this was 
equal in rOME+ ears and rOME— ears. Complete follow-up data up to a maximum of 6 
months after tube extrusion, were obtained from 210 ears; 61 ears (29%) did not develop 
OME recurrence, whereas 149 ears (71%) did develop recurrence (Figure 2). In 62 ears, 
OME recurrence could not be assessed because of the next reasons: loss to follow-up, 
censored data indicated that the tympanostomy tubes were still in situ at the end of the 
study, or the follow-up period of six months had not yet elapsed. 
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N = 49 
Λ/=2 ILI 
/V=9 ICI 
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Ν = 74 
1 1 
ΓΟΜΕ + 
N = 1 3 
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Ν = 61 
Total extruded tubes Ν = 230 
Figure 2. Profile of the check-ups with patent tympanostomy tubes and after documentation of 
tube extrusion when the ear was at risk of developing OME recurrence 
Below, the total number of ears may differ as a consequence of missing values on the 
various ET function tests. 
Forced Response Test 
Figure 3 shows the results of the forced response test in rOME+ and rOME- ears at the 
3, 6, 9 and 12 month check-ups after insertion of the tympanostomy tubes. The ETs of 17 
ears did not open at 600 daPa at one or more of the check-ups. We could not demonstrate 
a statistically significant difference in Po or Pc between rOME+ and rOME- ears. The 
overalldifference between rOME+ and rOME- ears was 10 daPa (95% CI: -24 to 43 
daPa) for Po and - 3 daPa (95% CI: -18 to 11 daPa) for Pc. When Po and Pc per visit 
were subtracted (Pdif), a small but non-significant difference was discernable 6 months 
after tube insertion (Figure 3). The overall difference between Po and Pc was 10 daPa 
(95% CI: -8 to 29 daPa) higher in rOME+ than in rOME- ears. 
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Figure 3. Box-plots of the distribution of forced opening pressures (Po), closing pressures (Pc) and 
difference between Po and Pc at check-ups 3, 6, 9 and 12 months after insertion tympanostomy 
tubes in ears with patent tubes. Separate box-plots for ears without OME recurrence (rOME-) 
and ears with OME recurrence (rOME + ) within 6 months after the documentation of tube 
extrusion. The length of each box represents the distance between P25 and P75; the horizontal 
line in the box represents the median (P50), while the vertical lines extend to the minimum and 
maximum value, excluding outliers and extreme values 
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Pressure équilibration test 
The majority of ears in the rOME+ and rOME- groups had poor active ET function, i.e. 
tubal function group III or IV (Table 2). No statistically significant differences were 
detected in the distribution of the four tubal function groups between rOME+ ears and 
rOME- ears (p > 0.70). Tubal function group IV applied slightly, but consistently, more 
often to rOME+ ears than to rOME- ears: 12% more (95% CI: -2% - 26%) in all ears, 
8% and 13% more in left and right ears, respectively. 
Sniff test 
The percentages of ears that were able to develop a negative pressure in the middle ear by 
sniffing forcefully, varied from approximately 10% to 39% over the follow-up period. No 
overall statistically significant differences ears could be demonstrated between rOME + 
and rOME- (p > 0.75; Table 2). 
Table 2. Results of the pressure equilibration test and sniff test m ears with OME recurrence 
(rOME + ) and ears without OME recurrence (rOME-) (N = number ears) 
Pressure equilibration test 
rOME+ (N = 127) 
rOME-(N = 61) 
OME recurrence* 
0 months 
3 months 
6 months 
Sniff test 
rOME+ (N = 113) 
rOME- (N = 51) 
OME recurrence* 
0 months 
3 months 
6 months 
Group 1 
1 % (1) 
2% (1) 
N = 1 
100% (1) 
0% (0) 
0% (0) 
Good protectior 
78% (88) 
69% (35) 
N = 88 
6 1 % (54) 
33% (29) 
6% (5) 
Group II 
6% (8) 
13% (8) 
N = 8 
75% (6) 
25% (2) 
0% (0) 
I 
Group III 
24% (31) 
30% (18) 
N = 31 
39% (12) 
39% (12) 
23% (7) 
Poor protection 
22% (25) 
3 1 % (16) 
Ν = 25 
4 8 % (12) 
36% (9) 
16% (4) 
Group IV 
69% (87) 
56% (34) 
Ρ > 0.70 ΐ 
N = 87 
64% (56) 
3 1 % (27) 
5% (4) 
Ρ = 0.03t 
Ρ > 0.75 ΐ 
Ρ = 0.18 t 
* OME recurrence was diagnosed 0, 3, 6 monlhs after documenlalion of lube extrusion 
t Likelihood ratio tesi χ 2 
i Fisher's exact test 
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Additional analyses 
As we were unable to demonstrate any differences in ET function between rOME+ and 
rOME- ears on each ET function test separately, we investigated whether rOME+ ears 
were more likely to have a combination of two unfavourable test results. No noticeable 
differences were detected between the two study groups with the combination of poor 
protection based on the sniff test and poor ventilatory function based on the forced 
response test, or with the combination of the sniff lest and the pressure equilibration lest 
(data nol shown). 
We also studied ihe timing of OME recurrence in relation with ET function test results. 
Differences were found in ihe timing of OME recurrence between the tubal function 
groups (Table 2, ρ = 0.03). In lubal function group IV, 64% had developed OME 
recurrence at the first check-up after check-up with documented exlrusion of the tubes, 
while in group III, this had occurred in only 3 9 % of the ears (p <0.01). No differences 
were seen in the liming of check-ups wilh OME recurrence for ears with good and poor 
protection as reflected by the results of the sniff lest (Table 2, ρ = 0.18). 
Discussion 
This prospective cohort study was designed to gain more insighl into factors that 
contribute to OME recurrence by comparing the results of three different ET function 
tests in ears with and without OME recurrence after initial treatment with tympanostomy 
tubes. Passive ventilatory ET function did not differ between ears with and without OME 
recurrence within a period of six months after spontaneous lube extrusion: the distribution 
of Po, Pc and Pdif during follow-up was similar for ears wilh and without OME 
recurrence. 
We expecled that a higher proportion of ears with OME recurrence would be in the lubal 
function groups III or IV than in groups I and II, as function groups III and IV indicate 
poor active ventilatory ET function. The dala from this study provide some support for this 
hypothesis: ears in group IV were more likely to develop recurrent OME and did so at an 
earlier date, but the effects were fairly small. It should be noted that the study population 
contained a high proportion of ears with poor active ET ventilatory function. In the sludy 
by Einer et al., group IV frequencies were 7% in healthy adults, compared to 4 5 % in 
healthy children and 72% in of children with recurrent ( > 11) AOM episodes."1 4 
We hypothesized that more ears with OME recurrence would be able to induce a negative 
pressure after forceful sniffing than ears without recurrence. Less than one third of all 
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ears were able to develop a negative pressure in the middle ear. These figures are 
comparable with those reported in other populations of children with OME.9'11 No 
differences in sniff test results were found in our study between ears that developed 
recurrent OME and those that did not. 
In conclusion, the results of our study showed that there were no substantial differences in 
ET function between ears that developed OME recurrence and ears with transient OME. 
In an earlier study, we have posed the question of whether the forced response test and 
the pressure equilibration test are responsive enough to middle ear conditions and 
sufficiently discriminative in children with various degrees of middle ear effusion. In the 
current study, we could not demonstrate any convincing consistent differences in ET 
function between ears with and without OME recurrence. It has to be emphasized that this 
does not mean that the ET does not play a role in the developmenl of OME. On the 
contrary, in our population of children with a minimum of three months of bilateral OME, 
both active ET ventilation function and protection function were poor. Therefore, we must 
conclude that within a population of children treated with tympanostomy lubes for OME, 
the discriminative power of these tests is too low to distinguish children who will develop 
recurrent OME from children with transient OME. It is also likely that in this group of 
children with pre-existing poor ET function, other factors, such as the immune response to 
respiratory pathogens, play a more important role in distinguishing children with rOME 
from children with transient OME. 
Conclusion 
In this prospective cohort study based on a population of children with a minimum of 
three months of bilateral OME before study entry, no differences were found in ET 
dysfunction between ears that developed OME recurrence and ears that did not develop 
OME recurrence after treatment with tympanostomy tubes. Consequently, we conclude 
that the forced response test, the pressure equilibration test and the sniff test that measure 
the ventilatory and the protective function of the ET have no value in predicting whether a 
child with a previous episoded of OME has an increased risk of OME recurrence. 
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Abstract 
Background Otitis Media with Effusion (OME) has adverse effects in children with a 
chronic or recurrent condition. There is a need to distinguish children who will develop 
recurrent OME from the total group of OME children early in the course of the disease as 
intervention should be focused on this group. Immunological parameters may enable early 
recognition of children at risk of OME recurrence. 
Objective To study the role of serum immunoglobulin levels, mannose-binding lectin and 
Fc gamma receptor polymorphisms on the development of recurrent OME. 
Methods The study population comprised children aged between two and seven years 
whose first clinical episode of OME persisted for at least three months. All children 
received bilateral tympanostomy tubes and immunological parameters were investigated 
in relation with OME recurrence within six months after tube extrusion. 
Results No statistically significant differences in serum immunoglobulin levels were 
present between children with and without OME recurrence. In children with bilateral 
recurrence (n = 56), median levels of mannose-binding lectin were 1.39 mg/1 compared to 
1.88 mg/1 and 2.48 mg/1 in children with unilateral (n=17) and no OME recurrence 
(n=17), respectively (p value 0.29). In addition, 34% of the children with bilateral 
recurrence were homozygotic for the genotype FcyRIIa-R/R131, whereas 13% of the 
children with unilateral recurrence and 19% of those without recurrence were 
homozygotic for this Fey receptor (p value 0.26). 
Conclusion These findings suggest that serum immunoglobulins do not have any 
predictive role in the recurrence of OME. In contrast, lower serum mannose-binding 
lectin and FcyRIIa-R/R131 polymorphism were associated with bilateral OME 
recurrence. 
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Introduction 
Otitis media with effusion (OME) is a highly prevalent ear disorder in young children; at 
least 80% of children experience one or more episodes of OME by the age of four years. ; 
OME is characterised by a high rate of spontaneous recovery, but also by a high rate of 
recurrence.3 As adverse effects of OME mainly occur in the group of children with a 
history of recurrent or chronic OME, it is necessary to distinguish these children from the 
total group of OME children early in the course of the disease to focus intervention 
measures such as tympanostomy tubes in this particular groupe"8 Predisposing factors for 
the recurrence of OME are believed to be related to its aetiology. OME is a multifactorial-
generated condition in which the inflammatory response to respiratory pathogens, both 
bacterial and viral, seems to be a crucial element.'' In order to distinguish children with 
transient OME from those with recurrent OME, we studied three aspects of the immune 
response to respiratory tract pathogens in a group of children with chronic OME. These 
children were referred for bilateral tympanostomy lube insertion. Serum immunoglobulin 
levels, functional mannose-binding lectin serum levels (MBL) and Fey receptor 
polymorphisms were assessed. 
Low serum immunoglobulin levels, despite infections or chronic inflammatory processes, 
may form subtle indication of immunodeficiency.Iü;11 This phenomenon was the basis of 
our first hypothesis: children with low IgA, IgG (subclass) or IgM levels early in the 
course of the disease are more likely to develop recurrent OME.12"14 
Independent of antibodies, MBL is able to initiate the complement pathway and may 
directly opsonize infectious pathogens by binding to specific oligosaccharides. l j ;16 
Increased susceptibility to bacterial and viral respiratory infections in early childhood is 
associated with low and absent serum MBL levels.17;18 This phenomenon led us to the 
second hypothesis: children who have lower functional MBL serum levels early in the 
course of OME are more likely to develop recurrent disease. 
Leukocyte antibody receptors for IgG (FcyR) plays an important role in IgG-facilitated 
phagocytosis of bacteria. Genetically-determined functional polymorphisms for three 
classes of human FcyR have been described.19:20 In FcyRIIA, the bi-allelic polymorphism 
consists of the presence of either Arginine (R) or Histidine (H) at position 131. Only the 
H131-allotype is capable of binding IgG2 opsonized bacteria, such as Streptococcus 
pneumoniae. In FcyRIIIA, the Phenylalanine (F) allotype at position 158 has been shown 
to bind complexed IgGl, IgG3 and IgG4 less avidly than the Valine (V) allotype. 
FcyRIIIb bears the neutrophil antigen (NA) polymorphism. NA1 homozygotes have higher 
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phagocytosis capacity for IgGl and IgG3 opsonized bacteria than NA2 homozygotes. 
Recently, it has become evident that some of these genetically-determined functional 
polymorphisms may contribute to susceptibility to infections.21"20 Thus our third 
hypothesis was: children with recurrent OME are more likely to be homozygous for the 
polymorphic form of the Fey receptors with the lower binding affinity for IgG subclasses 
IgGl, IgG2 and lgG3 (FcyRIIa-iaiR) and IgGl, IgG3 and IgG4 (FcyRIIIa-158F) and 
IgGl and I g G 3 (Fc7RIIIb-NA2). 
To test these three hypotheses, we conducted a cohort study on a group of children with 
their first clinical episode of OME. Follow-up of these children enabled us to study the 
role of immunological status on the subsequent probability of developing recurrent OME. 
Methods 
Patients and study design 
In the Netherlands, health insurance companies require formal referral by a general 
practitioner (GP) before refunding specialist care. Therefore, nearly all patients with 
OME are initially seen by their GP. According to the guidelines of the Dutch College of 
General Practitioners, children with chronic OME should only be referred to an otologist 
after repeated observations of middle ear effusion over a period of at least three months. 
Children were eligible for the study if they were aged between two and seven years, their 
first clinical episode of bilateral OME had persisted for at least three months as 
documented by their GP and they had been referred for the first time to the Departments 
of Otorhinolaryngology of one of the three participating hospitals in Nijmegen or 
Winterswijk (the Netherlands) between December 1999 and March 2002. Children with 
Down's syndrome, cleft palate, or daily treatment with inhalation or topical corticosteroids 
for at least one month per year were excluded, as were children with proven 
immunodeficiency or previous adenoidectomy. The Medical Ethical Committees of the 
participating hospitals approved the study protocol. Signed informed consent was 
obtained from the parents or legal guardians. At study entry, all the children received 
bilateral tympanostomy lubes for OME under general anaesthesia. Blood samples were 
collected during this surgical intervention. Serum and DNA were isolated and stored at -
20 C until required for analysis. To monitor OME recurrence, an otologist examined the 
ear status of each child once every three months until six months after documentation of 
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spontaneous tube extrusion The date of tube extrusion was taken as the date of the first 
check-up during which extrusion had been observed (per ear) 
Definition of OME recurrence 
OME was defined in accordance with an algorithm, which is primarily based on 
tympanometry 2 6 Tympanograms were classified in accordance with Jerger 2 OME was 
considered to be present when tympanometry resulted in a type Β tympanogram or a type 
C2 tympanogram with otoscopie findings that suggested the presence of effusion in the 
middle ear and the absence of an acute ear infection 2 6 If tympanometry (Rexton Danplex 
TYMP 87 A/S Copenhagen, Denmark) could not be performed, otoscopie findings that 
suggested effusion in the middle ear were considered to diagnose OME Childien were 
categorised into those who developed bilateral OME (bil_rOME), children with unilateral 
OME recurrence (uni_rOME) and children who did not develop OME in the follow-up 
period (no_rOME) 
Immunological tests 
Total serum immunoglobulin concentrations of IgA, IgM and IgG as well as IgG 1, IgC2, 
IgG3 and IgG4 subclass concentrations were determined by radial immunodiffusion 
(Behring Werke, Mannheim, Germany and Central Laboratory of the Red Cross Blood 
Transfusion Service, Amsterdam, the Netheilands) 2 B To determine functional mannose-
binding lectin levels in serum, the assay described by Kuipers el al. was used "' This 
assay is based on the principle of yeast-induced bystander lysis of chicken erythrocytes 
In short, serum samples were diluted and incubated with a standardised amount of fleshly 
cultured baker's yeast (S cerevisiae) to activate the MBL pathway. Chicken erythrocytes 
were used as the target for haemolysis due to MBL pathway activation Haemoglobin 
release was measured in an ELISA reader at 405 nm. Percentages of haemolysis were 
calculated using controls for 100% (water lysed) and 0% (buffer control) haemolysis 
Genomic DNA was extracted from whole blood using a QIAamp DNA Blood Kit (Qiagen, 
Westburg, the Netherlands). FcyRIIa and FcyRIIIb genotypes were determined by means 
of PCR amplification methods as described previously i 0 FcyRIIIa genotyping was 
performed in two separate reactions using allele-specific primers as previously described 
in detail 1 1 
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Statistical analyses 
As most of the immunoglobulin and MBL levels were not normally distributed, non-
parametric Kruskal Wallis tests were performed lo compare distributions of 
immunoglobulins and MBL levels belween OME groups. To study ihe possible 
confounding effect of age, gender and day care attendance, slratified analyses were 
performed.32 The distributions (combinations) of Fcy-receptor polymorhisms in OME 
groups were compared using Fisher's exact test. 
All analyses were performed with the Statistical Analysis Syslems (SAS version 8.0). 
Results 
Study population 
A lolal of 186 children mei the inclusion criteria; 136 of them (73%) participated in the 
study. The median age of the children at study entry was 5.3 years (range, 2.1 to 7.5 
years). Owing to mostly practical problems during ihe study period 15 children were lost 
to follow-up. In the 90 children with complete follow-up data al ihe end of ihe study 
(August 2003), OME recurrence was high: 56 children (62%) developed bilateral OME, 
17 children (19%) developed unilateral OME and only 17 children (19%) did nol develop 
OME. 
The groups were comparable except for age, gender and exposure to smoking at home 
(Table 1). The group of children without OME recurrence contained fewer boys and fewer 
children had been exposed to smoking at home. Children who developed bilateral OME 
were slightly younger, both at study enlry and when extrusion of the lasl lube was 
documented. Tympanostomy lubes appeared to be extruded a median of 9 months after 
insertion. The documentation date of tube extrusion ranged from 3 to 27 months (Table 
1). Due to missing serum samples, immunological data were not always complete in the 
90 children who completed follow-up. 
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Table 1. Characteristics of the study population 
No rOME Uni rOME Bil rOME 
(n=17) (n=17) (n = 56) 
Male sex (%) 35 59 54 
Median age (range) at study entry 
Median age (range) at start of follow-up 
Children aged between 2 4 years at study entry (%) 
Children aged between 5 7 years at study entry (%) 
Attending day care at study entry (%) 
Children aged 2-4 years and attending day care at 
study entry (%) 
Siblings present (%) 
Exposure to smoking at home (%) 
Father born in the Netherlands (%) 
Mother born in the Netherlands (%) 
Median check-up (range) tube extrusion 
From left ear 
From right ear 
5 4 (2 7-7 2) 
6 2 (3 6 9 1) 
41 
59 
18 
12 
94 
18 
94 
94 
9 (3 27) 
9 (3 24) 
5 7 (2 4 7 5) 
6 9 (3 4-8 9) 
29 
71 
24 
18 
94 
35 
100 
95 
12 (3 27) 
9 (6 18) 
5 0 (2 8 7 2) 
6 0 (3 5-8 3) 
48 
52 
18 
18 
93 
36 
93 
88 
9 (3-27) 
9 (3 21) 
Immunoglobulins and subclasses 
Median concentrations of all immunoglobulins expect for IgM were similar in the 
no_rOME group, the uni_rOME gioup and the bil_rOME group (Figuie 1, Table 2) After 
slralificalion by gender, the differences in IgM levels between the uni_rOME and 
bil_rOME became smaller, while the diffeiences with the no_rOME group lemained the 
same. Adjustment for age, day care attendance and the presence of siblings did not affec I 
the overall results. However, IgM levels and all the other immunoglobulins levels weie 
within the normal range of age-matched healthy children (Table 2). 
Mannose-binding lectin 
Children in the bil_rOME group tended to have lower functional MBL semm levels at 
baseline (median 1.38 mg/1) than the children in the no_rOME group (median 2.48 mg/1) 
and the uni_rOME group (median 1.88 mg/1) (Kruskal Walhsp = 0 29) (Figure 2, Table 
2). In the bil_rOME group and the uni_iOME group, about 3 3 % of the children had MBL 
levels of below 1.0 mg/1, compared to 24% in the no_rOME group (Chi2 p = 0.48). 
Stratified analyses for age and gender showed the same, but non-significant, trend towards 
lower MBL levels in the bil_rOME group. The largest difference in MBL between the 
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bil_rOME group and the other two groups was seen in the youngest age category (p value 
0.09, data not shown). 
Fcy-receptor polymorphisms 
Distribution of the FcyRIIa receptor suggested that the proportion of children with less 
effective binding affinity of complexed IgG2 (homozygous FcyRlIa-R/RlSl genotype) 
tended to be higher in the bil_rOME group than in the no_rOME group and uni_rOME 
group (Table 3). Approximately one third of the children in the bil_rOME group were 
homozygous for Arginin (131R/R), compared to only 19% in the no_rOME group and 
1 3 % in the uni_rOME group (Fisher's Exact Test ρ =0.26). For the FcyRIIIa receptor, the 
same trend was seen towards a higher proportion of children with less effective binding 
affinity for IgCl, IgC3 and IgG4 homozygotic FcyRIIIa-F/FlSS genotype in the bil_rOME 
group (44%) than in the no_rOME (14%) and uni_rOME group (0%) (Fisher's Exact Test 
ρ=0.07). In contrast, the proportion of the bil_rOME group (32%) with less effective 
binding affinity for IgCl and IgC3 homozygotic FcYRIIIb-NA2/NA2 genotype was smaller 
than in the no_rOME group (56%) and uni_rOME group (50%). Again, this difference 
was not statistically significant (Table 3, Fisher's Exact Test/>=0.4.2). 
Analysis of combinations of variant genotypes of FcyRIIIa and Fcylllb did not suggest 
overrepresenlalion of one or more combinations of variant genotypes in any of the three 
OME groups (data not shown). 
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OME bilrOME 
no rOME um rOME 
Figure 1. Serum immunoglobulin levels (g/l) 
in children without recurrent OME 
(no_rOME), children with recurrent unilateral 
OME (uni_rOME) and children with recurrent 
bilateral OME (bilrOME). The length of each 
box represents the distance between P25 
and P75; the horizontal line in the box 
represents the median (P50), while the 
vertical lines extend to the minimum and 
maximum value. Outliers and extreme values 
are excluded 
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o; Table 2. Serum immunoglobul in and mannose-binding lectin levels in each of the OME groups 
Immunoglobulines 
Ig level (g/L) 
IgA 
IgM 
IgG 
IgGI 
lgG2 
lgG3 
lgG4 
Functional MBL 
No rOME 
N = 1 7 
median 
1.05 
1.65 
10.65 
8.67 
1.35 
0.40 
0.25 
Ν = 1 7 
range 
0.25-2.25 
0.85-4.30 
7.60-13 51 
5.53-12.87 
0.05-2 60 
0.15-0.90 
0.05-1.55 
%low' 
12% 
0% 
6% 
0% 
12% 
0% 
6% 
%ή^ΐν 
24% 
6 5 % 
35% 
4 1 % 
0% 
0% 
12% 
Uni rOME 
Ν = 16ί 
median 
1.08 
1.00 
9.67 
8 47 
1 28 
0 40 
0 33 
Ν = 1 7 
range 
0.30-2 20 
0.60-2 25 
5.90-14.34 
4.12-14.03 
0.25-2.10 
0.15-0.70 
0.05-1.90 
%low' 
6% 
0% 
13% 
0% 
20% 
0% 
0% 
%hιgh , 
4 4 % 
19% 
50% 
2 5 % 
19% 
0% 
13% 
Bil rOME 
Ν = 56 
median 
0 95 
1 40 
9 44 
7.54 
1 25 
0 40 
0 25 
Ν = 56 
range 
0.10-2.40 
0 50-2.95 
5 11-14 34 
5.08-11.44 
0 55-2.95 
0 15-0.85 
0.05-1.45 
%low' 
5% 
7% 
4 % 
0% 
2% 
0% 
0% 
%high' 
30% 
55% 
36% 
36% 
0% 
0% 
7% 
Kruskal 
wallis 
Ρ value 
0.50 
0.01 
0.28 
0.33 
0 84 
0 95 
0 86 
MBL-level (mg/L) 
< 0.20 
0.20 - 0.42 
0 . 4 2 - 1.0 
1 . 0 - 2.5 
2.5 - 7.5 
> 7 5 
2.48 
0% 
18% 
6% 
35% 
4 1 % 
0% 
0.21-7.32 1.88 
6% 
12% 
18% 
24% 
35% 
6% 
0.19-7.98 1.38 
7% 
7% 
20% 
4 3 % 
20% 
4 % 
0 07-11.58 0 29 
C h i 2 
0.48 
* Concentration below age-specific normal value 
t Concentration above age-specific normal value 
t Serum from one child was missing 
Inimunoloi. 
Figure 2. Mannose-binding lectin levels (mg/l) in children w i t h o u t recurrent OME ( n o r O M E ) , 
children w i t h recurrent unilateral OME ( u n i r O M E ) and children w i t h recurrent bilateral OME 
(b i l rOME). The length of each box represents the distance between P25 and P75; the horizontal 
line in the box represents the median (P50), whi le the vertical lines extend to the minimum and 
maximum value. Outliers and extreme values are excluded 
Table 3. Distribution FcyR-polymorphism 
FcyRlla genotype 
FcYRIIa-R/R131 
FcYRIIa-R/H131 
FcYRIIa-H/H131 
FcyRllla genotype' 
FcYRIIIa-F/F158 
FcyRllla-V/F158 
FcYRIIIa-V/V158 
FcyRlllb genotype 
FcyRlllb-NA2/2' 
FcYRIIIb-NA1/2 
FcyRlllb-NAI/l 
No_rOME * 
Ν = 16 
19% (3) 
6 3 % (10) 
19% (3) 
Ν = 7 
14% (1) 
7 1 % (5) 
14% (1) 
Ν = 16 
56% (9) 
3 8 % (6) 
6% (1) 
Uni rOME * 
Ν = 15 
13% (2) 
4 7 % (7) 
4 0 % (6) 
Ν = 6 
0 % (0) 
66.7% (4) 
33.3% (2) 
Ν = 15 
5 0 % (7) 
4 3 % (6) 
7% (1) 
Bil rOME * 
Ν = 53 
34% (18) 
4 9 % (26) 
17% (9) 
Ν = 32 
44% (14) 
50% (16) 
6% (2) 
Ν = 53 
32% (17) 
59% (31) 
9% (5) 
Fisher's Exact 
Test 
Ρ = 0.26 
Ρ = 0.07 
Ρ = 0.42 
* In six children, blood samples for extracting genomic DNA were unavailable 
t Due to technical problems, not all available serum could be analysed for FcyRIIIa-genotype 
t One child with unilateral OME lacked the FcyRlllb-genotype 
Discussion 
In a clinically homogenous cohort, we evaluated the role of serum immunoglobulin levels, 
MBL and Fey receptor polymorphisms in the aetiology of recurrent OME. All the children 
in this cohort had had OME for a period of at least three months and had been referred to 
the otologist for the first time for this indication. No significant difference in 
immunoglobulin levels was demonstrated between children who did or did not develop 
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recurrent bilateral OME. However, consistently lower median levels of IgA, IgG, IgGl, 
IgG2, and IgM were found in the group of children with bilateral OME recurrence (Figure 
I). Il should be noted that immunoglobulin deficiencies were rare in this cohort. The 
proportion of children with immunoglobulin levels of below two standard deviations below 
the age-specific mean varied from 0% to 20%. In fact, a substantial proportion of children 
in all the OME groups had IgA, IgG and IgM levels of higher than two standard deviations 
above the age-specific mean, which has also been demonstrated in a large group of Dutch 
children with recurrent acute otitis media (AOM)." Recently, significant associations 
(Veenhoven et a l )" and non-significanl associations (Berman et al.11 and Drake-Lee et 
al.'0) have been reported between otitis media and serum immunoglobulin levels. All 
three studies found a trend towards lower serum immunoglobulin levels in the children 
with frequent recurrent otitis media than in the control group without otitis media or only 
occasional otitis media episodes. Our results are in concordance with these findings. Non-
significant lower serum levels of IgA, IgG, IgGl, IgG2, and IgM were measured at 
baseline in the children who developed recurrent bilateral OME within a period of six 
months after the first OME episode had been resolved. The consistency of this trend in so 
many studies, even after adjustment for age and gender, makes it unlikely to be solely due 
to chance. However, in our opinion total serum immunoglobulin levels do not seem to 
have any clinical value in predicting which child will recover from OME and which child 
will develop recurrent OME, based on these findings of only small differences in serum 
immunoglobulin levels. 
Deficiencies in classical and alternative complement pathways are rare, but at least 20% 
of the Caucasian population were found to have decreased or absent MBL levels in 
association with respiratory tract infections.1''"1 We demonstrated a non-significant trend 
in functional MBL serum levels towards lower levels at baseline in children who 
subsequently developed bilateral OME. In a cross-sectional hospital-based study, a 
similar non-statistically significant, trend was shown towards lower median functional 
MBL levels in 22 Danish children with OME than in 15 children without OME.3* 
Moreover, a second Danish study provided evidence thai severe recurrent otitis media was 
associated with MBL variant alleles that result in low MBL serum levels."1 However, a 
retrospective community-based study on associations between MBL genotypes and a 
history of AOM failed to show these trends.',;> This lack of trends may be due to the 
limitations of a retrospective study design. Both our study population and that of Garred 
et al. J t comprised older children, which suggests that in older children, MBL serum levels 
are associated with the course of recurrent OME, as had been postulated earlier.1. 
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Genetically-determined variation in Fey receptor function may play a role in the 
recurrence of OME.21 In this study, we found differences in the proportion of children 
homozygous for the allotypes with lower binding affinity for IgG2 complex (FcyRIIa-
131R) or the complex IgGl, IgG3, IgG4 (FcyRIIIa-158F). Although these differences 
were not statistically significant, a trend was visible in line with our a priori hypotheses. 
Comparable figures were shown for the FcyRIIa-R/RlSl genotype in a cross-sectional 
study on AOM: 3 1 % of the children with frequent recurrent episodes of AOM or sinusitis 
were homozygous for the R-allotype, compared to 24% of the healthy controls.20 ib A 
similar but unique observation was made for the FcyRIIIa-F/FlSS genotype: 44% of the 
children with bilateral OME recurrence had this genotype, compared to 15% of the 
children in the rest of the population. In a study by Van der Pol et al. who compared 
survivors of meningococcal disease to control subjects, no differences were demonstrated 
in the FcyRIIIa genotype.37 Study results on the FcyRIIIb genotype do not support our a 
priori hypothesis that children with OME recurrence are more likely to have the 
FcyRIIIb-NA2/NA2 genotype. Elsewhere, we also reported that there was no potentially 
increased frequency of the latter genotype in children with recurrent acute otitis media.2, 
The proportion of children in our study with the FcyRIIIb-NAl/l genotype was smaller 
(10%) than the proportions found in children with recurrent AOM and in healthy controls 
^(^c).25 ·36 ·38 Future studies should elucidate whether this difference reflects a 
characteristic of OME children or is merely due to chance. 
This is the first prospective study in which baseline immunological parameters were 
evaluated in relation with the subsequent risk of OME recurrence in a homogeneous 
population of children treated for their first clinical episode of bilateral OME. By using 
this cohort design, we were able to exclude selection bias and avoid discussions about 
what is cause and what is effect. Although the study size is limited and hence statistical 
significance was not reached, the results are not likely to be merely due to chance, as 
most of these accord with etiological hypotheses postulated a priori. 
In conclusion, serum immunoglobulin levels only seemed to play a limited role in the 
aetiopathogenesis of recurrent OME, while MBL, FcyRIIa and FcyRIIIa genotypes may 
provide interesting clues towards the discovery of mechanisms to explain OME recurrence 
in children. 
65 
cu \ΡΤΙ·:Κ ; ι 
Acknowledgements 
We thank the parents and the children who took part in this study, the ENT surgeons and 
staff at the Department of Otorhinolaryngology of the University Medical Centre 
Nijmegen, the Canisius-Wilhelmina Hospilal Nijmegen and the District Hospital Queen 
Beatrix Winterswijk, P. Aerts and Prof. H. van Dijk from the Centre for Microbiology, 
Infectious Diseases and Inflammation of the University Medical Centre Utrecht for testing 
serum samples for MBL, and Sonja van Oosterhout from the Department of Epidemiology 
and Biostatistics of the University Medical Centre Nijmegen for study management and 
data entry. This study was supported by a grant from ZonMW, the Netherlands 
Organisation for Health Research and Development (no. 904 61 092). 
References 
1 Zielhuis GA, Rach GH, Van den Broek P. The occurrence of otitis media with effusion in Dutch pre­
school children. Clin Otolaryngol. 1990;15:147-153. 
2 Zielhuis GA, Rach GH, Van den Bosch A, Van den Broek P. The prevalence of otitis media with 
effusion: a critical review of the lileralure. Clin Otolaryngol. 1990;15:283-288. 
3 Gates GA, Avery CA, Prihoda TJ, Cooper JC, Jr. Effectiveness of adenoidectomy and tympanostomy 
tubes in the treatment of chronic otitis media with effusion. Ν Engl J Med. 1987;317:1444-1451. 
4 Ryding M, Konradsson K, Kalm 0, Prellner K. Sequelae of recurrent acute otitis media. Ten-year 
follow-up of a prospectively studied cohort of children. Acta Paedialr. 1997;86:1208-1213. 
5 Schilder AG, Snik AF, Straatman Η, Van den Broek P. The effect of otitis media with effusion at 
preschool age on some aspects of auditory perception at school age. Ear Hear. 1994;15:224-231. 
6 Schilder AG, Zielhuis GA, Haggard MP, Van den Broek P. Long-term effects of otitis media with 
effusion: otomieroscopic findings. Am J Otol. 1995;16:365-372. 
7 Zielhuis GA, Gemiseli AA, Gorissen WH, Dekker LJ, Rovers MM, Van der Wilt GJ, Ingcls K. Hearing 
deficits at school age; the predictive value of otitis media in infants. Ini J Pedialr Olorhinolaryngol. 
1998;44:227-234. 
8 Daly KA, Hunter LL, Giebink GS. Chionic otitis media with effusion. Pedialr Rev. 1999;20:85-93. 
9 Straelemans M, Van Heerbeek Ν, Tonnaer E, Ingels KJAO, Rijkers GT, Zielhuis GA. A comprehensive 
model for the aetiology of otitis media with effusion. Medical Hypotheses. 2001;57:784-791. 
10 Drake-Lee AB, Hughes RG, Dunn C. Serum IgA and IgG functional antibodies and their subclasses to 
Streptococcus pneumoniae capsular antigen found in two age-matched cohorts of children with and 
without otitis media with effusion. Clin Otolaryngol. 2003;335-340. 
11 Veenhoven RH, Rijkers GT, Schilder AGM., Adelmeijer J, Uilerwaal C, Kuis W, Sanders EA. 
Immunoglobulins in otitis-prone children. Pediatric Research. 2004;55:1-4. 
12 Yamanaka N, Holomi M, Shimada J, Togawa A. Immunological deficiency in "otitis-prone" children. 
Ann Ν Y Acad Sci. 1997;830:70-81. 
13 Prellner Κ, Kalm O, Pedersen FK. Pneumococcal antibodies and complement during and after periods 
of recurrent olilis. Int J Pedialr Olorhinolaryngol. 1984;7:39-49. 
14 Freijd A, Hammarstrom L, Persson MA, Smith CI. Plasma anti-pneumococcal antibody activity of the 
IgG class and subclasses in otitis prone children. Clin Exp Immunol. 1984;56:233-238. 
15 Roy S, Knox K, Segal S, Griffiths D, Moore CE, Welsh KI, el al. MBL genotype and risk of invasive 
pneumococcal disease: a case-control study. Lancet. 2002;359:1569-73. 
16 Sumiya M, Super M, Tabona P, Levinsky RJ, Arai Τ, Turner MW, Summerfield JA. Molecular basis of 
opsonic defect in immunodeficient children. Lancet. 1991;337:1569-1570. 
66 
Immunologi 
17 Koch A, Melbye M, Sorensen Ρ, Homoe Ρ, Madsen HO, Molbak Κ, Hansen CH, Andersen LH, Hahn 
GW, Garred P. Acute respiratory tract infections and mannose-binding lectin insufficiency during 
early childhood. JAMA. 2001;285:1316-1321. 
18 Garred P, Madsen HO, Hofmann Β, Svejgaard A. Increased frequency of homozygosity of abnormal 
mannan-binding-protein alleles in patients with suspected immunodeficiency. Lancet. 1995;346:941-
943. 
19 Van der Pol W., Van de Winkel JG. IgG receptor polymorphisms: risk factors for disease. 
Immunogenetirs. 1998;48:222-232. 
20 Lehrnbecher T, Foster CB, Zhu S, Leitman SF, Goldin LR, Huppi K, Chanock SJ. Variant genotypes of 
the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma 
receptor polymorphisms in control and disease populations. Blood. 1999;94:4220-4232. 
21 De Haas M. IgG-Fc receptors and the clinical relevance of their polymorphisms. Wien Klin 
Wochenschr. 2001;113:825-831. 
22 Platonov AE, Shipulin GA, Vershinina IV, Dankerl J, Van de Winkel JG, Kuijper EJ. Association of 
human Fc gamma Rlla (CD32) polymorphism with susceptibility to and seventy of meningococcal 
disease. Clin Infect Dis. 1998;27:746-750. 
23 Vedeler CA, Raknes G, Myhr KM, Nyland H. IgG Fc-receplor polymoiphisms in Guillain-Barre 
syndrome. Neurology. 2000;55:705-707. 
24 Domingo P, Muniz-Oiaz E, Baraldes MA, Anlla M, Barquet N, Pericas R, Juarez C, Madoz P, Vazquez 
G. Associations between Fc gamma receptor IIA polymorphisms and the risk and prognosis of 
meningococcal disease. Am J Med. 2002;112:19-25. 
25 Sanders LA, Van de Winkel JG, Rijkers GT, Voorhorst-Ogink MM, De Haas M, Capei PJ, Zegers BJ. 
Fc gamma receptor IIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract 
infections. J Infect Dis. 1994;170:854-861. 
26 Engel J, Anleunis L, Volovics A, Hendriks J, Marres E. Prevalence rales of otitis media with effusion 
from 0 to 2 years of age: healthy-bom versus high-nsk-bom infants. Int J Pediatr Otorhinolaryngol. 
1999;47:243-251. 
27 Jerger J. Clinical experience with impedance audiometry. Arch Otolaryngol. 1970;92:311-324. 
28 Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by single radial 
immunodiffusion. Immunochemistry. 1965;2:235-254. 
29 Kuipers S, Aerts PC, Sjoholm AG, Harmsen T, Van Dijk H. A hemolytic assay for the estimation of 
functional mannose-hinding lectin levels in human serum. J Immunol Methods. 2002;268:149-157. 
30 Breij EC, Van der Pol WL, Van Winsen L, Jansen MD, Dijkstra CD, Van de Winkel JG, Uitdehaag 
BM. No association of FcgammaRIIa, FcgammaRIIIa and FcgammaRIIIb polymorphisms with MS. J 
Neuroimmunol. 2003;140:210-215. 
31 Leppers-Van de Straal FG, Van der Pol WL, Jansen MD, Sugila Ν, Yoshie Η, Kobayashi Τ, Van de 
Winkel JG. A novel PCR-based method for direct Fc gamma receptor Illa (CD16) allolyping. J 
Immunol Methods. 2000;242:127-132. 
32 Matsuoka A, Shilara T, Okamoto M, Sano Η. Immunological aspects of inflammatory middle ear 
diseases in children: sex differences. In: Mogi G, ed. Recent Advances in Otitis Media: Proceedings of 
the Second Extraordinary International Symposium on Recent Advances in Otitis Media. Kugler 
Publications; 1994:141-145. 
33 Berman S, Lee B, Nuss R, Roark R, Giclas PC. Immunoglobulin G, total and subclass, in children with 
or without recurrent otitis media. J Pediatr. 1991;121:249-51. 
34 Garred P, Brygge K, Sorensen CH, Madsen HO, Thiel S, Svejgaard A. Mannan-binding protein levels 
in plasma and upper-airway secretions and frequency of genotypes in children with recurrence of otitis 
media. Clin Exp Immunol. 1993;94:99-104. 
35 Homoe P, Madsen HO, Sandvej K, Koch A, Garred P. Lack of association between mannose-binding 
lectin, acute otitis media and early Epstein-Barr virus infection among children in Greenland. Scand J 
Infect Dis. 1999;31:363-366. 
67 
(ΊΚΚΠΗ ì 1 
36 Van der Pol WL, Jansen MD, Sluiter WJ, Van de Sluis Β., Leppers-van de Slraal FG, Kobayashi T, 
Westendorp RG, Huizinga TW, Van de Winkel JG. Evidence for non-random distrihulion of Fcgamma 
receptor genotype combinations. Immunogcnetics. 2003;55:240-246. 
37 Van der Pol WL, Huizinga TW, Vidarsson G, Van der Linden MW, Jansen MD, Keijsers V, De Slraal 
FG, Westerdaal NA, De Winkel JG, Westendorp RG. Relevanre of Fcgamma receptor and interleukin-
10 polymorphisms for meningococcal disease. J Infect Dis. 2001;184:1548-1555. 
38 Huizinga TW, Roos D, Dem Bome AE. Fc-gamma receptors: mediators, targets and markers of 
disease. Baillieres Clin Haematol. 1991;4:889-902. 
68 
Chapter 4.2 
Review of randomised controlled trials on 
pneumococcal vaccination for prevention of 
otitis media 
Masja Straetemans 
Elisabelh Sanders 
Reinier Veenhoven 
Anne Schilder 
Roger Damoiseaux 
Gerhard Zielhuis 
Pediatrie Infeclious Disease Journal 2003;22:515-24 
( l u m n 12 
Abstract 
Background Increasing resistance to antibiotics of the pathogens causing acute otitis 
media (AOM) emphasize the need for effective methods to prevent episodes of otitis 
media in young children. 
Objective To assess the effectiveness of pneumococcal vaccination for prevention of 
AOM in children aged 12 years and younger. 
Methods Systematic review of 11 randomised controlled trials including 46,074 children 
in whom pneumococcal vaccination against AOM was compared with a control treatment. 
Vaccine effect was estimated as a rate ratio (RR): AOM episodes per child month in 
pneumococcal vaccination group divided by the AOM episodes per child month in control 
group. 
Results A moderate effect of pneumococcal polysaccharide vaccination was found in 
children aged 24 months and older (RR: 0.78, 95% confidence interval (CI) 0.63 to 
0.97). Pneumococcal polysaccharide vaccine had little effect on prevention of AOM in 
children without previous documented episodes before vaccination (RR: 0.92, 9 5 % CI 
0.85 to 0.99). Better efficacy was seen in those children with documented prior AOM 
before vaccination (RR: 0.81, 9 5 % CI 0.72 to 0.91). Pooled results of pneumococcal 
conjugate vaccine trials in infants vaccinated as early as 2 months of age and in toddlers 
attending day care showed only a small effect on prevention of AOM (RR: 0.92, 9 5 % CI 
0.85 to 0.99). 
Conclusion Based on these results, a large-scale pneumococcal vaccination program for 
a primary indication of preventing AOM in infancy is not indicated. The results of ongoing 
trials should provide more information whether the conjugate vaccine is effective in high-
risk (olitis-prone) children after one year of age. 
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Introduction 
Acute otitis media (AOM) is one of the most common diseases in early infancy and 
childhood. By the age of one year and three years, 62% and 8 3 % will have experienced at 
least one episode of AOM, respectively.1 Up to 5% of all children are considered to be 
otitis prone with at least three AOM episodes within six months, or four or more episodes 
within one year.2 In view of the long-term effects of recurrent episodes of OM, rapid 
emergence of drug resistant bacteria associated with AOM worldwide and huge estimated 
direct and indirect annual financial costs associated with OM there is need for an 
effective vaccination program to prevent otitis media (OM).1 B 
Vaccine development has focused on pneumococcal vaccines because Streptococcus 
pneumoniae is the most common bactenal cause of AOM and community acquired 
pneumonia and a leading cause of invasive diseases like meningitis and bacteremia with 
high case-fatality rates 9 
The preventive effect of both pneumococcal polysaccharide vaccines and pneumococcal 
conjugate vaccines in AOM has been assessed in several trials. So far, no systematic 
review of the current available evidence regarding pneumococcal vaccination for 
prevention of AOM has been published. In this review we aim to estimate the 
effectiveness of both pneumococcal polysaccharide and pneumococcal conjugate vaccines 
in the prevention of AOM in infants and children and to identify subgroups for which the 
vaccine might in particular be useful. 
Methods 
Search 
All published randomised trials were identified by searching the following electronic 
databases: the Cochrane Acute Respiratory Infections Group's trial register (updated on 
September 2002), the Cochrane Library (Issue 3, 2002) and Medline (January 1966-
August 2002). The following search terms were used: exploded MeSH headings· bactenal 
vaccines, vaccination, otitis media and the free text terms: pneumococc* near immuni*, 
pneumococc* near vaccin*, otitis next media. We also used the bibliographies to identify 
other published studies and contacted Merck, Sharp & Dhome and Wyeth Lederle 
Vaccines for information about unpublished studies. All randomised controlled clinical 
trials on pneumococcal vaccination with prevention of AOM as outcome in children aged 
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younger than 12 years and a follow—up period of at least six months were included in this 
systematic review. 
Data extraction and outcome measure 
Data extraction was performed independently by the first two authors followed by a 
consensus conference to resolve any differences. Dala exlraclion included: description of 
participants, description of intervention, description of control condition, total number of 
children in each study group, total number of AOM episodes and follow-up period in 
months. Bacteriological data on episodes of AOM after vaccination were extracted to 
establish whether the vaccines had protected against specific serotypes of pneumococoi 
presenl in ihe vaccine. The main oulcome measure was the lolal number of AOM episodes 
during follow-up. Another outcome measure was the number of AOM episodes caused by 
pneumococcal serotypes present in the vaccine, or caused by pneumococcal serotypes not 
present in the vaccine. First or corresponding aulhors were conlacled lo obtain additional 
information where necessary. 
Quality assessment 
Study quality was assessed independently by five of the authors using the Jadad criteria 
consisting of a three-item quality scale wilh a score ranging from zero lo five. One poinl 
was allocaled for randomisation, double blinding, and description of withdrawals and 
dropouts; an extra point was added for melhods of randomisation and blinding that were 
well described and adequate. Studies that used a clearly inadequate method of 
randomisation or blinding lost the point allocated. Disagreement was resolved by 
discussion. 
Statistical analyses 
Vaccine effect was estimated as a rate ratio defined as follows: (total AOM episodes 
pneumococcal vaccination group / number of children pneumococcal vaccination 
group*follow-up in months) / (total AOM episodes control group / number of children 
control group*follow-up in months). Overall and age specific rate ratios were analyzed 
with loglinear Poisson regression. Fixed effecls models are presented with allowance for 
extra Poisson variation to account for heterogeneity when the p-value of the lest for model 
fit without exlra Poisson varialion was below 0.05." ' ' 2 Standard errors of estimates 
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multiplied by the square root of Deviance divided by degrees of freedom in the classical 
Poisson regression gave the standard errors in the case of extra Poisson variation. 
Loglinear Poisson regression was undertaken with the Genmod procedure in Statistical 
Analysis System (SAS version 6.12). Subgroup analyses were conducted on children who 
had a history of documented episodes of AOM prior to study entrance. 
Sensitivity analysis was performed once by excluding the study with the lowest 
methodological quality score and once by excluding the study in which randomisation had 
failed due to large randomisation blocks. Publication bias was assessed by a scatter plot 
(funnel-plot) of the log rate ratios (x-axis) versus precision defined as 1/standard error (y-
axis) of the eight studies with respect to pneumococcal polysaccharide vacci nation.1Λ 
Results 
Results of the literature search 
The Medline search yielded 16 potentially relevant randomised controlled tr ials . ' 4 2 0 An 
additional relevant trial was found in the Cochrane Controlled Trial Register and in the 
Cochrane Acute Respiratory Infections Group trial register.10'11 Two studies were 
excluded because AOM was not an outcome.1 4"1 0 One citation was excluded because it 
was found to include an additional analysis of Sloyer (1981) but no additional 
information.1' The search yielded three double citations, leaving 12 trials on the effect of 
pneumococcal vaccination against AOM in children. Quality assessment of these studies 
revealed that one study was nol a trial and therefore it was excluded.1 6 This left 11 trials. 
Table 1 and table 2 show qualitative and quantitative results of the included trials, 
respectively. It should be mentioned that 8- to 14-valent polysaccharide vaccines were 
used in the reviewed studies, because 23-valent polysaccharide vaccine was not yet 
available. 
The quality score of the included studies varied from zero to five (Table 1). Although 
Rosen (1984) 2 j did not mention the use of randomisation, the reviewers believe there is 
no reason to assume that this study was not randomised. According to the guidelines 
however no points were assigned. All the other studies were reported as randomised, but 
in most of them the method of randomisation was not described.2 2 , 2 1 '2 6"2 8 In two of the five 
studies that did report on the method of randomisation, this was done inappropriate by 
sequentially assigning intervention 2 0 and too large randomisation blocks resulting in 
unequal groups.2 4 Except for Makela (1981) 2 0 and Schuller (1983)2 1, the studies were 
double blinded and the method of double blinding was appropriate. The method of double 
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blinding was not described in Sloyer (1981)21 and Eskold (2000)28. Apart from Schuller 
(1983)2 \ Douglas ( i g S ^ 2 1 , Eskold (2000)2n and Dagan (2001)2", no information about the 
number of withdrawals and dropouts was given in any of the studies. 
The funnel-plot (Figure 1) suggests a lack of publications on small sized studies that did 
not demonstrate any beneficial effect of the pneumococcal polysaccharide vaccine. 
Results of meta-analysis 
Pneumococcal polysaccharide vaccination: effect of age 
The pooled rate ratio for the effect of pneumococcal polysaccharide vaccination after 
adjustment for age and study was 0.90 (95% confidence interval 0.81 to 1.00; Table 3; 
Figure 2). The rale ratio in children younger than 24 months was 0.93 (95% confidence 
interval 0.83 to 1.05), while the rale ratio in children older than 24 months was 0.78 
(95% confidence interval 0.63 to 0.97). Exclusion of the study with the lowest quality 
score did not affect the results.20 In the study on Aboriginal children randomisation errors 
had resulted in unequal sized groups and no information on previous episodes of AOM 
was given.11 Therefore, this study was excluded from further analyses. Pneumococcal 
polysaccharide vaccination was found to have a moderate effect on the prevention of AOM 
episodes in children older than 24 months. 
Pneumococcal polysaccharide vaccination: effect of previous AOM history 
The overall pooled rale ratio in the group of children without any previous documented 
AOM episodes was 0.92 (95% confidence interval 0.85 to 0.99; Table 3; Figure 3). In 
children younger than 24 months, the rate ratio was 0.94 (95% confidence interval 0.87 
to 1.02); in children older than 24 months the rate ratio was 0.81 (95% confidence 
interval 0.68 to 0.98). These results show that, independent of age, pneumococcal 
polysaccharide vaccination had only a small effect on the prevention of AOM in children 
without a previous history of AOM. 
Subgroup analysis on children with documented AOM episodes prior to vaccination 
showed a pooled rate ratio of 0.85 (95% confidence interval 0.74 to 0.98) in the younger 
age group versus 0.74 (95% confidence interval 0.62 to 0.90) in the older age group. 
Regardless of age the rate ratio was 0.81 (95% confidence interval 0.72 to 0.91; Table 3; 
Figure 4). Pneumococcal polysaccharide vaccination seemed to prevent AOM effectively, 
independent of age, in children with documented AOM episodes before vaccination. 
7-1 
Iminuiiuloiiì 
Pneumococcal conjugate vaccine 
Two studies conducted in healthy Califomian and Finnish infants immunized as early as 
2 months of age have addressed the effect of 7-valent pneumococcal conjugate 
vaccination against AOM.27'2B A third study addressed the effect of 9-valent pneumococcal 
conjugate vaccination against acute respiratory infections, including otitis media, in 
toddlers 12-35 months of age, attending day care, receiving vaccination at 12-35 months 
of age.29 In the Finnish study of healthy infants28, a rate ratio of 0.93 (95% confidence 
interval 0.86 to 1.00) was calculated using intention-to-treat data. Results of the Israeli 
trial 29 suggest that 9-valent pneumococcal conjugate vaccination prevents otitis media in 
toddlers attending day care, with a rate ratio of 0.83 (95% confidence interval 0.67-1.03). 
Because the California study27 did not provide any details on follow-up duration, only the 
results of the Finnish28 and Israel29 studies could be pooled, leading lo a rate ratio of 0.92 
(95% confidence interval 0.85-0.99; Table 3). 
As the California and Finnish study had a similar design, both immunizing healthy infants 
at 2,4,6 months of age and again at 12-15 months of age, we compared the vaccine 
efficacy against recurrent AOM (at least three episodes within six months, or at least four 
episodes within one year). According to the inlenlion-lo-lreat analysis, the risk of 
recurrent AOM was reduced by 9% (95% confidence interval 4% to 14%) by 
pneumococcal conjugate vaccination in the California study and also by 9% (95% 
confidence interval -12% to 27%) in the Finnish study. 
Efficacy against pneumococcal serotypes 
Three studies addressing the effect of pneumococcal polysaccharide vaccination, 
provided detailed information on the number of AOM episodes after vaccination caused 
by vaccine and non-vaccine pneumococcal serotypes.20'21,26 Regardless of age and 
previous AOM history, the pooled rate ratio of AOM episodes caused by pneumococcal 
serotypes present in the polysaccharide vaccine was 0.92 (95% confidence interval: 0.64 
to 1.33). The pooled rate ratio of AOM episodes caused by pneumococcal serotypes not 
present in the polysaccharide vaccine was 0.91 (95% confidence interval: 0.62 to 1.33). 
These results do not show a clear effect of pneumococcal polysaccharide vaccination in 
preventing AOM episodes caused by specific pneumococcal serotypes present in the 
vaccine. 
The pneumococcal conjugate vaccine was more effective in preventing the number of 
AOM episodes caused by pneumococcal serotypes present in the vaccine, with a rate ratio 
of 0.43 (95% confidence interval 0.34 to 0.54).28 However, the rate of AOM episodes 
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caused by non-vaccine pneumococcal serotypes was increased in the pneumococcal 
conjugate vaccine group, with a rate ratio of 1.32 (95% confidence interval 1.01 to 1.72), 
indicating a shift in pathogens towards non-vacccine pneumococcal serotypes. 2 8 
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Figure 1. Slightly asymmetric funnel plot. Points indicate log rate ratios (x-axis) from eight trials 
regarding pneumococcal polysaccharide vaccination included in analyses versus precision (y-axis) 
defined as (1/standard error). This funnel plot indicates that smaller studies showing no 
statistically significant effect are lacking 
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Table 1. Trials included in systematic review 
Trial Methods Participants and setting Intervention 
Makela et al 2 0 Random allocation Finland multicentre trial on 827 14-valent PPV 
Single blind children with AOM aged 3 months- booster 6 
6 years; otorhmolaryngology / months after 
Paediatnc clinic study entrance 
Sloyer et al 2 1 Random allocation US trial on 179 children aged 6-21 8-valent PPV 
double blind months with at least 1 AOM 
episode before 10 months age, 
paediatnc clinic 
Teele et al 2 2 Random allocation US trial on 124 children with at 8-valent PPV 
double blind least 3 AOM episodes aged 5-21 
months, birth cohort 
Schuller et al 2 3 Random allocation US trial on 72 asthmatic children 14-valent PPV 
double blind aged 2-6 years with at least 4 OM 
episodes previous 12 months, 
paediatnc allergy clinic 
Douglas et al 2 4 Random allocation Australia multicentre trial on 1273 14-valent PPV 
double blind healthy children aged 6-54 months, 
general practitioner 
Rosen et al 2 S Pair-matched Sweden multicentre trial on 405 14-valent PPV 
double blind children aged 6 months-5 years, 
day care centre 
Karma et al 2 6 Random allocation Finland multicentre trial on 3340 14-valent PPV 
double blind infants aged 6 11 months, well booster 5 
baby clinics months after 
study entrance 
Douglas et al ^ Random allocation Australia multicentre trial on 60 14-valent PPV 
double blind aboriginal children aged 6 months-5 
years; aboriginal community 
Black et al " Random allocation US multicentre trial on 37868 7-valent PCV 
double blind healthy infants aged 2 months, 2, 4, 6, 12 to 
medical centre 15 months 
Eskola et a l 2 β Random allocation Finland multicentre trial of 1662 7-valent PCV 
double blind children aged 2 months; prenatal 2, 4, 6, 12 
health clinics months 
Dagan et al 2 9 Random allocation Israeli multicentre trial on 264 9-valent PCV 
double blind healthy children aged 12 to 35 
months, day care centre 
PPV, p n e u m o c o c c a l po lysacchar ide v a c c i n e ; PCV, p n e u m o c o c c a l c o n j u g a t e v a c c i n e 
Control Length of Diagnosis acute otitis media Quality 
follow up Score 
Saline (placebo) vaccine 6 months Effusion verified by myringotomy 0 
booster + signs/symptoms of acute 
infection 
7-valent PPV 24 months Effusion by pneumatic otoscopy 3 
+ 
aspiration effusion 
7-valent PPV mean 22 months Effusion by pneumatic otoscopy 3 
and tympanometry + 
signs/symptoms of acute infection 
Amoxicillin during AOM 24 months Effusion by pneumatic otoscopy 2 
episode and tympanometry + fever 
Saline (placebo) vaccine mean 15.6 months Symptom diary of acute infection 5 
Saline (placebo) vaccine 24 months Effusion verified by myringotomy 2 
+ signs/symptoms of acute 
infection 
Saline (placebo) vaccine 13 months Effusion by otoscopy + 3 
booster signs/symptoms of acute infection 
Saline (placebo) vaccine 18 months Not mentioned 3 
Meningococcus type C unspecified Computerized data sources on 3 
Vaccine clinical diagnoses of acute otitis 
media 
Hepatitis Β vaccine 22 months Effusion by pneumatic otoscopy 3 
+ signs/symptoms of acute 
infection 
Meningococcus type C 24 months Parental report of otitis media 5 
Vaccine 
-J Table 2. Quanti tat ive details of trials included in systematic review 
Trial 
Makela et al J 0 
< 24 months 
> 24 months 
overall 
Sloyer et al 2 I 
< 24 months 
(overall) 
Teele et al 2 2 
< 24 months 
(overalll 
Schuller et al " 
> 24 months 
(overalll 
Douglas et al " 
< 24 months 
> 24 months 
overall 
Rosen et al 2 b 
< 24 months 
> 24 months 
overall 
Karma et al 2 6 
< 24 months 
(overall) 
Douglas et al 3 ' 
< 24 months 
> 24 months 
overall 
Black et al " 
Eskola et al 2 S 
loverall) 
Dagan et al 2 9 
(overall) 
Intervention 
Ν children 
198 
269 
467 
89 
64 
12 
190 
387 
577 
44 
154 
198 
1515 
15 
15 
30 
18927 
831 
131 
Ν ΑΟΜ events 
101 
51 
152 
136 
139 
74 
161 
200 
361 
67 
75 
142 
1020 
34 
15 
49 
m ν 
1251 
153 
Person months 
1188 
1614 
2802 
2136 
1408 
288 
2964 
6037 
9001 
1056 
3696 
4752 
19695 
270 
270 
540 
m v. 
18282 
2797 
Rate 
0 085 
0.032 
0 0 5 4 
0 0 6 4 
0 099 
0.257 
0 0 5 4 
0.033 
0 0 4 0 
0 0 6 3 
0 0 2 0 
0 0 3 0 
0 052 
0 126 
0 0 5 6 
0 091 
m ν 
0 068 
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Table 3. Results of meta-analysis of randomised controlled trials on pneumococcal vaccination against otitis media 
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Poisson variation 
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Without extra Poisson With extra Poisson of freedom 
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Pneumococcal polysaccharide vaccine 
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Effect of age < 24 months 
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Previous AOM history 
No overall 
No < 24 months 
No > 24 months 
Yes overall 
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Pneumococcal serotypes 
Non-vaccine serotypes 
Vaccine serotypes 
20-22,24 
26,31 
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Pneumococcal conjugate vaccine 
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Figure 2. "Forest plot" showing results from all randomised controlled trials on pneumococcal 
polysaccharide vaccination against otitis media. Trials are ordered by year of publication. The 
black dot and horizontal line correspond to the tnals's Rate Ratio and 95% Confidence Interval 
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Figure 3. "Forest plot" showing results from randomised controlled trials on pneumococcal 
polysaccharide vaccination against otitis media in children without any previous documented 
AOM episodes. The black dot and horizontal line correspond to the tnals's Rate Ratio and 95% 
Confidence Interval 
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Figure 4. "Forest plot" showing results from randomised controlled trials on pneumococcal 
polysaccharide vaccination against otitis media in children with documented AOM episodes prior 
to vaccination. The black dot and horizontal line correspond to the trials's Rate Ratio and 95% 
Confidence Interval 
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Discussion 
Multivalent pneumococcal polysaccharide vaccine tends to prevent 10% of AOM episodes 
in young children, regardless of age. However, the pooled results of the pneumococcal 
polysaccharide vaccination trials support the general opinion that the pneumococcal 
polysaccharide vaccine is at best moderately effective in children older than 24 months 
and not effective in children younger than 24 months.9 This conclusion is consistent with 
the knowledge that the vaccine pneumococcal polysaccharides are T-cell independent 
antigens that are in general poorly immunogenic before 18-36 months of age, and fail to 
induce a memory response. 
In contrast, conjugated vaccines induce a T-cell-dependent immune response from as 
early as 2 months of age. Repeated immunizations have been shown to induce IgG 
immune responses at this early age due to the immunological memory induced by the 
conjugate vaccine. 
In general, pneumococcal conjugate vaccine would significantly prevent 8% of AOM 
episodes in infants and toddlers. The results of the Israeli study29 suggest that the 
pneumococcal conjugate vaccination is moderately effective in toddlers attending day 
care; vaccination tends to prevent 17% of AOM episodes. The seemingly higher 
vaccination impact in this specific group of children may be explained by the possible 
effect of environmental infection pressure with higher rales of respiratory tract infections 
and acute otitis media, caused by antibiotic-resistant pneumococcal serotypes included in 
the vaccine. 
In children with a previous documented history of AOM pneumococcal polysaccharide 
vaccination would significantly prevent 19% of AOM episodes; whereas in children 
without previous documented AOM vaccination prevents 8% of AOM episodes. The 
precise reason why children with recurrent AOM would benefit more of vaccination is 
unknown. One of the hypotheses might be that having experienced one episode of AOM 
predisposes to a higher risk of a second AOM episode, possibly by changed conditions in 
the middle ear cavity. Statistically, the child with a higher risk for AOM will benefit more 
of prevention by vaccination. Consequently, vaccination could have more impact in 
children with a history of recurrent AOM. This may even outweigh the fact that children 
with recurrent respiratory tract infections may be poor responders to some weak 
immunogenic pneumococcal serotypes included in the vaccine.12"11 The pneumococcal 
conjugate vaccine may overcome not only poor responses at infant age but also in toddlers 
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and older children who failed to respond to the T-cell independent polysaccharide 
vaccine.34·35 
With respect to the individual pneumococcal polysaccharides and prevention of AOM by 
that particular type, no clear distinction was observed between vaccine and non-vaccine 
serotypes after polysaccharide vaccination. However, a better protective effect against 
those serotypes with the highest IgG antibody response was observed in the study of 
Makela (1980)20 Protection against non-vaccine serotypes however, may be induced by 
cross-reactive antibodies. This was clearly shown in the Finnish study for serotypes 6A 
and 19A, after vaccination with the 7-valent pneumococcal conjugate vaccine including 
serotypes 6B and 19F.28 Noteworthy, in this same trial an increase in AOM episodes 
caused by non-vaccine pneumococcal serotypes without cross-reactive activity was 
observed. This indicates that a shift has occurred towards infection by non-vaccine 
pneumococcal serotypes that may have pathogenic potential and important clinical 
implications in the long term.28 For that reason it should be emphasized that the results of 
further studies on the effect of pneumococcal conjugate vaccination studies in infants and 
older children are required. Importantly, post-implementation studies are indicated 
because of this potential pathogenic replacement of non-vaccine pneumococcal serotypes, 
before wide-spread implementation of the pneumococcal conjugate vaccine for AOM. 
29,36,37 
The validity of the results of this systematic review may be questioned, mainly due to 
differences of the studies in AOM definition, inclusion criteria of the children, 
methodological study quality and due to publication bias. One important difference in 
studies is the definition of the clinical outcome AOM. In seven out of eleven studies, 
AOM is defined as having one or more acute symptoms of infection (e.g. fever, earache, 
otorrhoea, vomiting and diarrhea) in addition to the presence of fluid in the middle ear as 
verified by pneumatic otoscopy, tympanometry or myringotomy.20·21'2'"23,20'28 Two studies 
have used parental report to record the frequency of AOM,24·38 one study used 
computerized data on diagnoses registered by emergency physicians and pediatricians27 
and from one study it was unclear which definition was used.31 Although these differences 
in AOM diagnosis might explain variability in AOM rate per study, the double blind 
design of most studies should prevent reporting bias. Consequently, we believe that 
differences in AOM definitions would not invalidate the results of this systematic review. 
With respect to the inclusion criteria, only Rosen (1984)21 and Black (2000)27 excluded 
children known to be at risk for (recurrent) AOM, or to be likely to show a poor vaccine 
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response because of a known immunodeficiency disorder. Although exclusion of the study 
of Rosen (1984) in the overall analyses did not influence the results, we cannot predict 
whether these exclusion criteria will have positively or negatively influenced vaccine 
efficacy. Overall, the quality of the various studies was fairly comparable and excluding 
the study with the lowest quality score 20 did not influence the overall results. The Jadad 
method showed to be very sensitive to written information of the published manuscripts. 
Most studies lost 1 or 2 points, on a 5 point scale, because the method of randomisation 
was not described and/or information about withdrawals and dropouts was missing. 
Overall, the interpretation of the funnel-plot suggests a lack of publications on small sized 
studies that did not demonstrate any beneficial treatment effect of the pneumococcal 
polysaccharide vaccine. This may imply that the effect of pneumococcal polysaccharide 
vaccination on the prevention of AOM is overestimated in this review. However, the plot 
is only slightly asymmetric and therefore not very convincing. Consequently, it can be 
concluded that bias was insubstantial and the results of the vaccination effect against 
AOM described in this systematic review are valid.39 
Despite the limitations pointed out, and from the perspective of evidence based medicine 
at this moment, this is the best evidence available. Based on this systematic review, we 
cannot recommend large-scale pneumococcal vaccination to prevent otitis media in 
general. Results of ongoing trials should be awaited before making any recommendations 
about vaccination of specific high-risk (otitis prone) populations, like children attending 
day care or children with recurrent otitis media. 
This review is also available in the Cochrane Library (Issue 2, 2002). It will be regularly 
updated with new data and comments on the manuscript. 
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Abstract 
Objective To explore the effect of a pneumococcal conjugate vaccine on the risk of otitis 
media with effusion and to search for subgroups in which the vaccine had a higher or 
lower effect. 
Methods Analyses were performed on data from the Finnish Otitis Media Vaccine Trial, a 
randomised controlled double-blind Inai lo evaluate the efficacy of pneumococcal 
conjugate vaccination against acute otitis media. Data on the vaccination effect against 
otitis media with effusion were obtained by means of symptom interview and pneumatic 
otoscopy during pre-scheduled follow-up visits at the age of 7 and 24 months. Two 
endpoint definitions were consideied: otitis media/tube (otitis media or tympanostomy 
tube in situ) as the primary endpoint and otitis media with effusion as the secondary 
endpoint. No evidence was found of an age-dependent association with vaccination effect. 
Therefore, the final marginal logistic regression analyses were performed on the combined 
data from the two follow-up visits. 
Results The risk of otitis media tended to be lower in the pneumococcal vaccine group. 
The odds ratio for otitis media/tube was 0.94 (95% confidence interval 0.77-1.14) and the 
odds ratio for otitis media with effusion was 0.90 (95% confidence interval 0 69-1.19). 
Presence of older siblings increased the nsk of otitis media/tube and otitis media with 
effusion at 7 months of age In addition, it appeared that children without older siblings 
and attending day care at 24 months of age tended to benefit more from the pneumococcal 
conjugate vaccine. In this subgroup, the odds ratio for otitis media/tube was 0.81 (95% 
confidence interval 0.55-1.20) and for otitis media with effusion the odds ratio was 0 43 
(95% confidence interval 0.22-0.86). 
Conclusion The effect of pneumococcal conjugate vaccination on the risk of otitis media 
with effusion was concordant with the efficacy seen against acute otitis media, although 
not distinguishable from no effect in the overall analysis. In children without older 
siblings, vaccination appeared to reduce the point prevalence of otitis media with 
effusion; this effect was not apparent in children with older siblings. 
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Introduction 
Otitis media with effusion is characterised by accumulation of fluid in the middle ear in 
the absence of signs and symptoms of an acute infection.1,2 Otitis media with effusion, a 
common childhood disease, is highly prevalent in young children during the first seven 
years of life.3'* Diagnosis of otitis media with effusion is based on (pneumatic) otoscopy, 
tympanometry or a combination of these two methods. Wide variation exists in the 
reported prevalences of otitis media with effusion: rates around 5% to 10% have been 
detected in Finland3,6, versus 3 3 % in the Netherlands.' 
Eustachian lube dysfunction and the immunologic response to environmental pathogens 
are the two core elements in the development of otitis media with effusion. A bacterial or 
viral infection, or most commonly a combined infection, in the upper respiratory tract can 
lead to the development of effusion in the middle ear.8 The optimal treatment strategy 
remains controversial and there is wide international variability in clinical practice.9 
Long-term effects of recurrent episodes of otitis media, rapid emergence of drug-resistant 
respiratory tract bacteria worldwide and huge estimated direct and indirect annual costs 
associated with otitis media have emphasised the need for an effective vaccination 
programme to prevent otitis media. The recently licensed pneumococcal conjugate 
vaccine with polysaccharides conjugated to protein CRM197 (PncCRM) has shown 
excellent efficacy against invasive pneumococcal disease in young children.11 In two 
studies it has reduced acute otitis media episodes by 6-7%11, '2 However, the efficacy of 
pneumococcal conjugate vaccination against otitis media with effusion has not been 
addressed, although Streptococcus pneumoniae is one of the most prevalent bacteria found 
in effusion samples from children with otitis media with effusion.11 
As there is ongoing debate about the best vaccination strategy14, it is not clear whether the 
whole infant population should be vaccinated or high-risk groups only. Candidale high-
risk groups for otitis media with effusion are children with immature immune system (e.g. 
those born prematurely) or children with increased exposure to pathogens (e.g. those 
attending day care or having older siblings).'1"20 
The purpose of the current study was to assess the effect of PncCRM vaccine on otitis 
media with effusion in infants. Furthermore, we wanted to assess the impact of different 
factors on the vaccine effectiveness to find groups with the largest vaccination effect for 
otitis media with effusion. 
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Subjects and methods 
Study population 
The present analyses were performed on data from the Finnish Otitis Media (FinOM) 
Vaccine Trial, a randomised controlled double-blind trial conducted in the communities 
of Tampere, Kangasala and Nokia (Finland) between December 1995 and March 
1999. ,2The study was conducted according to provisions of the Declaration of Helsinki 
(as amended in Hong Kong, 1989). The study protocol was evaluated before the start of 
the trial by the ethics committee of the National Public Health Institute of Finland, by the 
National Agency for Medicines in Finland, and by relevant local health authorities (the 
ethics committee and the health board of Tampere, and the health boards of Kangasala 
and Nokia). The primary goal of the trial was to evaluate the efficacy of two heptavalent 
conjugate vaccines for preventing acute otitis media. The results of efficacy regarding 
acute otitis media and the safety of the PncCRM vaccine have been published 
elsewhere.12 
The criteria for enrolment were: (I) infants who attended their own child health care 
centre before the age of 13 weeks and were judged to be in good health; (II) the family 
was living permanently in the study area; (III) at least one of the parents/guardians was 
able to communicate fluently in Finnish. Exclusion criteria were: (I) hypersensitivity to 
the vaccines under study; (II) known or suspected impairment of immunologic function; 
(III) history of invasive pneumococcal disease; (IV) prior vaccination with pneumococcal 
vaccine or hepatitis Β vaccine; (V) contraindications to routine childhood immunisation; 
(VI) and any medical condition that in combination with the study procedures or 
vaccinations might cause health risk or endanger the well-being of the child. 
Written parental informed consent was obtained from all subjects at enrollment to the 
study at two months of age. Infants eligible for inclusion in the study were randomised by 
block randomisation after informed consent had been obtained. In total, 1662 children 
were randomised at two months of age to receive either the PncCRM vaccine (PncCRM 
group) or a Hepatitis Β vaccine (control group). The vaccine was administered at the age 
of approximately 2, 4, 6 and 12 months. The study was double-blind, neither the parents 
nor the study personnel knew which vaccine each child had received. 
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Follow-up 
The study children were followed from 2 to 24 months of age at study clinics established 
specifically for the purpose. Parents were instructed to visit the study clinic with their 
child whenever there were complaints suggestive of a respiratory infection or acute otitis 
media. 
In addition to the visits related to acute illness, all children made altogether 8 scheduled 
visits to the study clinic for vaccination, parental interview and laboratory samples as 
scheduled. At the 7 and 24-month visits, the study physicians assessed the middle ear 
status by means of tympanometry (GSI 38 Aulolymp; Grasonstadler, Milford, NH, USA) 
and pneumatic otoscopy (Welch Allyn 20200 Otoscope; Welch Allyn, Skaneateles Falls, 
NY, USA).21 At each scheduled visit, the parents were interviewed about potential risk 
factors for otitis media, including day care-attendance. As the focus of our analyses was 
on otitis media with effusion, which mostly goes unnoticed by the children and their 
parents, we only used data obtained at the pre-scheduled follow-up visits at the age of 7 
and 24 months, when full otological evaluation was performed. 
Definition of endpoints 
As the FinOM Vaccine Trial was not primarily focused on otitis media with effusion we 
employed two different endpoint definitions based on the results of symptom interview 
and pneumatic otoscopy (Figure 1). 
The endpoint Otitis Media with Effusion (OME) encompasses the presence of middle ear 
effusion visualised by pneumatic otoscopy in the absence of signs and symptoms of an 
acute infection as assessed by the study physicians of the FinOM Vaccine trial. Regarding 
the endpoint OME, children with tympanostomy tubes in situ were considered as not 
having OME if no effusion was visualized at the scheduled visit. Also, children with AOM 
were considered not having OME, because these children were not free of symptoms. 
However, the distinction between AOM and OME may occasionally be subtle, although 
uniform criteria to define children with acute otitis media were used in the FinOM 
Vaccine trial.12 
Because of a possible interference of the presence of tympanostomy lubes with the 
endpoint OME and because of the difficulties in making distinction between AOM and 
OME, we decided to use a broader category of middle ear disease as the primary endpoint 
in our analyses. This endpoint Otitis Media/Tube (OM/T) encompasses the presence of 
any otitis media, i.e. OME and AOM, and the presence of an tympanostomy tube in situ. 
91 
CIl.MTKR 4.3 
Otitis media was defined as the presence of effusion visualized by pneumatic otoscopy 
(abnormal finding regarding colour, position and/or mobility of the tympanic membrane) 
with or without signs and symptoms of an acute infection, thus including acute otitis 
media. A child was considered to have the endpoint of interest when its criteria were 
established in at least one ear at the scheduled visit. 
Statistical analyses 
All analyses were performed according to the intention to treat principle, separately for 
both endpoints. To adjust for potential confounders in the estimation of the vaccination 
effect on the prevalence of an endpoint and to identify possible effect modifiers 
(interactions), logistic regression models were constructed. In addition to the vaccination 
status, the following explanatory variables (subgroups) were considered, based on 
dichotomization of available data on risk factors: gestational age (< 37 or > = 37 weeks), 
birth weight (<2500 g or > = 2500 g), presence of older siblings (yes/no), and attending 
day care outside the home at the scheduled 7 and 24- month visits (yes/no). 
Multiple logistic regression models were first constructed to estimate the vaccination 
effect separately at each of the two scheduled visits. Interaction terms with vaccination 
status were added to the multivariate model to see whether the effect of vaccination was 
modified in any of the subgroups. 
As there was no evidence of interaction between vaccination status and visit (7 or 24 
months), the effects of vaccination status and subgroups on the average outcome of the 
two visits were next considered in multiple marginal logistic regression. Associations 
between the two observations in each child were specified according to a marginal (log) 
odds ratio. Interaction terms with vaccination status and subgroups were added to the 
model to see whether vaccination had a different effect in any of the subgroups. The 
generalised estimating equation (GEE) with alternating logistic regression implementation 
(ALR) was used to estimate the regression and association parameters. All analyses were 
performed with the Statistical Analysis Systems (SAS version 8.1). 
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Figure 1 . Definitions of the two endpoints: otitis media/tube (OM/T) and otitis media with 
effusion (OME) 
Results 
Study population 
At enrolment, 1662 children were randomised lo receive either the PncCRM vaccine 
(N=831) or the Hepatitis Β vaccine (N=831). Follow-up compliance was excellent: 9 9 % 
and 9 6 % of the participants attended the scheduled visits at 7 months and 24 months, 
respectively. A total of 30 children dropped-out of pneumococcal and control groups, most 
commonly due to migration out of the study area, or withdrawal of consent; thus 801 
children remained in each of the two groups at the 24-month visit. 
All the children who attended the 7-month and/or 24-month visits were included in the 
analyses, irrespective of the number of vaccinations they received. The mean age of the 
children at the 7- month visit was 6.8 months (range 5.6 to 9.7) and at the 24-month visit 
23.9 months (range 21.5 to 25.7). As expected after a successful randomisation, there 
were no noticeable differences between the PncCRM group and the control group with 
respect to the distribution of risk factors for otitis media (Table 1). Furthermore, the 
proportion of children with tubes in at least one ear was highly comparable. Less than 1% 
of the children had tubes in situ at the 7-month visit. At the 24-month visit these 
proportions were higher, being 17% in both groups. 
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Table 1 . Subject characteristics and distr ibution of potential risk factors for otit is media 
PncCRM group (N = 831) Control group (N = 831) 
Male sex 
Premature birth (<37 weeks) 
Low birth weight (<2500 g) 
Having older siblings * 
Attending day care outside home 
At 7 mo t 
At 24 mo t 
52% 
5% 
3% 
5 1 % 
0% 
4 1 % 
52% 
6% 
5% 
50% 
0.4% 
41% 
1 missing value in the control group, t 17 missing values, t 65 missing values The missing values were 
equally distributed in both groups 
Otitis Media with Effusion (OME) 
Al the 7-nionlh visil, ihe prevalence of otitis media with effusion (endpoint OME) in ihe 
PncCRM group (7.3%) was slightly lower lhan that in the control group (8.4%); overall, 
the prevalence was higher at ihe 7-month visit than at the 24-month visit (Table 2). 
Table 2. Proportion of infants w i th otit is media w i th effusion (OME) and otitis media or 
tympanostomy tube in situ (OM/T) at the 7 and 24-month visits. 
7-month visit 24-month visit 
PncCRM group Control group PncCRM group Control group 
(N = 824) (N = 823) (N = 801) (N = 801) 
OME 7 .3% 8 4 % 6 . 1 % 6 . 1 % 
OM/T 1 3 . 2 % 12 6 % 2 5 . 2 % 2 7 . 2 % 
The odds ratiot. for OME in the PncCRM group as compared to the control group at the 7-
monlh visil and the 24-month visit were 0.84 (95% CI: 0.58-1.21) and 1.00 (95% CI: 
0.66-1.51), respectively (Table 3). At ihe age of 7 months, only the presence of older 
siblings was associated with a higher risk of OME (OR 2.47, 95% CI: 1.67-3.64). 
Children allending day care at 24 months of age had a higher risk of OME al ihe 24-
month visit than children not attending day care (OR 1.61, 9 5 % CI: 1.07-2.43). Children 
with older siblings did nol have an increased risk of OME at 24 months of age compared 
to children without older siblings (OR 0.86, 9 5 % CI: 0.57-1.30), but the interaction 
between the vaccine status and ihe presence of older siblings turned oui to be statistically 
significanl (p value: 0.01) indicating that the effect of the vaccine might be dependent on 
the existence of older siblings. Indeed, the OR for the vaccine effecl on the prevalence of 
OME al the age of 24 monlhs was 1.79 (95% CI: 0.96-3.35; Table 3) in the children with 
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older siblings, whereas the corresponding OR was 0.61 (95% CI: 0.34-1.08) in the 
children without older siblings. Although the interaction between vaccination and the 
presence of older siblings was not statistically significant at the 7-month visit, the data 
showed this same trend, favouring the beneficial effect of the PncCRM vaccine against 
OME in children without older siblings, already at 7 months of age (OR 0.56, 9 5 % CI: 
0.28-1.09; Table 3.) 
An almost statistically significant interaction term between attending day care al the 24-
month of visit and vaccination suggested that children without older siblings and 
attending day care at 24 months of age might benefit most from PncCRM vaccination (OR 
0.43, 9 5 % CI: 0.22-0.86; Table 3). 
There was no evidence of differences in the effects on the prevalence of any of both 
endpoints between the 7-month visit and 24-month visit. Therefore, to use ihe data more 
efficiently, a model was constructed using information from both visits, taking into 
consideration that the observations within subjects were dependent. The results of this 
combined model concern average effects of PncCRM vaccination on the prevalence of 
OME at 7 and 24 months of age (Table 4). Statistically significant interactions between 
vaccine status and the presence of older siblings (p value: 0.01) indicated a difference in 
vaccination effect between this subgroup. Table 4 shows the results of the multiple 
marginal logistic model when the interaction between siblings and vaccination was 
included. PncCRM vaccination was effective against OME in the group of children 
without older siblings (OR 0.58, 95% CI: 0.38-0.91, Table 4). The proportion of children 
with OME in this subgroup was 4 .3% in the PncCRM group and 7 .1% in the control 
group. 
Otitis Media or Tube (OM/T) 
The difference in the prevalence of Otitis Media/Tube (endpoint OM/T) between the 
PncCRM and control groups at the 7- month visit was again very small: 13.2% in the 
PncCRM group and 12.6% in the control group (OR 1.04, 9 5 % CI: 0.77-1.39; Tables 2 
and 3). At 24 months of age the proportion of children with OM/T was considerably higher 
than at 7 months of age due to a larger number of children with tympanostomy lubes. The 
effect of PncCRM vaccination at ihe 24-month visit was only slightly more prominent: a 
difference of 2.0% in prevalence was found, in favour of the effect of the PncCRM 
vaccine (OR 0.89, 9 5 % CI: 0.71-1.12). An increased risk of OM/T al the 24-month visit 
was found in ihe subgroup of children attending day care (OR 2.30, 9 5 % CI: 1.83-2.89, 
Table 3) at the age of 24 monlhs. 
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The average pneumococcal vaccine effect on OM/T showed an OR of 0.94 (95% CI: 0.77-
1.14, Table 4). Although there was no statistically significant evidence of a difference in 
vaccination effect on OM/T within the subgroups with or without older siblings, data were 
in concordance with the enclpoint OME. The OR for OM/T in the group of children 
without older siblings was 0.81 (95% CI: 0.61-1.09; Table 4). The proportion of children 
with OM/T in this subgroup was 13.7% in the PncCRM group versus 16.3% in the control 
group. 
Table 3. Results of mult iple logistic regression models of the effect of the PncCRM vaccination 
and potential risk factors on the prevalence of OME and OM/T at the 7-month visit and the 2 4 -
month visits 
OR OME ( 9 5 % C I ) * OR OM/T ( 9 5 % CI)* 
7-month visit 
Having received PncCRM,t 0 . 8 4 ( 0 . 5 8 - 1 . 2 1 ) 1 . 0 4 ( 0 . 7 7 - 1 . 3 9 ) 
Having older s ib lmgst 2.47 (1.67-3.64) 2.87 (2.09-3.95) 
Premature b i r t h t 0 . 7 9 ( 0 . 2 3 - 2 . 1 6 ) 1 . 1 9 ( 0 . 5 8 - 2 . 4 6 ) 
Low birth w e i g h t t 0 . 7 8 ( 0 . 2 3 - 2 . 6 1 ) 0 . 6 2 ( 0 24-1.61) 
Having received PncCRM, no older siblings 0 . 5 6 (0.28-1.09) 0 . 7 6 (0.45-1.29) 
Having received PncCRM, having older 1.01 (0.65-1.56) 1 . 1 9 ( 0 . 8 4 - 1 . 6 9 ) 
siblings 
Ρ value, interaction of vaccine and siblings 0.14 0.17 
24- month visit 
Having received PncCRMt 1 . 0 0 ( 0 . 6 6 - 1 . 5 1 ) 0 . 8 9 ( 0 . 7 1 - 1 . 1 2 ) 
Having older s ibl ingst 
Attending day c a r e t 
Premature b i r t h t 
Low birth w e i g h t t 
Having received PncCRM, no older siblings 
Having received PncCRM, having older 
siblings 
Ρ value, interaction of vaccine and siblings 
Having received PncCRM, no older siblings, 
attending day care 
Ρ value, interaction of vaccine and siblings 
Ρ value, interaction of vaccine and day care 
* Odds ratios (OR) and 95% confidence intervals (95% CI) 
t The effect is estimated from a multiple logistic regression model without interaction 
0.86 (0.57-1.30) 
1.61 (1.07-2.43) 
0.30 (0.06-1.43) 
1.44 (0.38-5.41) 
0.61 (0.34-1.08) 
1.79 (0.96-3.35) 
0.01 
0.43 (0.22-0.86) 
0.02 
0.07 
1.47 (1.17-1.85) 
2.30 (1.83-2.89) 
0.86 (0.47-1.57) 
0.99 (0.49-1.99) 
0.82 (0.59-1.15) 
0.95 (0.70-1.30) 
0.53 
0.81 (0.55-1.20) 
0.54 
0.88 
9 6 
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Table 4. Results of multiple logistic regression models of the average effect of the PncCRM 
vaccination on the prevalence of OME and OM/T 
OR OME ( 9 5 % CI) » OR OM/T ( 9 5 % CI) ~ 
Having received PncCRM t 0 . 9 0 ( 0 . 6 9 - 1 . 1 9 ) 0 . 9 4 ( 0 . 7 7 - 1 . 1 4 ) 
Having received PncCRM, no older siblings 0.58 (0.38-0.91) 0.81 (0.61-1.09) 
Having received PncCRM, having older 1.22 (0.84-1.76) 1.04 (0.79-1.39) 
siblings 
Ρ value, interaction of vaccine and siblings 0.01 0.21 
* Odds ratios (OR) and 95% confidence intervals (95% CI). 
t The effect is estimated from the multiple marginal logistic regression model without interaction 
Discussion 
This study showed that overall, the PncCRM vaccine did not appear to affect the 
prevalence of either of the two endpoints that represent otitis media with effusion. The 
overall vaccination effect on otitis media with effusion was concordant with the efficacy 
results for acute otitis media found in the Northern California Kaiser trial and the FinOM 
Vaccine trial." , 2 Both trials used the same pneumococcal conjugate vaccine. The 
Northern California Kaiser trial showed a 9% reduction in visits due to clinically 
identifiable otitis media in the per protocol analyses and the FinOM Vaccine trial showed 
a 6% reduction in clinical acute otitis media episodes.11 u Although the FinOM study was 
not designed to study otitis media with effusion or to detect differences at individual point 
prevalences or to conduct subgroup analyses, we do believe that this study provided 
valuable data to explore the effect of pneumococcal vaccination on the prevention of otitis 
media with effusion. 
In a more detailed evaluation, the PncCRM vaccine appeared to reduce the average risk 
of having OME at 7 and 24 months of age in a subgroup of children who where likely to 
have been spared from exposure to infections during the first months of life, i.e. children 
without older siblings. In the children with older siblings, these effects were absent. 
The trial protocol advised an active treatment policy, including placement of 
tympanostomy tubes for recurrent acute otitis media or prolonged otitis media with 
effusion. Although children with tubes represent the group with the highest risk of otitis 
media, epidemiologic studies usually only consider the children with otorrhea through a 
tympanostomy tube as having middle ear effusion.18'23 Because patent tympanostomy 
tubes in situ are likely to reduce the risk of middle ear effusion, considering children with 
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patent tubes as not having OME may have biased the association between PncCRM 
vaccination and the prevalence of otitis media with effusion in this population. 
However, the bias in the estimate of the vaccination effect on OME is probably small, 
because the percentages of children with tubes were similar in the PncCRM group and 
the control group. In this study, the placement of tubes was also associated with the 
presence of older siblings and attendance of day care at 24 months of age. Consequently, 
diagnostic bias could have influenced the vaccination effect in these subgroups regarding 
the endpoint OME. 
The endpoint OM/T is less susceptible to bias and should therefore be considered as ihe 
primary endpoint in the present study. The vaccination effect on OM/T was less 
pronounced in the subgroup of children without older siblings compared to the 
vaccination effect on the endpoint OME, but the trend was similar with this endpoint. We 
do feel that the consistent trend seen with the endpoints OME and OM/T supports the 
conclusion that the vaccine may have afforded protection against otitis media with 
effusion in children without older siblings. 
We find it interesting that, as far as the risk of OME at 24 months of age is concerned, the 
subgroup of children who had no older siblings but who where attending day care seemed 
to benefit most from the PncCRM vaccine. In Finland, practically all infants are cared for 
at home up to 9-12 months of age, thanks to long maternity leaves with governmental 
subsidiary system. The vaccine showed beneficial effect on the prevalence of OME at the 
24-month visit in children without older siblings whose exposure to infections had 
probably increased at or after 12 months of age when they entered day care. This finding 
suggests that the effect of the vaccine may depend on timing of exposure. Infants with 
early exposure to infections (e.g. those with older siblings) are not protected against this 
condition, whereas those with later exposure (e.g. those with no siblings but potentially 
starting day care around 12 months of age) seem to benefit. In fact, infants with early 
exposure to infections may already have developed otitis media with effusion or al least 
predisposition to this illness, when the vaccine reaches its full effect at 6 to 7 months of 
age. Although this hypothesis is not convincingly supported by the results obtained with 
the primary endpoint OM/T, we believe that the relation between timing of vaccination 
and major exposure to infections deserves attention in further studies. 
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Conclusion 
This study was the first to show a trend towards a different effect of the PncCRM vaccine 
on otitis media with effusion within subgroups of children with and without older siblings. 
We recommend that investigators in ongoing studies also focus attention on these 
subgroups in order to provide data for decision-making between different vaccination 
policies against Streptococcus pneumoniae. 
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CHAPTER 5.1 
Summary 
Objective To study the association between birth characteristics and the recurrence of 
otitis media with effusion. 
Methods Prospective cohort study on 136 children aged 2-7 years, who received 
tympanostomy tubes for bilateral otitis media with effusion. Check-ups were planned one 
week after tube insertion and once every three months thereafter. An otologist examined 
the ear status to assess tube extrusion and otitis media with effusion recurrence. Outcome 
measure was the recurrence of otitis media with effusion within 6 months after 
documentation of spontaneous tube extrusion. Birth characteristics were investigated in 
relation with the recurrence of otitis media with effusion in 90 children with known 
clinical outcome. 
Results No statistically significant associations were found between various birth 
characteristics and the recurrence of otitis media with effusion. Multivariate analyses 
showed positive but fairly weak associations between recurrence of otitis media with 
effusion and low birth weight (< 2500 g) and/or low gestational age (< 37 weeks) and/or 
a history of incubator care (OR 1.95, 9 5 % CI: 0.21-18.2), male sex (OR 1.85, 95% CI: 
0.56-6.13) and maternal medication use during pregnancy (OR 4.80, 95% CI: 0.57-
40.72). A remarkable finding was the asymmetrical distribution of certain birth 
characteristics within the group of children with recurrence of otitis media with effusion: 
children with unilateral recurrence had a relatively lower gestational age, lower birth 
weight, lower 'birth length to birth weight' ratio than the children with bilateral 
recurrence. 
Conclusion These findings suggest that determination of birth characteristics cannot help 
us in the treatment strategy for recurrent otitis media with effusion in childhood. 
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Introduction 
Otitis media with effusion (OME) is a highly prevalent, multifaclorial-generated disease 
in childhood, with peak prevalences in the first to fourth years of life.1"3 At least 80% 
infants will have experienced one or more episodes of OME before their first birthday. * J 
Owing to the high prevalence rate and the self-limiting nature, OME appears to be a 
physiological disorder during childhood.1'3 Nevertheless, several studies have shown that 
persistent and/or recurrent OME in childhood may have detrimental effects on hearing, 
behaviour and speech or language development. Thus OME is a topic for concern, which 
requires prevention and treatment.6'9 Early identification of groups with a high risk of 
recurrent OME would enable care providers to apply efficient treatment policies. Besides 
well-known risk factors associated with an increased risk for the development of recurrent 
or persistent OME, such as the onset of otitis media at an early age, bilateral OME, day 
care attendance and the presence of siblings,4 ' 0 " H certain birth characteristics may be 
associated with an increased risk of developing recurrent OME. 
Eustachian tube (ET) dysfunction and the inflammatory response to viruses and bacteria 
that enter the middle ear are considered to be core elements in the development of 
OME. 0 ' Some birth characteristics are likely to impair the immune system, or ET 
function, or both, and thus contribute to a higher risk of developing OME. Several 
hypotheses have been put forward on the association between birth characteristics and the 
recurrence of OME. First, babies bom prematurely start with lower levels of maternal IgC 
and reach immune competence later than their full-term counterparts,1 8 2 ' which increases 
their susceptibility to upper respiratory tract infections. Second, the ET of babies bom 
prematurely may be underdeveloped, both anatomically and physiologically, which may 
increase the risk of middle ear infection. Third, nasogastric, nasotracheal or 
nasopharyngeal tubes used during incubator care may lead to ET dysfunction and/or 
increased infection risk.22 
Several studies have investigated the role of birth characteristics in the prevalence of 
OME. Children who were bom very prematurely ( < 33 weeks) or with very low birth 
weight (< 1500 g) had a higher prevalence of OME up to 24 months of age than their full-
term counterparts.1 In an earlier study on a group of infants who had received care at the 
Neonatal Intensive Care Unit (NICU), we have shown that the factors small for gestational 
age, impaired neuromotor function and naso-tubes for ventilatory assistance were 
positively associated with persistent and recurrent OME during two year follow-up.22 It 
remains to be investigated whether this increased risk persists with increasing age. 
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In a cross-seclional study on a population of 2069 healthy children aged 2.5 lo 6 years, 
Van Cauwenberge et al. showed lhat low birth weight ( < 2400 g) and a skull 
circumference of below the 2.5'h percentile were significantly associated with a high 
prevalence of OME.2 1 Clark et al.2 1 investigated the association between certain fetal 
growth patterns and recurrent or persistent OME in a case-conlrol study. They showed 
lhat children who were referred for tympanostomy tube insertion or had been referred for 
this treatment on a previous occasion, had a lower ratio of 'head circumference to total 
length at birth' and a lower ponderai index at birth than the children who had been 
admilled for tonsillectomy and/or adenoidectomy. These findings need to be confirmed in 
studies wilh better classification of the oulcome, i.e. recurrence or persistence of OME. 
The aim of the present study was to investigate possible relations between certain birth 
characteristics and the occurrence of recurrent OME during childhood. A prospective 
cohort study was designed on children who were followed-up after ihe spontaneous 
extrusion of bilateral tympanostomy lubes. Our study design enabled other risk factors for 
OME to be taken into consideration as polential confounders. 
Subjects and methods 
Study population 
In the Netherlands, nearly all patients with OME are first seen by a general practitioner 
(GP). According to the guidelines of the Dulch College of General Praclitioners, children 
with chronic OME should only be referred lo an otologist after repeated observations of 
middle ear effusion over a period of at least three months. Children aged between Iwo and 
seven years whose firsl clinical episode of bilateral OME had persisted for at leasl ihree 
months and who had been referred by iheir GP lo one of ihe three participating hospitals 
in Nijmegen and Winterswijk (the Netherlands) between December 1999 and March 
2002 were eligible to participate in this prospective cohort study. Children with Down's 
syndrome, cleft palate, or daily treatment with inhalation or topical corticosteroids for at 
least one month per year were excluded from our study, as well as children with proven 
immunodeficiency or previous adenoidectomy. The Medical Ethical Commitlee of the 
referral hospitals approved the study protocol. Signed informed consent was obtained from 
the parents or legal guardians. Al study entry, all the children received bilateral 
tympanostomy lubes under general anaesthesia. To study ihe recurrence of OME, an 
otologist examined the ear status of each child al the three-monthly check-ups. 
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Outcome 
The date of the first check-up at which tube extrusion was observed (per ear) was taken as 
the start of the follow-up period for OME recurrence. The outcome of interest was OME 
recurrence within the first six months of this follow-up period. OME was defined in 
accordance with an algorithm, which is primarily based on tympanometry.' The 
tympanograms were classified according to Jerger.2 0 OME was considered to be present 
when tympanometry resulted in a type Β lympanogram or a type C2 tympanogram in 
combination with otoscopie findings that suggested the presence of effusion in the middle 
ear and the absence of an acute ear infection. If tympanometry (Rexton Danplex TYMP 87 
A/S Copenhagen, Denmark) could not be performed, otoscopie findings that suggested the 
presence of effusion in the middle ear were used to diagnose OME. Below, children who 
developed unilateral or bilateral OME recurrence are referred to as belonging to as 
yes_rOME; children who remained effusion-free during the follow-up period of six months 
per ear, are referred to as no_rOME. 
Birth characteristics 
In this study, features and events associated with birth and pregnancy were defined as 
birth characteristics. Using a questionnaire, information was collected about the following 
birth characteristics: gender, gestational age, birth weight, birth length, craniofacial 
circumference at birth, meconium stained amniotic fluid, incubator care with or without 
artificial ventilation or nasogastric tubes for feeding. Information was also obtained about 
pregnancy characteristics: whether the mother had smoked during the pregnancy or used 
medication and her age at the time of the birth of this child. 
The 'birth weight to birth length ratio' and the 'craniofacial circumference to birth length 
ratio' were calculated. Children with a gestational age of under 37 weeks, a birth weight of 
less than 2500 grams and/or a history of incubator care (with or without nasogastric tube 
or artificial ventilation), were categorised into the summary variable 'LBW-incubator-
neonates'. 
Other risk factors 
The questionnaire also collected information about other potential risk factors for OME 
recurrence that may confound the association between birth characteristics and OME 
recurrence. These were: the age of the child at study entry and at the start of the follow-up 
period, breast-feeding, presence of siblings, attending day care at study entry, breathing 
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habits e g mouth breathing, snonng and sniffing, family members with a history of otitis 
media (OM), exposure to passive smoking at home and socio-economic status (SES) The 
latter was based on the net year income per household (in Euros) 
Statistical analyses 
The Chi-square test or Fisher's exact lest was used to compare the distribution of birth 
chdracteristics in the yes_rOME and no_rOME groups Odds ratios (OR) with 
corresponding 9 5 % confidence intervals (CI) were calculated to test the association 
between birth characteristics and OME recurrence If univariate logistic regression 
analyses showed an association between birth characteristics or possible confounders and 
OME recurrence, only those variables that showed an association with an OR of larger 
than two for dichotomous variables oi with a ρ value of < 0 20 for continuous vanables 
were selected for multivariate logistic regression l· actors that affected the association 
between birth characteristics and OME recuirence were maintained in the final model 
All the analyses were performed with the Statistical Analysis Systems (SAS version 8 0) 
Results 
A total of 136 out of the 186 eligible children participated in our study The median age 
of the children at study entry was 5 3 years (range 2 1 years to 7 5 years) Tympanostomy 
tubes were found to have been extruded at between 3 and 27 months aftei insertion 
At the end of the study (August 2003) 90 children had completed the follow-up period, 
while 15 children were lost to follow-up, mostly owing to practical problems In the group 
of 90 children with complete follow-up, the OME recuirence rate was high bilateral OME 
recurrence occurred in 56 (62%) children, unilateral OME occurred in 17 (19%) children 
and only 17 (19%) children did not develop recunenl OME With a few exceptions, the 
children with and without OME recurrence were comparable with respect to potential risk 
factors for OME recurrence (Table 1) Potential confounders that showed an association 
with OME recurrence were snoring (OR 2 5), sniffing (OR 3 9), paternal history of OM 
(OR 5 1) and exposure to smoking at home (OR 2 6) 
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Yes rOME 
Ν = 73 * 
5.1 [2 4-7.5] 
6.1 [3.4-8.9] 
28 (38) 
36 (49) 
40 (55) 
23 (32) 
14(19) 
31 (46) t 
25 (35) 
15 (21) 
19 (27) 
13 (19) 
28 (41) 
20 (29) 
5 (7) 
42 (65) t 
26 (36) 
14 (23) t 
No rOME 
N = 17 * 
5.3 [2.7-7.2] 
6.3 [3.6-9.1] 
5 (29) 
8 (47) 
11 (65) 
5 (29) 
3(18) 
9 (53) 
3 (18) 
1 (6) 
1 (7) t 
4 (27) Τ 
6 (38) 
4(25) 
2 (13) 
7 (50) t 
3 (17) 
4(25) t 
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Table 1 . Distr ibution of potential risk factors in children w i t h and w i t h o u t OME recurrence 
Mean age at study entry in years [range] 
Mean age at start of fol low-up in years [range] 
Breast-feeding > 4 months (%) 
Older siblings present (%) 
Younger siblings present (%) 
> 1 sibling present (%) 
Attending day-care at study entry (%) 
Mouth breathing (%) 
Snoring (%) 
Sniffing (%) 
Paternal history of otit is media (%) 
Maternal history of otit is media (%) 
Siblings w i t h history of acute otit is media (%) 
Siblings w i t h history of OME/tubes (%) 
Siblings w i t h history of chronic otit is media (%) 
Family members w i t h history of otit is media (%) 
Exposure to smoking at home (%) 
SES < Euro's 2 0 , 0 0 0 (%)§ 
* Values are numbers (%) unless stated otherwise 
t 6-12% of subjects had missing data on this variable 
1 15-18% of subjects had missing data on this variable 
§ SES = socio-economic status 
No statistically significant associations were found in the univariate analyses between any 
of the birth characteristics and OME recurrence. The strongest associations (OR > 2) 
were present for male sex, 'LBW-incubalor-neonates' and maternal medication use during 
pregnancy (Table 2). In addition, the 'cranioiacial circumference to birth length' ratio 
tended to be positively associated with OME recurrence with a mean difference of 3.1 
(95% CI: -0.7 to 6.9). Data on this ratio were only available in 34 children, so this 
variable was not included in the multivariate analyses. The multivariate analyses showed 
thai exposure to smoking at home was the sole factor that confounded the association 
between birth characteristics and OME recurrence. After adjustment for the effect of 
exposure to smoking at home on OME recurrence, positive but non- significant, 
associations remained in the multivariate analyses for the effect of 'LBW-incubator-
neonates' (OR 1.95, 9 5 % CI: 0.21-18.20), maternal medication use during pregnancy 
(OR 4.80, 9 5 % CI: 0.57-40.72) and male sex (OR 1.85, 9 5 % CI: 0.56-6.13). 
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Table 2. Univariate analyses on birth characteristics in children w i t h and w i t h o u t OME recurrence 
Child-related characteristics 
Mean birth weight in grams [range] 
Mean birth length in cm [range] 
Mean cranofacial circumference in cm [range] 
Mean 'birth weight to birth length ratio' [range] 
Mean 'craniofacial circumference 
to birth length ratio' [range] 
Gender, boys (%) 
Born with meconium-stamed amniotic fluid (%) 
'LBW-incubator-neonate' score yes n (%) 
Gestational age < 37 weeks (%) 
Low birth weight (%) 
Incubator (%) 
Artificial ventilation (%) 
Nasogastric tube (%) 
Pregnancy-related characteristics 
Mean maternal age at childbirth in years [range] 30.3 (21.0-42.1 
Smoking during pregnancy, yes (%) 
Medication use during pregnancy, yes (%) 
* Values are numbers (%) unless stated otherwise 
t Mean difference and 95% confidence intervals (CI) 
t Odds ratios (OR) and 95% confidence intervals (CI) 
§ 11 % of subjects had missing data on this variable 
li A child was assigned a positive score on this variable when at least one of the following variables was 
present gestational age of under 37 weeks, birth weight lower than 2500 g, incubator care and/or 
treated with artificial feeding or ventilation tubes in postnatal period 
Yes rOME 
N = 7 3 ( % ) * 
3458 [1690-5200] 
50.5 [45-56] 
36.4 [32.5-41.0] 
69 1 [42.6-104] 
71.4 166.0-79.0] 
40 (55) 
12 (18) § 
10 (14) 
4(5) 
5 (7) 
8(11) 
1 (1) 
2 (3) 
(21.0-42.1) 
13 (18) 
15 (21) 
No rOME 
N = 17 (%) * 
3660 [2600-5010] 
51 0(48-58] 
35.4(33.0-37 0] 
71.6 [54 2-89 8] 
68.3 162 9-77 1] 
6 (35) 
3 (19) 
1 (6) 
0 ( 0 ) 
0 ( 0 ) 
1 (6) 
0 ( 0 ) 
0 ( 0 ) 
30 2 (25.0-37.8) 
3 (19) 
1 (6) 
Difference 
(95% CI) t 
-202 (-542 to 139) 
-0.47 (-1.6 to 0.7) 
-0.99 (-0 8 to 2.7) 
-2 5 (-8.3 to 3.4) 
3 1 (-0 7 to 6 9) 
OR (95% CD* 
2.22 (0.74 to 6.65) 
0.98 (0 24 to 3.99) 
2.46 (0.92 to20.72) 
Not estimable 
Not estimable 
1.91 (0 22-16.41) 
Not estimable 
Not estimable 
Difference 
(95% CI) t 
0.1 (-2.3 to 2.4) 
OR (95% c m 
0.97 (0 24 to 3 91) 
3.82 (0 46 to 31.42) 
The distribution of certain birth characteristics was asymmelrical in the different 
categories of OME recurrence. The proportion of children with a geslalional age of < 37 
weeks, birth weight of < 2500 grams and 'LBW-incubator-neonates' was significantly 
higher in the group of children with unilateral OME recurrence than in the children with 
bilateral OME recurrence. Birth weight, birth length and ihe 'birth weight to birlh length' 
ratio were significantly lower in the group of children with unilateral OME recurrence 
than in the children with bilateral OME recurrence (Table 3). Children who developed 
unilateral OME recurrence were on average 0.8 years (95% CI: 0.1 —1.6) older al the 
start of the follow-up period than the children who developed bilateral OME recurrence. 
As gestational age, birlh weight, birth length and consequently the 'birth weight to birth 
length ratio' were highly correlated, our further analyses focused on the association 
between OME recurrence and the variable 'LBW-incubator-neonate'. In the group of 
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children with OME recurrence, the 'LBW-incubator-neonates' were more likely to 
develop unilateral OME recurrence than bilateral OME recurrence (OR 5.28, 9 5 % CI 
1.21-23.10) after adjustment for age at the start of the follow-up period. 
Table 3. Univariate analyses on age and birth characteristics in children w i t h unilateral and 
bilateral OME recurrence 
Mean age at study entry in years [range] 
Mean age at start of follow-up in years [range] 
Mean birth weight in grams [range] 
Mean birth length in cm [range] 
Mean 'birth weight to birth length' ratio [range] 5 
Gestational age < 37 weeks (%) 
Low birth weight < 2500 grams (%) 
Incubator (%) 
Artificial ventilation (%) 
Nasogastric tube (%) 
'LBW-mcubator-neonate' n (%) 
Uni rOME 
N = 17 * 
5.5 (2.4-7.5) 
6 8 (3.4-8 9) 
2952(1690-4500) 
49 5 (45.0-52 0) 
60 2 (42.6-88 2) 
3 (18) 
5 (29) 
4(24) 
1 (6) 
1 (6) 
35 
Bil rOME 
Ν = 56 * 
5.0(2.8-7.2) 
6.0 (3 5-8 3) 
3615 (2575-5200) 
50.8 (47.0-56 0) 
71.4 (52.6-104) 
1 (2) 
0 
4(7) 
0(0) 
1 (2) 
7 
Difference 
95% CI t 
0.6 (-0.1 to 1.3) 
0 8 (0.1 to 1.6) 
-663 (-972 to - 354) 
-1.2 (-2 4 t o - 0 1) 
-11 3 (-17 3 to -5.3) 
OR (95% c u t 
11 79 (1.14 to 122.1) 
Not estimable 
3 85 (0.58 to 17.49) 
Not estimable 
3 31 (0 20-56 0) 
6 82 (1 64 to 28.31) 
* Values are numbers (%) unless stated otherwise 
t Mean difference and 95% confidence intervals (CI) 
t Odds ratios (OR) and 95% confidence intervals (CI) 
§ 9-24% of subjects had missing data on this variable 
M A child was assigned a positive score on this variable when at least one of the following variables was 
present: gestational age of under 37 weeks, birth weight of lower than 2500 g, incubator care and/or 
treated with artificial feeding or ventilation tubes in postnatal period 
Discussion 
In our prospective cohort of children whose first clinical episode of OME had persisted for 
at least three months and who had been followed-up for OME recurrence after initial 
treatment, no strong and consistent associations could be demonstrated between any of 
the birth characteristics and OME recurrence. As the number of children with known 
clinical outcome was fairly small (n=90) and only 17 (19%) of these children remained 
effusion-free during the follow-up period, we had to focus the analyses on birth 
characteristics that had the strongest association with OME recurrence. Initially, our 
analyses showed a positive association between male sex, 'LBW-incubator-neonates', 
maternal medication use during pregnancy and OME recurrence. However, after 
adjustment for potential confounding factors, these associations disappeared. A 
retrospective study by Stenström et al. on children aged 3 to 7 years also failed to show 
any significant associations between premature birth (< 37 weeks), low birth weight (< 
2500 g) and proneness to otitis media.26 Daly et al. were also unable to demonstrate any 
significant associations between premature birth (< 37 weeks), neonatal breathing 
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assistance, head circumference of < 25 lh percentile, low birth weight and early otitis 
media onset ( < 6 months of age) in a prospective study.2' Albo et al. followed 2512 
children prospectively from before birth to the age of two years and detected only weak 
associations between low birth weight (< 2500 g) and more than two episodes of OME 
recurrence. 
Although, the 'craniofacial circumference to birth length' ratio was only known in 34 
children, the mean difference in ratio unit (3.1, 9 5 % CI:-0.7 to 6.9) was intriguing, 
because it suggests that disproportionate growth (e.g. small birth length relative to 
craniofacial circumference) was associated with an increased risk of OME recurrence. 
Clark et al. found the opposite results: children who were long in relation to their head 
size at birth had a higher risk of recurrent or persistent OME in early childhood.21 It is 
possible thai the head size to length ratio is a marker of programmed changes in the 
immune system, and that body proportions at birth and OME are linked by the immune 
system.29 At present, it is impossible to conclude whether and which aspects of 
asymmetrical growth retardation may be associated with OME recurrence, because Clark 
et al.'s study and the present study have their limitations. However, the results do suggest 
that disproportionate growth may be associated with OME recurrence. 
A remarkable finding that has not been reported before was that the children with 
unilateral OME recurrence were more likely to have had lower gestational age, lower birth 
weight, lower 'birth weight to birth length ratio' than the children with bilateral OME 
recurrence. Additionally, one third of the group with unilateral recurrence were 'LBW-
incubator-neonales', compared to less than 10% in the group with bilateral OME 
recurrence. These results suggest that unilateral factors may be relevant to the recurrence 
of OME. Hogan et al. has previously speculated that bilateral effusions may be derived 
from systemic factors, whereas unilateral effusions may be derived from peripheral and 
local conditions,30 such as one-sided position during incubator care or one-sided sleeping 
position in infancy. The latter hypothesis was supported by several studies that 
demonstrated an association between a prone sleeping position of babies and a higher risk 
of otitis media during the first six months of life.'1'1'12 In addition, a prone sleeping position 
was seen more frequently in very low birth weight infants, but with increasing age, this 
position had mostly been replaced by side-sleeping.33 The data collected in our study did 
not permit us to test these hypotheses. 
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One of the questions of importance for clinical practice was whether certain birth features 
and events could help us to discriminate between children who are likely to develop 
recurrent OME and those who are not. This was not found to be the case, because no 
strong associations were detected between any of the birth characteristics and OME 
recurrence. It should be noted that our study population contained very few children who 
had been bom very prematurely, i.e. neonatal intensive care children, or children treated 
with nasogastric tubes. No definite answers can be given with respect to the recurrence 
risk in this specific subgroup. 
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Abstract 
It has recently been hypothesised that large amounts of amniotic fluid cellular content 
(AFCC) in the middle ear may lead to chronic inflammation and predispose young 
children to recurrent middle ear infections. Because children bom with meconium-
stained amniotic fluid (MSAF) have higher AFCC in the middle ear we performed a 
retrospective cohort study to determine whether children born with MSAF had a higher 
risk of OM during infancy. Children born between May 1998 and April 2000 formed two 
groups based on the absence or presence of MSAF at birth as documented in the hospital 
birth records. In April 2002, home visits were made to take tympanometric measurements 
and administer a questionnaire on OM history and possible confounders. Logistic 
regression models were constructed to assess odds ratios (OR) as a measure of the effect 
of MSAF on OM and to adjust for potential confounders. There were no differences in the 
point prevalence of a type Β tympanogram at the home visit (OR 0.81; 9 5 % confidence 
interval: 0.38-1.76). Also, no statistically significant association was found between the 
proportion of children with OM diagnosed in the first year of life (OR 0.86, 9 5 % 
confidence interval: 0.27-2.73) and in the proportion of children that had ever been 
diagnosed with OM (OR 0.91, 9 5 % confidence interval: 0.40-2.91). It can be concluded 
that children bom with MSAF do not constitute a high-risk group for OM in early 
childhood. A long-term OM effect, especially in severe MSAF cases, cannot be excluded. 
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Introduction 
Early identification of high-risk groups for otitis media (OM) would enable differentiated 
treatment policies for high-risk children. Next to well-known high-risk groups for the 
development of OM like premature children, children with Down's syndrome and children 
with cleft palate1"4 it was recently hypothesised that children bom with meconium-stained 
amniotic fluid (MSAF) might constitute another high-risk group.'^ 
Large amounts of amniotic fluid cellular content (AFCC) enter the middle ear via the 
Eustachian tube through swallowing amniotic fluid during pregnancy, or by aspiration of 
the amniotic fluid during delivery.1,6 In the late nineteenth and early twentieth century, it 
had already been shown that the presence of AFCC in the middle ear could lead to sterile 
neonatal otitis media as a consequence of the toxic effect of squamous epithelial cells, 
lanugo hair, inflammatory cells and meconium.7'8 More recent histological studies on 
newborn temporal bones have confirmed these findings and found AFCC to be present in 
many neonatal ears.^9 '10 Freely floating AFCC can be propelled out of the mesotympanum 
to the pharynx by the Eustachian tube. However, any foreign material that adheres to the 
tissues in the middle ear cannot be expelled by this cleaning process and gives rise to a 
foreign body giant cell reaction.10 Epithelial defects develop in the non-ciliated flat 
epithelium, while the growth of capillaries and the entrance of fibrocytes into the cell 
clusters lead to tissue fixation of the AFCC, which starts the organisation process.10 Large 
amounts of granulation tissue in the middle ear and hyperplastic mucosa with newly 
formed secretory elements are likely to increase the susceptibility of the middle ear to 
viral and bacterial infections.9 These infections in turn create new granulation tissue and 
thereby increase the existing difficulties with drainage of the inflammatory fluid.9 The 
development of dense scar tissue around the ossicles could lead to irreversible adhesive 
otitis media.9 A combination of these inflammatory processes may predispose young 
children to recurrent middle ear infections.D;11 Because MSAF increases the amount of 
AFCC in the middle ear, it is hypothesised that children bom with MSAF may be at 
greater risk of OM.3'6,9,11,12 To test this hypothesis, we conducted a retrospective cohort 
study in young children. 
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Subjects and methods 
Two equal sized groups of children born at the University Medical Centre Nijmegen and 
the Canisius-Wilhelmina Hospital Nijmegen (the Netherlands) between May 1998 and 
April 2000 were selected based on the absence or presence of MSAF at birth, as 
documented in the hospital birth records. Children with a gestational age of below 37 
weeks, congenital malformations, and children bom to parents living outside the city 
Nijmegen were excluded. The medical ethical committee of the University Medical Centre 
Nijmegen approved the study. The parents of the selected children were asked to 
participate in April 2002, when the children were two and three years of age. After 
obtaining informed consent from the parents, a home visit was made. During this home 
visit the middle ear status of the child was determined with tympanometry (Welch Allyn 
Microtymp) using a modified version of the classification of Jerger. ' 3 1 4 A child was 
considered to have middle ear effusion when a type Β tympanogram was recorded in at 
least one ear (outcome: OM tympanogram). Using a questionnaire, information was 
collected concerning diagnosed OM episodes in the first year of life (outcome: OM first 
year) and the total frequency of OM episodes from birth to the follow up visit (outcome: 
OM ever). These OM episodes had to have been diagnosed by a general practitioner (GP) 
or an ear, nose and throat (ENT) specialist. An overall OM measure (outcome: OM 
overall) was derived by combining the three outcomes. When a child had a positive score 
on one of the three outcomes, this child was considered to be positive on the outcome OM 
overall. Children with missing values on one of the three outcomes were excluded from 
this combined OM measure. 
The questionnaire also gathered information about potential risk factors for OM that might 
confound the association with MSAF: gender, gestational age, birth weight, artificial 
ventilation, the presence of older siblings, attending day care and the frequency of colds 
during the lifetime. The analyses on the prevalence of OM tympanogram included the 
additional variables: attending day care at the time of the home visit and the number of 
cold episodes in the twelve months before the home visit. 
Statistical analyses were performed to assess odds ratios (OR) with 9 5 % confidence 
intervals (CI), as a measure of the effect of MSAF on OM. To adjust for potential 
confounders, logistic regression models were constructed. Only factors that influenced the 
OR of the effect of MSAF on any of the four OM measures were included in the final 
logistic regression models. All statistical analyses were performed using SPSS version 
10.0 for Windows. 
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Results 
A total of 127 children aged between 2.0 and 3.9 years were included in this study; 64 
were bom with MSAF and 63 without MSAF. The mean age of the children was around 
three years. Comparison of the two groups (Table 1) showed that the cohort born with 
MSAF contained more girls, fewer older siblings, fewer children attending day care and 
fewer children with frequent cold episodes. Tympanometry was highly successful; a valid 
tympanogram was obtained in 9 4 % of the ears. Exceptions were due to the presence of 
excessive cerumen in the outer ear canal or the children were too distressed. Only one 
child had bilateral tympanostomy tubes in situ; as one tube was not functioning due to 
obstruction, tympanometry could be performed. 
Table 1 . Characteristics of the study population 
Without MSAF (n = 63) With MSAF (n = 64) 
Male sex 59% 
Mean age (years) 2.9 
Mean gestational age (weeks) 39.9 
Mean birth weight (grams) 3413 
Artificial ventilation (yes) 3% 
Presence of older siblings (yes) 48% 
Attending day care (yes) 84% 
Ever attended day care (yes) 87% 
Ν colds previous year > 4 31 % 
Ν colds during lifetime > 6 53% 
45% 
3.1 
40.4 
3493 
5% 
33% 
73% 
77% 
24% 
45% 
There were no differences in the occurrence of OM on any of ihe four outcomes between 
the two birth cohorts (Table 2). At the home visit, ihe prevalence of middle ear effusion 
(outcome: OM tympanogram) was slightly lower in the group of children born with MSAF 
(32%) than in those without (40%). The only risk factor associated with an increased risk 
for OM tympanogram was the occurrence of more lhan three cold episodes in the previous 
year (OR 2.57, 9 5 % CI: 1.11-5.93). After correction for cold episodes in the previous 
year, MSAF was not associated wilh an increased risk of OM tympanogram (OR 0.81, 
9 5 % CI: 0.38-1.76). The proportions of children who had ever had an episode of OM 
diagnosed by a GP or an ENT specialist as well as the proportions of children who had 
had an episode of OM in the firsl year of life were comparable in the two groups (Table 2). 
In addition, the distribution of ihe frequency of OM episodes was similar. More than half 
of the children (54%) had ever been diagnosed with an episode of OM and aboul 12% of 
the children had been diagnosed with an episode of OM in the first year of life. 
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Children with more than six cold episodes during their lifetime had an increased risk of 
being diagnosed with OM (OR 2.63, 9 5 % CI: 1.13-6.15). After correction for cold 
episodes, children born with MSAF did not have a higher risk of OM being diagnosed 
during their lifetime (OR 0.91, 9 5 % CI: 0.40-2.91). 
We looked at the difference in OM episodes diagnosed in the firsl year of life, because 
MSAF might have an effect in the early months. Artificial ventilation during neonatal 
intensive care showed an increased risk of OM in the first year of life (OR 2.23, 9 5 % CI: 
0.23-21.70), but the small numbers (only five children) produced a wide confidence 
interval. After correction for artificial ventilation, children born with MSAF did not show 
an increased risk of OM in their first year (OR 0.86, 9 5 % CI: 0.27-2.73). 
The combination measure "OM overall" was in concordance with the other results. 
Children with more than six cold episodes had an increased risk of OM overall (OR 1.67, 
9 5 % CI: 0.79-3.58). Attending day care also influenced the association between MSAF 
and OM overall, but after correction for cold episodes and attending day care, children 
born with MSAF did not show an increased risk of OM (OR 0.79, 95 % CI: 0.46-2.08). 
Table 2. Proportion (%) of children with OM according to history of MSAF 
Without MSAF (N = 63) With MSAF (N = 64) 
Λ/=62 * 
3 2 % 
/V=63 * 
71.4% 
19.0% 
3.2% 
4.8% 
0 % 
1.6% 
2 9 % 
Λ/=61 * 
88.5% 
9.8% 
1.6% 
1 1 % 
Λ/=59 * 
45.8% 
40.7% 
11.9% 
1.7% 
54% 
Due to missing values, the number of children included in the analyses is not equal over the four 
outcomes. 
OM tympanogram 
OM ever 
OM ever 
OM first year 
OM first year 
OM overall 
OM overall 
0 episodes 
1 episode 
2 episodes 
3 episodes 
4 episodes 
5 episodes 
0 episodes 
1 episode 
2 episodes 
0 score 
1 score 
2 score 
3 score 
N = 60 
40% 
Λ/ = 63 
71.4% 
15.9% 
6.3% 
4.8% 
1.6% 
0 % 
29% 
N=62 
88.7% 
9.7% 
1.6% 
1 1 % 
Λ/=59 
47.5% 
33.9% 
11.9% 
6.8% 
5 3 % 
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Discussion 
This study did not find an increased prevalence of OM in children of two and three years 
of age bom with MSAF relative to children bom without MSAF. In addition to the 
prevalence of OM, the presence of MSAF did not increase the lifetime occurrence of OM 
episodes in these children or affect the occurrence of OM episodes in the first year of life. 
In a clinical study by Cioce and Canubi, an association was suggested between neonatal 
OM and MSAF, because the percentage of neonates (younger than 25 days) with OM was 
26% in the group of children bom with MSAF compared to 14% in the group of children 
bom with clear amniotic fluid.1'1 By contrast, and in accordance with our findings, a study 
by Jaber et al in children of younger than one year did not show any increase in the risk of 
OM in children with MSAF: OM was diagnosed in 4 5 % of the children bom with 
meconium aspiration and in 56% of those without.16 
Next to tympanometry, we used a questionnaire to collect information about OM history. 
Parents were not informed about the specific hypothesis of the study. Instead, they were 
told that the main interest was in the influence of birth characteristics on the occurrence 
of upper respiratory tract infections. Furthermore, the observant who did the 
tympanometry and collected the questionnaire was not aware whether the child had been 
bom with or without MSAF. It is recognised that some OM episodes, especially OME, may 
have been missed by this retrospective study design, because only OM episodes 
diagnosed by a GP or an ENT specialist were recorded. However, it is unlikely that 
missed OM episodes were unevenly distributed in both study cohorts. 
The main limitation of this study was that we could not classify the children according to 
the severity and/or actual aspiration of MSAF. Histological changes in the middle ear are 
known to be more severe in ears with high AFCC contamination'^9 and likely increase 
with severity of MSAF. Therefore the possibility exists that MSAF only affects OM in 
children with severe MSAF 6;12. Suction of the nasopharynx during delivery or just after 
birth might prevent contamination of the middle ear with AFCC.16 This procedure is 
performed routinely in babies bom with MSAF at the hospitals from which the children 
were recruited for this study. Bias would occur if the MSAF group had contained a large 
number of children born with MSAF, but without AFCC contamination of the middle ear. 
However, we believe that AFCC contamination had already taken place by swallowing 
MSAF during pregnancy.'1 From this study, we conclude that children bom with MSAF do 
not constitute another high-risk group for OM in infancy and hence do not need additional 
care because of concern for OM risk. Although it cannot be excluded that severe MSAF 
has an effect on OM in later life, we feel that such a long-term effect is not very likely. 
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Abstract 
Objective To study the combined role of immune status and Eustachian tube function in 
the development of recurrent bilateral otitis media with effusion. 
Design Prospective cohort study. 
Setting Olorhinolaryngology clinics at one University hospital and two general hospitals 
in Nijmegen and Winterswijk (the Netherlands). 
Participants 136 children aged 2-7 years who received tympanostomy tubes for bilateral 
otitis media with effusion. 
Main outcome measure Recurrence of bilateral otitis media with effusion within a 
follow-up period of six months after spontaneous tube extrusion. 
Results Univariate analyses on different immunological factors (IgA, IgGl, IgG2, IgG3, 
IgC4, mannose binding lectin, FcyRIIa-H/R131-genotype) and Eustachian tube function 
(forced response test) did not show any significant associations with bilateral OME 
recurrence. Multivariate analyses showed that children with closing pressures > 7 5 " 
percentile and IgA or IgG2 levels below the 50' percentile of the cohort were more likely 
to develop recurrent OME than children with closing pressures > 75'h percentile and IgA 
or IgG2 levels above the 501'' percentile. The corresponding risk ratios were 6.3 (95% 
confidence interval 1.0 to 40.1) for IgA and 3 0 (95% confidence interval· 1 1 to 8.2) for 
IgG2. The multivariate analyses also revealed that increasing levels of functional 
mannose binding lectin were associated with decreasing probabilities of developing 
recurrent OME (odds ratio 0.7; 9 5 % confidence interval: 0.6 to 1.0). 
Conclusion Development of bilateral recurrent OME depends on a combination of low 
IgA or low IgG2 levels with poor Eustachian tube ventilation function and decreased 
levels of mannose binding lectin. 
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Introduction 
Otitis media with effusion (OME) is a highly prevalent condition and the most important 
cause of hearing loss in childhood. In most children, the natural course is self-limiting 
and favourable; however, around 10% of children suffer from recurrent or persistent 
OME.' Adverse effects of OME associated with hearing loss, such as impairment of 
speech and language development, mainly occur in the group of children with recurrent or 
persistent OME.2"4 As therapeutic interventions, e.g. insertion of tympanostomy tubes, 
should be focused on this particular group of children, it is relevant to distinguish 
children who are prone to recurrent or persistent OME from the total group of OME 
children early in the course of the disease. Eustachian tube function at an early age and 
the inflammatory response to viruses and bacteria entering the upper airway are two core 
elements in the development of OME.a Clinical studies have shown only subtle 
differences in parameters of the immune system6"8 and Eustachian tube (ET) funclion9:lü 
in children with and without recurrent or persistent OME. Apparently, the discriminative 
capacity of a single parameter of either ET function or the immune system is insufficient 
to predict the recurrence of a multifactorial-generated condition such as OME. Combining 
parameters of ET function with immunological parameters may have more predictive 
power. Interaction between ET dysfunction and immunosuppression and the development 
of OME has only been demonstrated in one experimental animal study." To test the 
hypothesis that the prognosis of OME depends on a combination of ET function and the 
immune status, we conducted a prospective cohort study on children treated with 
tympanostomy lubes for their first clinical episode of OME. At the time of tympanostomy 
tube insertion, several factors were measured that are considered to be involved in the 
immune response to upper respiratory pathogens.12"14 Passive ET function was determined 
in the presence of tympanostomy tubes, while both ET function and immunological 
parameters were inverstigated in relation with bilateral OME recurrence after 
spontaneous tympanostomy tube extrusion. 
Participants and methods 
Participants 
Inclusion criteria for this prospective study were: age between 2 and 7 years; first episode 
of OME that persisted for at least three months as documented by the general practitioner; 
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referral to one of the two general hospitals or one University hospital in Nijmegen and 
Winterswijk (the Netherlands) between December 1999 and March 2002 Exclusion 
criteria were. Down's syndrome, cleft palate, cystic fibrosis, daily treatment with 
inhalation or topical corticosteroids for at least one month per year, documented 
immunodeficiency and previous adenoidectomy. The Medical Ethical Committees of the 
referral hospitals approved the study protocol. Signed informed consent was obtained from 
the parents or legal guardians. 
Study design 
At study entry, all the children received bilateral tympanostomy tubes Blood samples 
were taken, serum and DNA were isolated and stored at —20° C. Check-up visits were 
planned one week after tube insertion and once every three months thereafter. An 
otologist performed otomicroscopy to assess tympanostomy tube patency or extrusion and 
recurrence of OME. ET function tests were performed on ears with patent tympanostomy 
tubes. The primary outcome measure was the number of children who developed bilateral 
recurrence of OME within the follow-up period. The follow-up period for the recurrence of 
OME began at the first check-up at which tube extrusion was observed (per ear) Follow-
up ended when OME was diagnosed, or six months after the observation of spontaneous 
tympanostomy tube extrusion, or at the predetermined end-point of the study. OME was 
defined according to an algorithm primarily based on tympanometry with classification of 
tympanograms in accordance with Jerger ' ' l û If no valid tympanogram could be obtained, 
otomicroscopic signs of OME were used to determine the outcome 
Tests for Eustachian tube function 
Tympanometry and ET function tests were performed with the TYMP 87 analyser (Rexton 
Danplex A/S Copenhagen, Denmark). ET function tests were performed at each check-up 
with patent tympanostomy tubes as described previously.17 The forced response test was 
used to assess the ET ventilation function, with opening pressure (Po) and closing 
pressure (Pc) as outcome variables. These pressures reflect the resistance to passive tubal 
opening when experimentally-induced increased middle ear pressure is applied and the 
forces that act to close the open tube. 
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Tests for immunological status 
Serum immunoglobulin concentrations of IgA, IgGl, IgG2, IgG3 and IgG4 were 
determined by radial immunodiffusion 18 To determine functional mannose binding lectin 
(MBL), an assay was used based on the pnnciple of yeast-induced bystander lysis of 
chicken erythrocytes 19 To determine FcyRIIa H/R131, genomic DNA was extracted from 
whole blood using a QIAamp DNA Blood Kit (Qiagen, Westburg, the Netherlands) 
FcyRIIa H/R131 genotypes were determined by means of PCR amplification methods as 
described previously 20 
Other risk factors 
Questionnaire information on other potential risk factors for OME recurrence was 
obtained at the first check-up visit gestational age, birth weight, incubator care with or 
without artificial ventilation or nasogastric tubes for feeding, breast-feeding, siblings, 
habitual sniffing, day care, family history of otitis media, exposure to smoking at home, 
diagnosis of otitis media by a general practitioner or an otologist both in the first year of 
life as well as in the year before study entry 
Statistical analyses 
Children with bilateral OME recurrence were compared to the rest of the cohort regarding 
ET tube function and immunological status If the follow-up data to classify OME status 
were inadequate , the child was excluded A single measure was defined lor both the 
opening and closing pressures in each child, based on the mean pressure from all test 
results obtained at the three monthly check-ups with patent tympanostomy tubes 
Means and confidence intervals were calculated for continuous variables Odds ratios and 
corresponding confidence intervals were calculated for categoncal variables To 
investigate whether a combination of ET tube function and immunological status made a 
greater contribution to bilateral OME recurrence than the separate effects of the two 
parameters, interaction terms were included in the multivariate logistic regression 
models Potential confounders were also included in these models The full model was 
reduced through manual stepwise backwards regression analyses to obtain the final model 
that included the vanables that showed significant associations with bilateral OME 
recurrence Odds ratios obtained for continuous independent variables reflect the 
association with bilateral OME recurrence per unit increase in these independent 
vanables The final prognostic model included all the variables that contnbuted to the 
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prediction of bilateral recurrence of OME. Model discrimination was measured by the 
area under the receiver operator characteristics curve (c-index).21 All analyses were 
performed with the Statistical Analysis Systems (SAS version 8.0). 
Results 
A total of 136 out of the 186 eligible children participated in this study; 90 of them had 
complete follow-up at the pre-determined end of the study (August 2003). Fifteen 
children were lost to follow-up, mostly for practical reasons. Bilateral OME recurrence 
occurred in 56 children, whereas 44 children had unilateral or no recurrence (Figure 1). 
The median time of documentation of tympanostomy tube extrusion was 9 months (range 3 
to 27 months) after insertion in children with and without bilateral OME recurrence. 
Children with bilateral OME aged between 2 and 7 years 
referred to otorhmolaryngologist and eligible for study In = 1Θ6Ι 
Informed consent obtained {n= 136) 
Bilateral tympanostomy tube insertion In - 1 35) 
and blood sample taken In = 127) 
Check ups in ears with patent tubes 
Eustachian tube function tests 
Check ups in ears without ventilation tubes 
Assessment ol OME recurrence within follow up period 
(6 months alter observation of tube extrusion) 
1 child received unilateral tympanostomy tube 
Lost to Follow up η = 15 
Children with incomplete lollow up in either 1 or 2 ears (n = 31), 
tO children did not develop OME in ear with complete follow-up 
Unilateral recurrent OME 
tn=ni 
No recurrent OME 
In =171 
Bilatéral recurrent OME 
|η = 5β] 
Non bilateral recurrent OME 
In = 441 
Figure I.Flow diagram of participants and diagnosis of bilateral OME recurrence 
Children with bilateral OME recurrence were comparable with those without, except for 
age at the start of follow-up, habitual sniffing and the proportion of children with either 
low birth weight ( < 2500 g) or low gestational age ( < 37 weeks) or incubator care with or 
without artificial ventilation or nasogastric tubes for feeding (Table 1). 
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Table 1 . Characteristics of the children w h o developed bilateral OME recurrence (rOME) and the 
children w h o did not develop bilateral OME recurrence wi th in the fol low-up period. Values are 
numbers (%) of patients unless stated otherwise 
Full Cohort 
N = 1 3 6 
Bilateral rOME 
Ν = 5 6 
No bilateral rOME 
N = 4 4 
Gender, boys (%) 
Median age at start of fol low-up in years [range] 
Mean birth weight in grams [range] 
Breast-feeding for > 4 months (%) 
'LBW-mcubator-neonate' score yes(%) § 
Diagnosis of otit is media in f irst year of life (%) 
Diagnosis of otit is media in year before study 
entry (%) 
Habitual sniff ing (%) 
Attending day care at study entry (%) 
Siblings present (%) 
Family w i t h history of otit is media (%) 
Exposure to smoking at home (%) 
68 (50) 
6.3 [3.4-9.1] * 
3444 [1380-5200] 
48 (36) 
27(21) t 
20 (17) t 
55 (43) t 
31 (23) 
28 (21) 
125 (93) 
70 (61) t 
30 (54) 
6.0 [3.5-8.3] 
3615 [2575-5200] 
21 (38) 
4(7) 
6 (13) t 
23 (46) X 
14(25) 
10 (18) 
52 (93) 
32 (65) ΐ 
21 (48) 
6.4 [3.4-9.1] 
3277 [1380-5010] 
16 (36) 
11 (26) 
6 (16) * 
19 (44) 
3(7) 
10(23) 
42 (95) 
25 (64) 
4 6 (34) 2 0 (36) 11 (25) 
* Based on 100 children with known clinical outcome 
t 5%-16% of the subjects had missing data on this variable 
t 10%-18% of the subjects had missing data on this variable 
S A child was assigned a positive score on this variable when at least one of the following variables was 
present, gestational age less than 37 weeks, birth weight less than 2500 g, incubator care and/or 
treated with artificial ventilation or nasogastric tubes in postnatal period 
Univariate associations 
Based on univariate analyses, no statistically significant associations were found between 
bilateral OME recurrence and immunoglobulin levels of IgA and IgG subclasses, 
functional mannose binding lectin levels, FcyRIIa-H/R 131 genotype or ET function test 
results (Table 2). 
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Table 2 Univariate analyses on serum immunoglobulins and mannose binding lectin levels, 
FcyRlla H/R131 genotype, opening and closing pressures and bilateral OME recurrence (rOME) 
Bilateral 
rOME 
Ν No bilateral 
rOME 
Ν Mean Difference 
(95% CD* 
Median IgA in g/L [range] 
Median IgGl m g/L [range] 
Median lgG2 in g/L [range] 
Median lgG3 in g/L [range] 
Median lgG4 in g/L [range] 
Median functional MBL in mg/L 
[range] 
0 9 5 ( 0 10-2 40] 56 
7 54 [5 08-11 44] 56 
1 25 [0 55 2 95] 56 
0 4 0 ( 0 15-0 85] 56 
0 25 [0 05 1 45] 56 
1 10 (0 25 2 25] 
8 67 [4 12-14 03] 
1 40 [0 05 2 60] 
0 40 [0 15 0 90] 
0 40 [0 05 3 00] 
42 
42 
42 
42 
42 
-0 19 (-0 3 8 - 0 01) 
-0 65 (-1 38 0 09) 
0 09 (-0 30-0 12) 
0 01 ( 0 07 0 09) 
0 18 ( 0 38 0 02) 
1 38 [0 07 11 58] 56 1 77 [0 09 10 68] 43 -0 51 ( 1 41 0 39) 
Eustachian tube 
Median Po in daPa [range] 
Median Pc in daPa [range] 
FcyRlla-genotype 
FcyRlla-R/RISI 
FcvRlla-R/H131 
FcyRlla-H/HISI 
336 [184 541] 
103 [20-231] 
34% 
49% 
17% 
48 
48 
53 
329 [154-508] 
98 [29 209] 
17% 
6 1 % 
22% 
43 
43 
41 
23 (-14- 60) 
4 (-14-22) 
Odds ratio 
(95% CI) * 
2 57 (0 72 9 17) 
1 04 (0 36-3 05) 
reference value 
* CI 95% confidence intervals 
Multivariate associations: interaction between immunoglobulins and closing 
pressure 
Based on the concept that OME is a multifactorial disease, we studied potential 
interactions between ET function and immunological parameters related to bilatéral OME 
recurrence. Backward regression analyses on the full multivariate model that contained 
all the immunological parameters, ET function and their combined effects, provided the 
final multivariate model that included all the variables with an independent significant 
association with OME recunence. 
Multivariate logistic regression analyses showed that higher MBL levels were associated 
with a lower probability of developing recurrent bilateral OME (odds ratio 0.7, 95% 
confidence interval: 0.6 to 1.0). No significant associations were found between bilateral 
OME recurrence and the separate effects of decreasing levels of IgA (odds ratio 0.5; 9 5 % 
confidence interval: 0.2 to 1 3), IgGl (odds ratio 0.9; 95% confidence interval: 0 7 to 
1.2), IgG2 levels (odds ratio 0.7; 95% confidence interval: 0.3 to 1.7) and closing 
pressure (odds ratio 1 0; 9 5 % . confidence interval 0.99 to 1.01). However, there was 
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evidence that the association between IgGl, IgG2, IgA levels and bilateral OME 
recurrence varied according to the closing pressure. 
To investigate these interactions, immunoglobulin levels and closing pressure were 
dichotomised around the median value (immunoglobulins) and the 75' percentile (closing 
pressure) of the data from the full cohort. 
Figure 2 shows the proportion of children with bilateral OME recurrence within 
combinations of closing pressure and IgA, IgGl or IgG2. A remarkably high proportion of 
OME recurrence was found within the category of children with high closing pressures 
and low IgA or low IgG2 levels. The corresponding risk ratios are 6.3 (95% confidence 
interval: 1.0 to 40.1) for IgA and 3.0 (95% confidence interval: 1.1 to 8.2) for IgG2 when 
compared to the children with high closing pressures and high IgA or IgG2 levels. No 
such interaction with closing pressure was found for IgGl (relative risk 1.0: 9 5 % 
confidence interval: 0.5 to 2.2) 
d doling pressure lgG2 and closing pressure 
Closing pressure 
IgGl and closing pre 
Closing ρ re sture 
Figure 2. Proportions of children with bilateral recurrent OME within categories of closing 
pressures combined with IgGl, lgG2, or IgA. Immunoglobulin levels were dichotomised around 
levels of equal to or lower than ( < = p 5 0 ) and higher than (> p50) the median value of the 
cohort; closing pressures were dichotomised around pressures of equal to or lower than 
( < =p75) and higher (> p75) than the 75* percentile of the cohort 
135 
CHAPTER 6 
Predict ive power 
All variables significantly associated with bilateral OME recurrence were entered into a 
predictive model. To obtain the most informative and efficient model, this predictive 
model was reduced until its corresponding c-index was less than 5% of the value of the 
predictive model that contained all the significant variables. The final predictive model 
included IgA, IgG2, closing pressures (Pc), their interactions and mannose binding lectin 
(MBL) functionality. This model had a c-index of 0.79 and can be described as: In (odds 
bilateral rOME= -8.6 -0.3MBL+2.01gA+5.0IgG2+0.1Pc-0.02IgA*Pc-0.05IgG2*Pc). 
The predicted probability of bilateral OME recurrence corresponded fairly well with the 
actual recurrence in our study population (Figure 3). Using a cut-off point of 0.61 (based 
on the maximum sum of sensitivity and specificity in the ROC curve), 80% of the 
children without bilateral OME recurrence and 65% of those with bilateral OME 
recurrence were correctly classified. 
0,875 
Predicted probability of deveioping biiateral recurrent OME 
Actual OME status 
Figure 3. Predicted probability of developing bilateral OME recurrence, based on the prognostic 
model in children with and without bilateral OME recurrence. Histogram bars are numbers of 
children with a No rOME or Yes rOME status within different probability categories 
Discussion 
This study yielded several unique results related to OME recurrence in a population that 
was homogenous with respect to OME status at baseline. First, ET dysfunction in the 
presence of decreased activity of several parameters of the immune system played a role 
in the development of OME recurrence. Children with a combination of high closing 
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pressure and low IgA or IgG2 levels were more likely to develop recurrent bilateral OME 
than children with high closing pressure and high IgA or IgG2 levels. The closing 
pressure measured by the forced response test reflected the extraluminal forces that are 
part of the total closing forces of the ET, i.e. the forces that keep the ET closed at rest. In 
order to open the ET actively, these forces must be overcome. Extraluminal forces are 
brought about by the elasticity of the cartilage and pressure from other surrounding 
tissues. High closing pressure thus indicates poor ET ventilation.22 Lower serum levels of 
IgG2 and IgA suggest decreased antibody response to viral and bacterial pathogens that 
enter the middle ear cavity.12:23 In other words, middle ear effusion may develop because 
of diminished immune response and may persist because of impaired ET ventilation. 
Second, this study showed significant associations between low functional mannose 
binding lectin (MBL) levels and bilateral OME recurrence. Low plasma MBL levels 
reduce effective opsonization of infectious pathogens and interaction with receptors on 
macrophages24 and may therefore lead to higher susceptibility to OME. Previous studies 
have also shown than median MBL levels were lower in children with OME than in 
children without OME.2 ' Associations have also been reported between severe recurrent 
otitis media and MBL variant alleles known to be associated with low MBL serum levels.26 
Third, univariate analyses showed a non-significant trend that supported our a priori 
hypotheses: children homozygous for the polymorphic form of the FcyRIIa receptor, with 
the lower binding affinity for IgG2 opsonized bacteria (FcyRIIa-R/RlSl), such as 
Streptococcus Pneumoniae, were more likely to develop bilateral OME recurrence than 
children with the FcyRIla-H/H131 genotype.1'5 The same non-significant trend was visible 
in the full multivariate model. 
More elaborate analyses were also done on e.g. active ventilatory ET function (pressure 
equilibration test), protective ET function (sniff test) 27 and the serum immunoglobulins 
IgM and IgG, but these analyses did not show any significant associations or interactions 
with OME recurrence (data not shown). 
As OME is a multifactorial-generated condition, it is possible that factors other than the 
two primarily addressed in this study play a role, such as low birth weight, (family) history 
of otitis media, day care attendance, siblings, habitual sniffing, or exposure to smoking at 
home.3 In our cohort, these factors were either equal at baseline, or their effect on 
recurrent OME could not be confirmed in the multivariate analyses. 
Our study results were obtained from a population of 100 children with known clinical 
outcome. We feel that this population is representative of the full cohort of children with a 
history of at least three months of bilateral OME, because the predetermined end-point of 
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the follow-up period and the reasons for los to follow-up were unrelated to the clinical 
outcomes and because the baseline characteristics of these 100 children were comparable 
with those of the full cohort population. The majority of our cohort developed OME 
recurrence; only 2 8 % of the ears remained effusion-free in the six months period after 
tympanostomy tube extrusion. Other studies on children treated with tympanostomy tubes 
for persistent OME with a comparable follow-up period demonstrated similar high 
recurrence rates.28:29 
As far as we know, this is the first prospective study to examine baseline immunological 
parameters and ET function tests in relation with bilateral OME recurrence. The 
discriminative power of the prognostic model with functional MBL levels, IgA, IgG2, 
closing pressure and the interaction between IgA, IgG2 and closing pressure, was fairly 
good, as reflected by a c-index of 0.8. This model requires external validation with 
independent data. Even if the model shows high external validity, its application to 
clinical practice is limited, because closing pressures can only be measured as part of the 
forced response test in ears with patent tympanostomy tubes. Alternative function tests 
that enable analysis of ET function in children with an intact tympanic membrane, e.g. in 
a pressure chamber or with sonotubometry, would add to the clinical value of the model. 
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General discussion 
CIIUTKR 7 
The main objective of this thesis was to gain further insight into the separate and 
combined roles of Eustachian tube (ET) function and the immune system in the 
development of recurrent otitis media with effusion (OME) in children. The main part of 
this thesis is based on the results of a prospective cohort study on a group of children 
aged between two and seven years who were treated with bilateral middle ear 
tympanostomy tubes for their first clinical episode of OME that persisted for at least three 
months. The results on the immune system were mostly in line with our a priori 
hypotheses, but effects were too small to be clinically relevant. Furthermore, our analyses 
did not show any relation between ET dysfunction and OME recurrence. However, the 
combined roles of some of the immunoglobulins and closing pressure supported the theory 
that OME is a disease with a multifactorial nature. 
In this chapter, the study strengths and weakness are initially addressed. Then, we 
discuss the insights gained from the study with respect to the separale and combined roles 
of ET function and the immune system in the recurrence of OME. Recommendations are 
made for further research and implications are outlined for clinical practice. 
Study strengths and weaknesses 
Prospect ive design 
Previous investigations on the role of immune status and the recurrence of OME 
comprised cross-sectional studies in which immune parameters and OME status were 
concurrently evaluated.1"6 Consequently, no conclusions could be drawn with respect to 
cause and effect. A major strength of our cohort study was that immune parameters and 
ET dysfunclion were measured prior to OME recurrence. This prospective design enabled 
us to draw conclusions about a possible causal role of the immune system and ET 
dysfunclion in the development of recurrent OME. Another unique element was lhat both 
the immune system and ET dysfunclion were included in our study, instead of only 
focusing on either one of these two elements. 
Accounting for dependency of observations 
Separate analyses were performed on the association between several aspects of ET 
function, the immune system, various birth characteristics and ihe recurrence of OME. 
These analyses took either the ear, or the child as the unit variables. When using ears as 
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the unit variables, statistical analyses were used that accounted for correlations between 
the left and right ears. The literature on ET function tests and OME contains several 
approaches to how the authors dealt with this within child dependency. Some studies 
ignored the assumption of independent observations by analysing data from all the ears as 
independent units.7"1' One of these studies also reported separate analyses on the left and 
right ears, in order to confirm the results of the main analyses.11 
Studies that used information from all the individual ears, but ignored within-child 
dependency in general, provided valid effect estimates, but unreliable standard errors. In 
these specific ET studies, this would probably have led to underestimation of the standard 
errors and therefore to loo small confidence intervals, due to unjustified inflation of the 
study size from e.g. η independent units of analysis (children) to 2n dependent units of 
analysis (ears). Two studies reported the data from one ear only, while neglecting the 
information from the contralateral ear, which reduced the statistical power. ' In our 
study, we used all the data available and we took statistical dependency into account by 
using General Linear Mixed Models and Generalised Estimation Equation Models, with 
an indicator variable for ear (left/right). In this way, we obtained the most precise study 
results without violating any statistical assumptions. Another approach to avoid violating 
the assumption of independence without any loss of information is to summarise all 
relevant information from each subject into one score. We used this approach in the 
analyses on the combined effect of ET dysfunction and parameters of the immune system 
and in relation with the recurrence of bilateral OME. Multiple observations from each 
child based on ears and repealed measurements over time were reduced to one summary 
measure for ET function that was used in the child-level based analyses. 
Design of analysis 
When we studied a combination of ET function and the immune system in predicting 
OME recurrence, we focused our analyses on the factors with the most predictive power in 
the development of bilateral OME. Bilateral OME is considered to represent a more 
severe condition than unilateral OME.1 4"1 0 To obtain maximal contrast with respect to ET 
function and immune status in relation with OME recurrence, we compared children with 
bilateral OME recurrence (cases) to children without bilateral OME recurrence whose 
clinical outcome was known at the end of follow-up (controls). This case-control approach 
led to estimates of mean differences in parameters between cases and controls, and to 
odds ratios. We acknowledge that for a valid estimate of risk ratios we would need 
controls sampled from the original cohort, i.e. a case-cohort approach. However, our study 
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did not aim to obtain risk ratio estimates. Moreover, a priori, we were unable to classify 
the distribution of immunoglobulins, mannose-binding lectin (MBL) and forced response 
test into low or high exposure levels. As there was neither intention nor opportunity to 
estimate relative risks, the case-control approach was justified for meeting the objectives 
of this study. 
Small numbers 
The relatively small number of children with known clinical outcome was a weakness of 
this study. As this limited the power to detect relevant differences, we have not restricted 
our presentation to significant results only. Instead, we discussed our results in the light 
of a priori hypotheses based on biologically plausible mechanisms and studies reported 
by other authors. 
Loss to follow-up 
Although children with unknown clinical outcomes were excluded, we believe that the 
sub-cohort of children with known clinical outcomes was representative of the full cohort 
and therefore not a threat to the interval validity of this study. The exclusion of children 
with unknown clinical outcomes as a consequence of either withdrawal from the study or 
incomplete follow-up due to the pre-delermined end of the study, was unrelated to clinical 
outcome, which made selection bias unlikely. Bias due to selective participation in the 
study was also unlikely, because the main reasons why parents of eligible children 
refused consent to participate were practical problems, i.e. the need for loo many check-
ups. Thus, this was totally unrelated to any of the parameters of the immune system or ET 
function. 
Measurement error of exposure 
Accuracy of exposure assessment 
As exposure (ET dysfunction, immune status, various birth characteristics) was 
documented before the outcome of interest (OME recurrence) was known, possible 
measurement errors in the exposure variables were independent of the outcome variable. 
Therefore, differential misclassification of exposure was prevented.1' Furthermore, 
exposure measurements were performed with standardised objective tests for 
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immunological parameters and the same ET function measurement protocol was followed 
in all the children. This approach was intented to yield reliable study results. 
Timing of exposure measurement 
It should be noted that in contrast with ET measurements, which occurred repeatedly over 
time, immune parameters were only measured once, i.e. at the start of the study. Although 
this immunoglobulin level is a momentary value, we assumed that it gives a realistic 
reflection of the immunological status of each child. Under normal circumstances, 
immunoglobulin levels are relatively stable and increase only slowly with increasing 
age.18 However, immunoglobulin production can also be stimulated by repeated 
infections, or by events related to increased exposure to pathogens, such as those that 
occure in low-socio-economic circumstances, day care attendance and with (a laige 
number of) siblings.19 Except for increasing age, the majority of our cohort are expected to 
have remained fairly constant with respect to these events during the study period. 
Furthermore, undetectable or low serum MBL levels are strongly associated with the 
presence of genelically-delermined MBL variant alleles.2 0 Consequently, serum MBL 
levels are likely to be fairly stable in children over time. The same holds true for 
genetically-determined polymorphisms of human Fey receptor function.21 
Misclassification of disease 
Accuracy of OME diagnosis 
As there are hardly any diagnostic tests with 100% sensitivity and 100% specificity, 
misclassification of disease plays a role in most epidemiological studies. The 
classification of OME is based on several sets of criteria, including the results of 
(pneumatic) otoscopy, tympanometry or a combination of these two methods. The results 
of pure-tone audiometry may sometimes be used as well. Although tympanometry is 
frequently used to diagnose OME, this also has suboptimal sensitivity and specificity. 
Sensitivity and specificity of a type Β tympanogram in a population of children with OME 
vary from 7 5 % to 9 0 % and from 6 6 % to 9 3 % , respectively.2 2 2 6 A combination of type Β 
and type C2 tympanograms as evidence of OME leads to a sensitivity that varies from 
8 8 % to 9 8 % and to a specificity that varies from 3 1 % to 72%. 2 4 2 5 2 7 
In order to minimise the chance of misclassification of OME both at study entry and in the 
outcome assessment, OME was defined according to an algorithm primarily based on 
tympanometry, while the tympanograms were classified in accordance with Jerger.2" 2 9 If 
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no vdlid tympanogram could be obtained, otoscopie observation of middle ear fluid was 
used to determine the outcome. The sensitivity and specificity of this algorithm are 
assumed to be fairly high: around 9 3 % and 8 4 % respectively.28 However, this algorithm 
has not been validated against the 'golden standard', i.e. the evidence of effusion at 
myringotomy. Consequently, non-differential misclassification of OME, independent of 
levels of exposure, might have weakened the observed associations between exposure and 
disedse in this study.1 ' Non-differentidl miscldssification leads to biased estimates 
towards the null hypothesis and might therefore have reduced the power of the study to 
detect any meaningful differences. n 
Timing of OME recurrence 
Misclassification of disease status with regard to OME recurrence might also have 
occurred due to the study design with three-monthly check-ups. Brief episodes of OME 
that occurred between two check-ups may have been missed because of their 
asymptomatic characteristics. Consequently, we cannot guarantee that a child who was 
diagnosed as effusion-free in the follow-up period had not suffered from one or more brief 
episodes of OME between the three-monthly check-ups. Most prospective studies used a 
three-monthly interval to determine the prevdlence of OME i i 3 2 Thus OME episodes of 
shorter than three months in duration may have gone undetected. Prevalence studies that 
used d more frequent measurement strategy demonstrated that many OME episodes are of 
shorter duration than two months. Casselbrdnt et al. evaluated OME status at monthly 
intervals over a period of one year in a group of day care children aged 2-6 years. They 
showed that 8 0 % of OME episodes lasted for a maximum of two months, while 67% had 
maximum duration of one month.1 3 Daily tympanometry over a period of four months in 
children aged 2-6 years showed that the average duration of an episode of middle ear 
effusion (with or without symptoms of acute infection) was 20.5 days, with a rdnge of 3 to 
129 days 3 1 In a group of children followed prospectively with monthly domiciliary visits, 
Hogan et al. showed that the average durations of an episode of unilateral OME, bilateral 
OME and an effusion-free period were 5, 8 and 22 weeks, respectively.30 Although these 
studies showed that many OME episodes were of shorter duration than two months in a 
population of healthy children, we assume that very few OME episodes were missed in 
our study, because the proportion of children with OME recurrence was fairly high In 
view of the high recurrence rates observed in our study, we have to question the clinical 
relevance of each of the OME episodes detected. It is possible that a proportion of the 
146 
(Λ nei al dii( ussion 
OME episodes in our follow-up (and hence a proportion of our cases) comprised 
insignificant, brief OME episodes that may have resolved spontaneously 
In view of the considerations mentioned above, the distinction between the groups of 
children with and without OME recurrence in our study may seem fairly aibitrary. 
However, our study population was selected on the basis of repeated OME observations 
by a general practitioner. Therefore the occurrence of a high proportion of 'false positives' 
is unlikely. Moreover, we assume that in this selected study population, OME episodes 
were of longer duration than those in healthy children. As a consequence, a high 
proportion of 'false negatives' is also unlikely 
Non-randomised study 
In this non-randomised study, confounding may have occurred if known and unknown 
risk factors for the development of OME had been associated with the determinants of 
primary interest. Risk of confounding was reduced in our study because immune status 
and ET function were measured at a time when all the childien were clinically identical 
with respect to ear status and therefore had similar prognoses for OME recurrence. The 
use of multivariate analysis techniques allowed us to correct for any possible distorting 
effects from factors such as age at the start of follow-up, premature birth and sniffing 
habit. Although these risk factors were unequally distributed in the two gioups, they did 
not distort the relation between immune status and/or ET function and bilateral OME 
recurrence. 
Generalizability 
Our cohort population consisted of children who were referred to one of the hospitals in 
Nijmegen for the first time by their general practitioner. Nijmegen is a city situated in the 
eastern part of the Netherlands, with approximately 160,000 inhabitants. We feel that the 
study results apply to all OME children who meet the criteria of the Dutch College of 
General Practitioners for referral to a secondary health care centre. These criteria include 
repeated observations of middle ear effusion. It should be emphasized that our study 
population did not include children with Down's syndrome, cleft palate, cystic fibrosis, 
regular corticosteroid use, and children with proven immunodeficiency or previous 
adenoidectomy. Furthermore, children of younger than 2 and older than 8 years of age, as 
well as asymptomatic children with OME identified by screening or coincidence, did not 
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form part of this cohort. Consequently, the results of this study cannot be generalised to 
the latter groups of children. 
Conclusion on strengths and weaknesses 
In conclusion, the main limitations of this study were related to the possible 
misclassification of disease and the limited statistical power, both factors tending to dilute 
any existing associations between determinants and outcome. Nevertheless, the 
prospective nature of this study, measurement of both ET function and parameters of the 
immune system, as well as appropriate analyses to prevent confounding, yielded valuable 
results that contribute to evidence-based knowledge on the separate and combined roles 
of the immune system and ET function in the development of OME recurrence in young 
children. 
What have we learned about the recurrence of Otitis Media with 
Effusion? 
The role of the Eustachian tube in the aetiopathogenesis of OME recurrence 
No substantial differences in ET function were present between ears that developed OME 
recurrence and ears that remained effusion-free. Van Heerbeek et al. addressed the 
question of which ET function test could best be used to discriminate between patients 
with various degrees of middle ear diseases, but were unable to answer this question 
because of their study design.10 Our study results indicated that the discriminative power 
of the forced response test, the pressure equilibration test and the sniff test were too low to 
distinguish children who later developed recurrent OME from children with only transient 
OME. It should be noted that overall, ET function was poor in our study population. 
Furthermore, no improvement or deterioration in ET function was demonstrated at the 
three-monthly check-ups. Consequently, we infer that poor ET function certainly plays a 
role in the development of OME, bul is probably unrelated to OME recurrence. 
The role of the immune system in the aetiopathogenesis of OME recurrence 
The role of serum immunoglobulin levels in OME recurrence was limited, as we only saw 
small clinically irrelevant differences in immunoglobulin levels prior to the recunence of 
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OME. Specific antibody levels against pneumococcal serotypes were not measured in this 
study, although previous investigations showed that children with recurrent acute otitis 
media (AOM) had lower IgG antibody levels against some pneumococcal serotypes and 
non- encapsulated Haemophilus influenzae.2'ib Recurrence of OME after the resolution of 
the first episode is not necessarily related to the specific antibody level at baseline, as 
various pathogens may play a role in recurrent episodes.1 ' Consequently, the recurrence 
of OME would not be explained by specific pneumococcal antibody levels at baseline, 
because recurrence may be attributed to other pneumococcal serotypes or other non-
pneumococcal pathogens. Furthermore, the limited effect of pneumococcal conjugate 
vaccination on the occurrence of OME supports the idea that specific pneumococcal 
immune factors do not form major determinants of OME recurrence. 
In our study, we could not demonstrate any associations between various birth 
characteristics and the recurrence of OME. However, our study population contained very 
few premature children, i.e. incubator children treated at neonatal intensive care units 
with or without nasogastric tubes. The immune system and/or ET function of children 
born very prematurely may be far less developed or far more impaired than in the 
children in our population. Consequently, the results of our study cannot provide answers 
to the recurrence risk of OME in this specific subgroup. 
The results of this study suggest that genetically-determined factors contribute to an 
increased risk of the recurrence of OME. Firstly, genetically-determined variation in Fey 
receptor function may play a role in the recurrence of OME, as we demonstrated a trend 
towards higher proportions of children homozygous for the genotypes related to lower 
binding affinity for IgG2 complex (FcyRIIa-lSlR) or the complex IgGl, IgG3, lgG4 
(FcyRIIIa-158F). Effective defence against infections with pneumococci depends on 
opsonisation by immunoglobulins and subsequent phagocytosis. The Fey receptor present 
on phagocytic cells is essential for phagocytosis of bacteria opsonized with IgG. A lower 
binding affinity for IgG-coated bacteria implies a decreased ability to kill the bacteria, 
regardless of serum immunoglobulin levels. Consequently, this contributes to higher 
susceptibility to infections, e.g. OME. Secondly, genetically-determined MBL variant 
alleles influence serum MBL levels. In our study, lower serum MBL levels were 
associated with an increased risk of bilateral OME recurrence. Low serum MBL levels 
impair opsonization and phagocytosis of infectious pathogens.''8 Previously, it has been 
postulated that in children of older than 2 years of age, MBL insufficiency might play a 
role in the clinical course of an ongoing disease.39 The results of our own study, obtained 
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from a clinically homogenous population with regard to OME history, supported this 
theory, as the clinical course of OME, expressed in terms of the recurrence rate, appeared 
to be poorer in children with a lower serum MBL level at baseline. 
The combined role of the Eustachian tube and immune status in the 
aetiopathogenesis of OME recurrence 
Combined analysis of immunoglobulin levels and the forced response test tended to show 
that low immunoglobulin levels contributed to an increased risk of developing OME in 
children with OME and ET dysfunction prior to recurrence. Associations between the 
immunoglobulins IgA and IgG2 and OME recurrence depended on the closing pressure of 
the Eustachian tube. A prognostic model that incorporated the interaction of these 
immunoglobulins and the closing pressure showed a higher c-index than ihe model 
without these interaction terms. This predictive model is only theoretical, whereas the 
development of OME recurrence is much more complex than the combined effect of the 
immunoglobulins IgA, IgG and the ventilation function of the ET. However, this is an 
intriguing finding that emphasizes the need for more elaborate research. 
Recommendations for future research 
In children with OME, identification of an inherent proneness to recurrence should 
ideally precede treatment. A limitation of the ET function tests described in this thesis is 
that they can only be performed on ears with an opening in the tympanic membrane (i.e. 
in ears with patent tympanostomy lubes or tympanic perforation). As the results of our 
study suggest that the association between IgA, IgG2 and the recurrence of OME depends 
on the ventilation function of the ET, it may be relevant to focus on ET function tests that 
can be performed on ears with an intact tympanic membrane. 
A method employing a mini-pressure chamber is an alternative for the forced response 
test to measure passive ventilation function. This method can be used on ears with an 
intact tympanic membrane.40 However, this procedure is very time-consuming and the test 
setting may be unpleasant, especially for children. Sonotubometry can be used to measure 
active ventilatory ET function in individuals with an intact tympanic membrane and is 
more convenient than the mini- pressure chamber method. In sonotubometry, the tubal 
opening is measured based on sound passing through the ET.11 Changes in sound 
intensities in the external auditory canal are recorded and related to swallowing when a 
constant sound source is applied to the nostril. When the ET opens, there will be an 
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increase in the sound intensity in the middle ear and hence in the external auditory 
canal.12 An increase in sound intensity is assumed to indicate active ET opening as a 
result of swallowing.4'1 The reliability of sonotubometry to measure active ET ventilation 
function and the value of this method in distinguishing between ears with and without 
OME recurrence should be further investigated, preferably in combination with 
measurements of the serum immunoglobulins IgA, IgG2 and mannose-binding lectin. At 
present, it is unclear which serum levels of functional MBL should be considered as 
predisposing in the recurrence of OME. Clinical implications of MBL deficiencies or low 
serum MBL levels in young children should be further investigated. 
Once we are able to distinguish children prone to OME recurrence from the total 
population of children with OME, we still have to decide which treatment would be the 
most appropriate for them. Although much controversy exists, the current symptomatic 
Ireatment strategy for children with chronic or recurrent OME is the surgical insertion of 
tympanostomy tubes, with or without concurrent adenoideclomy. ; '' Tympanostomy tubes 
are intended to replace the ventilation function of the ET. An enlarged adenoid may act as 
an obstructive mass or an infectious focus in the nasopharynx and contribute to the 
aetiopathogenesis of OME. Therefore adenoideclomy is considered as a means of treating 
and preventing recurrent OME.46 
A treatment strategy aimed at causative factors is needed to prevent OME recurrence. Our 
study results showed that a combination of poor ET function and poor immune status were 
associated with OME recurrence. As a consequence, we suggest that future therapeutic 
strategies should not be restricted to restoring ET function, but should also be directed 
towards stimulating the immune system. 
Prevention of complications of bacterial and/or viral otitis media after upper respiratory 
tract infection is an area of great interest. Upper respiratory tract infections and a history 
of acute otitis media episodes are well-known risk factors for the recurrence of OME.47;4fl 
OME may be viewed as a sequelae of either bacterial AOM, or a reaction to viral upper 
respiratory tract infections.49 Nowadays, viral respiratory infection is thought to be the 
primary event initialing secondary bacterial colonisation of the middle ear. Respiratory 
viruses may cause impairment of ET function and result in negative middle ear pressure 
that facilitates bacterial migration into the middle ear. Furthermore, respiratory viruses 
may promote bacterial colonisation of the nasopharynx, adherence of bacteria to epithelial 
cells and have immunosuppressive effects on polymorphonuclear leucocyte function; 
these respiratory-viral- induced effects may also increase susceptibility to secondary 
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bacterial infections ^ , ' Improving the immune response to viruses might therefore 
prevent the cascade of events that ultimately leads to the development of otitis media. At 
present, influenza vaccine is the only commercially available vaccine for the control of 
respiratory tract infections. Results of four randomised influenza vaccination trials 
indicated that prevention of viral upper respiratory tract infection was an effective way of 
preventing the development of AOM.02 " Different types of respiratory virus may vary in 
their ability to enhance the development of otitis media. Respiratory syncytial virus (RSV) 
is considered to be the principal virus that contributes to the development of OME. 
Effective vaccines against other major viruses, particularly against RSV, should 
theoretically have a great impact on the incidence of otitis media. However, the 
mullifaclonal aetiopalhogenesis of OME, suggests that a combined viral-bacterial vaccine 
would be more effective.56 
Implications for clinical practice 
The most relevant issue to clinical practice and efficiency in health care is to distinguish 
children at risk for recurrence of OME from those who are not. In the latter category, a 
more conservative therapeutic approach may be applicable. This thesis has provided 
insight into factors potentially related to OME recurrence. However, our study results 
have not yet provided adequate tools to identify children who are likely to develop OME 
recurrence. Immunoglobulin levels, functional MBL levels, Fcy-receptor polymorphism 
and ET function do not constitute reliable predictois of which child will develop 
recurrence of OME after resolution of the initial episode and which child will remain 
effusion-free. Thus, our study results do not have any direct clinical application, but they 
can be considered as a basis for further research. Fine-tuning of aspects of the immune 
system and tests for the assessment of ET function may eventually lead to clinically 
applicable prognostic tools. 
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Summary 
Otitis Media with Effusion (OME) is a highly prevalent ear condition in childhood that is 
characterised by the accumulation of fluid in the middle ear behind an intact tympanic 
membrane, in the absence of signs and symptoms of acute infection. In most children, the 
natural course is mild and transient, but around 10% of children suffer from recurrent or 
persistent OME. Adverse effects of OME associated with hearing loss, such as impairment 
of speech and language development and sequelae that include tympanic membrane and 
middle ear abnormalities, mainly occur in the group of children with recurrent or 
persistent OME. To enable early intervention and to prevent over-treatment, it is relevant 
to distinguish children who are prone to recurrent OME from the total group of OME 
children early in the course of the disease. 
Based on an extensive literature search, we first developed a model for the 
aetiopathogenesis of OME to enable the formulation of specific hypotheses on factors that 
are relevant in the recurrence of OME (Chapter 2). Careful study of the anatomy, 
physiology and immunology of the upper respiratory tract, with emphasis on the middle 
ear and Eustachian tube (ET) in relation with the development of OME, led to the 
conclusion that the development of OME is a multifactorial process. ET dysfunction and 
the immune response to viruses and bacteria in the upper airways are two core elements 
in the development of OME. We assumed that the development of recurrent or persistent 
OME follows the same pathways. Consequently, we postulated the core hypothesis that in 
children with recurrent or persistent OME, the systemic immune response and ET 
function are less adequate than in children without recurrent or persistent OME. This 
model was unable to show whether one of these aetiopathogenic factors causes OME 
recurrence, or whether both factors are responsible. 
To test the core hypothesis, we conducted a prospective cohort study. Children were 
included in this prospective study if they were aged between 2 and 7 years, their first 
clinical episode of OME had persisted for at least three months (as observed by their 
general practitioner) and they had been referred to one of the participating hospitals. At 
study entry, all the children received bilateral tympanostomy tubes and blood samples 
were taken. Check-ups were planned one week after lube insertion and once every three 
months thereafter. An otologist performed otomicroscopy to assess tympanostomy tube 
patency or extrusion and recurrence of OME. ET function tests were performed on ears 
with patent tympanostomy tubes. The follow-up period for the recurrence of OME began 
at the first check-up in which tube extrusion was observed (per ear). Follow-up ended 
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when recurrent OME was diagnosed, or six months after the observation of spontaneous 
tube extrusion, or at the pre-determined end of the study. 
Chapter 3 describes the results on the role of ET function in the recurrence of OME. ET 
ventilatory function was tested by the forced response test and the pressure equilibration 
test, while the protective ET function was assessed by the sniff test. No statistically 
significant differences were present in ET function lest results between ears with and 
without OME recurrence. We concluded that measurement of ventilatory and pioleclive 
ET function with the forced response test, the pressure equilibration lest and the sniff test 
has no value in predicting whether a child has an increased risk of OME lecurrence. 
In Chapter 4, we focused on the role of the immune system in the aetiopathogenesis of 
OME recurrence. First, we studied the role of sei urn immunoglobulin levels, serum 
mannose-binding lectin (MBL) levels and Fey receptor polymorphism in the development 
of recurrent OME (Chapter 4.1). As the study size was limited and hence statistical 
significance was not reached, we discussed the results on the basis of oui a prion 
hypotheses. All immunoglobulin levels were within the normal range of age-matched 
healthy children. Median levels of IgA, IgG, IgGl, IgG2 and IgM in the gioup of childien 
with bilateral OME recurrence were consistently lower than those in the group of children 
without OME recurrence, but these small non-significant differences had no clinical 
relevance. A non-significant trend was found towards lower serum MBL levels at baseline 
in children who subsequenlly developed bilateral recurrence of OME The proportion of 
children homozygous for the genotypes with the lower binding affinity for IgG2 (FcyRlla-
131R) or IgGl, IgG3, IgG4 (FcyRIIIa-158F) was higher in the children with bilateral 
OME recurrence than in the children without bilateral OME recunence. These 
differences supported our a prion hypotheses that children with OME recurrence are 
more likely to be homozygous for the polymorphic form of the Fey receptor with the lower 
binding affinity for IgG subclasses. Based on these results, we concluded that 
immunoglobulin levels seem lo play a limited role in the aetiopathogenesis of recurrent 
OME, whereas MBL, FcyRIIa and FcyRIIIa genotypes may provide interesting clues 
towards the discovery of mechanisms to explain OME recurrence in children. 
Vaccination is a causative treatment strategy that may generate a protective immune 
response to middle ear pathogens. This thesis addressed the preventive effect of 
pneumococcal vaccination against acute otitis media (AOM) (Chapter 4.2) and against 
OME (Chapter 4.3). Chapter 4.2 describes the results of a systematic review of 11 
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randomibed controlled trials on pneumococcal vaccination against AOM. Pneumococcal 
polysaccharide vaccination had a moderate effect in children of 24 months of age and 
older. Pneumococcal polysaccharide vaccination had little effect in the prevention of 
AOM in children without previous AOM episodes, whereas better efficacy was seen in 
children with a history of AOM episodes. Pooled results of pneumococcal conjugate 
vaccination trials on infants vaccinated as early as at 2 months of age and on toddlers 
attending day care showed only a small effect in the prevention of AOM. The effect of 
pneumococcal conjugate vaccination on the risk of OME was concordant with its efficacy 
against AOM, although indistinguishable from no effect in the overall analyses (Chapter 
4.3). This was demonstrated in analyses performed on data from the Finnish Otitis Media 
Vaccine study, a randomised controlled double-blind trial evaluating the efficacy of 
pneumococcal conjugate vaccination against AOM. Data on the vaccination effect on 
OME were obtained by comparing the prevalence of OME at pre-scheduled follow-up 
visits at the age of 7 and 24 months in the two groups of children receiving either the 
pneumococcal conjugate vaccine or a control vaccine. 
Chapter 5 describes two studies that focused on the association between various birth 
characteristics and OME. It is likely that some birth characteristics impair the functioning 
of either the immune system or the Eustachian tube or both and thus contribute to a 
higher risk of development of OME. Birth characteristics might also serve as relevant 
clinical tools in the early identification of high-risk groups for recurrent OME. In our 
prospective cohort study, weak positive but not statistically significant associations with 
recurrence of OME were present in children bom with low birth weight (< 2500 g) and/or 
low gestational age (< 37 weeks) and / or incubator care, male sex and maternal 
medication use during pregnancy (Chapter 5.1). Prompted by the hypothesis that large 
amounts of meconium-stained amniotic fluid cellular content in the middle ear may lead 
to chronic inflammation and predispose young children to recurrent middle ear infections, 
we conducted a retrospective cohort study (Chapter 5.2). Children bom between May 
1998 and April 2000 formed two groups based on the absence or presence of meconium-
stained amniotic fluid at birth as documented in the hospital birth records. In April 2002, 
home visits were made to take tympanometric measurements and administer a 
questionnaire on otitis media (OM) history and possible confounders. No differences were 
found in the point prevalence of type Β tympanogram at the home visit or the proportion of 
children with a medically confirmed OM history. The findings in the two studies 
suggested that birth characteristics cannot help to determine the best treatment strategy 
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for recurrent OME in childhood and that children born with meconium-stained amniotic 
fluid do not constitute a high-risk group for otitis media in early childhood. 
Chapter 6 describes the results of a study that focused on the combined role of immune 
status and ET function in the development of recurrent bilateral OME. Univariate 
analyses on different immunological factors (IgA, IgGl, IgG2, IgG3, IgG4, MBL, FcyRIIa-
H/R131-genotype) and ET function (forced response test) did not show any significant 
associations with recurrence of bilateral OME. However, multivariate analyses showed 
that children with closing pressures > 75'h percentile and IgG2 or IgA levels below the 
SO'*1 percentile of the cohort were more likely to develop recurrent OME than children 
with closing pressures > 75'1' percentile and IgG2 or IgA levels above the 50' percentile. 
Furthermore, multivariate analyses showed that children with lower MBL serum levels 
had a higher probability of developing OME recurrence. Based on these results, we 
suggested that the development of bilateral recurrent OME is influenced by a combination 
of diminished immune response and Eustachian tube dysfunction. 
In the general discussion (Chapter 7) we consider several study strengths (i.e. the 
prospective design, the measurement of immune parameters and ET function) and 
weaknesses (i.e. the small study population and the possible misclassification of disease). 
Furthermore, we elaborate on what we have learned about the aetiopathogenesis of OME 
recurrence. Recommendations for further research directions are made and given 
foundation, because this thesis does not yet provide adequate tools to identify children 
who are likely to develop OME recurrence. 
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Samenvatting 
Otitis Media met Effusie (OME) is een aandoening die vaak voorkomt bij kinderen OME 
wordt gekenmerkt door de aanwezigheid van vocht achter een intact trommelvlies, zonder 
dat er sprake is van een acute infectie. Bij de meeste kinderen geneest de aandoening 
spontaan, maar bij ongeveer 10% van de kinderen treedt recidiverende of persisterende 
OME op. Vooral bij deze laatste groep kinderen komen nadelige effecten van OME naar 
voren: verminderde taal- en spraakontwikkeling ten gevolge van gehoorverlies en/of 
afwijkingen van het tiommelvlies of middenoor Het is daarom belangrijk om kinderen die 
gevoelig zijn voor het ontwikkelen van recidiverende en/of persisterende OME in een 
vroeg stadium te kunnen onderscheiden van de totale groep kinderen met OME. Dit 
onderscheidingsvermogen zou de mogelijkheid bieden, vroegtijdige interventie selectief 
toe te passen en tegelijk overbehandelmg te voorkomen. 
In Hoofdstuk 2 worden de anatomie, fysiologie en immunologie van de bovenste 
luchtwegen beschreven, waarbij de nadruk ligt op het middenoor en de buis van 
Eustachius in relatie tot de ontwikkeling van OME Twee belangrijke elementen in de 
ontwikkeling van OME zijn het disfunctioneren van de buis van Eustachius en de 
immunologische afweer tegen virussen en bacteriën in de bovenste luchtwegen Voor de 
formulering van specifieke hypothesen met belrekking tot de invloed van factoren bij het 
recidiveren van OME werd op basis van literatuuronderzoek een model ontwikkeld voor 
de etiopathogenese van OME. Uitgaande van de veronderstelling dat de ontwikkeling van 
recidiverende OME dezelfde wegen volgt als de ontwikkeling van primaire OME, werd de 
volgende hypothese opgesteld: "Kinderen met recidiverende OME hebben, in vergelijking 
met hun leeftijdsgenoten zonder recidieven, een verminderde systemische 
immunologische afweerreactie al of niet in combinatie met een inadequate functie van de 
buis van Eustachius " 
Om deze hypothese te toetsen werd een prospectief cohort onderzoek opgezet bij kinderen 
tussen de 2 en 7 jaar die door een huisarts, na een eerste klinische OME episode van 
minstens drie maanden, naar één van de deelnemende ziekenhuizen waren verwezen. Bij 
alle deelnemende kinderen werden bij aanvang van de studie in beide oren 
trommelvhesbuisjes geplaatst en werd bloed verzameld. Controlebezoeken vonden plaats 
één week na het plaatsen van de trommelvhesbuisjes en vervolgens driemaandelijks. 
Tijdens deze controlebezoeken voerde een KNO-arts otomicroscopie uit om de 
functionaliteit van de trommelvhesbuisjes vast te stellen, dan wel om na uitvallen van het 
buisje het eventueel hernieuwde optreden van OME vast te stellen In oren met 
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doorgankelijke trommelvliesbuisjes werden testen met betrekking tot de buis van 
Eustachius functie uitgevoerd. De follow-up periode (per oor) voor het bestuderen van 
recidiverende OME startte op het moment dat het uitvallen van het trommelvliesbuisje 
was vastgesteld. Het einde van de follow-up periode werd bereikt op het moment dat 
OME werd gediagnosticeerd óf indien 6 maanden verstreken waren na de vaststelling van 
het uitvallen van hel buisje óf indien de vooraf bepaalde einddatum van de studie werd 
bereikt. 
In Hoofdstuk 3 worden de resultaten beschreven met betrekking tot de rol van de buis 
van Eustachius functie bij het recidiveren van OME. De ventilatiefunctie werd gemeten 
met behulp van de 'forced response test' en de 'pressure equilibration lest' en de 
beschermingsfunctie van de buis van Eustachius werd getest door middel van de 'sniff 
test'. Tussen oren met en zonder recidiverende OME bleken geen verschillen aanwezig Ie 
zijn in de uilslagen van de buis van Eustachius functietesten. Met alleen het testen van de 
functie van de buis van Eustachius blijkt het niet mogelijk te voorspellen welke kinderen 
een verhoogde kans hebben op het recidiveren van OME. 
De rol van het immuunsysteem in de eliopathogenese van recidiverende OME wordt 
beschreven in Hoofdstuk 4. Serum Immunoglobuline concentraties, serum mannose-
bindend ledine concentraties (MBL) en Fcy receptor polymorfismen werden bestudeerd 
in relatie lot recidiverende OME (Hoofdstuk 4.1). De Immunoglobuline concentraties in 
de onderzoekspopulatie waren normaal voor kinderen van dezelfde leeftijd. In de groep 
kinderen die dubbelzijdig recidiverende OME ontwikkelden werden consistent lagere 
mediane concentraties van IgA, IgG, IgGl, IgG2 en IgM aangetoond in vergelijking met 
de kinderen zonder recidiverende OME. De kleine verschillen waren echter klinisch 
irrelevant. Kinderen die gedurende de follow-up periode dubbelzijdige OME hadden 
ontwikkeld bleken een lagere concentratie serum MBL bij te hebben bij aanvang van de 
studie dan kinderen die geen dubbelzijdige OME hadden ontwikkeld. Tenslotte bleek, in 
overeenstemming met de vooraf opgestelde hypothese, de proportie kinderen dat 
homozygoot was voor de genotypen met lagere bindingsaffiniteit voor IgG2 (FcyRIIa-
131R) of IgGl, IgG3, IgG4 (FcyRIIIa-158) groter te zijn bij de kinderen met dubbelzijdig 
recidiverende OME dan in kinderen zonder dubbelzijdig recidiverende OME. Deze 
onderzoeksresultaten suggereren dat immunoglobulines een beperkte rol spelen bij de 
eliopathogenese van recidiverende OME. De bevindingen met betrekking tot serum MBL 
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en Fc-gamma receptoren geven daarentegen interessante aanwijzingen omtrent de 
mechanismen met betrekking tot het ontstaan van recidiverende OME bij kinderen. 
In dit proefschrift wordt tevens het preventieve effect van pneumokokkenvaccinalie legen 
otitis media (OM) beschreven. Vaccinatie stimuleert een afweerreactie, die kan 
beschermen tegen middenoorpathogenen en grijpt dus in op de factoren die bijdragen aan 
het ontstaan van OME. De resultaten van een systematische review met belrekking tot 11 
trials naar het effect van Pneumokokken vaccinatie op de preventie van acute otitis media 
(AOM), beschreven in Hoofdstuk 4.2, tonen aan dat Pneumokokken polysacharide 
vaccinatie een beperkte bescherming biedt tegen AOM bij kinderen ouder dan 2 jaar en 
bij kinderen met een gedocumenteerde voorgeschiedenis van AOM episoden. Ook de 
eerste resultaten van onderzoeken naar de effectiviteit van het Pneumokokken conjugaat 
vaccin ter preventie van AOM zijn weinig hoopgevend. Het effect van vaccinatie op OME 
werd bestudeerd in een secundaire analyse van de gegevens van de Finse Otitis Media 
Vaccinatie trial naar het effect van Pneumokokken conjugaat vaccinatie ter preventie van 
AOM (Hoofdstuk 4.3). Er werd een beperkt, niet significant, beschermend effect van 
vaccinatie op de frequentie van OME waargenomen, in lijn met de resultaten voor AOM. 
In Hoofdstuk 5 worden de resultaten weergegeven van twee studies naar de mogelijke 
associatie tussen verschillende geboortekenmerken en het optreden van OME. 
Geboortekenmerken kunnen het immuunsysteem en de functie van de buis van 
Eustachius beïnvloeden en daarom mogelijkerwijs bijdragen aan een verhoogde kans op 
hel ontwikkelen van OME. Geboortekenmerken zijn dan ook potentieel relevant bij de 
vroege identificatie van risicogroepen voor het ontwikkelen van recidiverende OME. In de 
prospectieve cohort studie werden zwak positieve associaties met recidiverende OME 
aangetoond voor kinderen geboren met een laag geboortegewicht (< 2500 g), korte 
zwangerschapsduur (< 37 weken) en/of behandeling in een couveuse, geslacht en 
medicijngebruik van de moeder gedurende de zwangerschap (Hoofdstuk 5.1). 
Geïnspireerd door de hypothese dat relatief grote hoeveelheden van meconiumhoudend 
vruchtwater in het middenoor kunnen leiden tot chronische ontstekingen, waardoor 
kinderen mogelijk gevoeliger zijn voor het optreden van recidiverende 
middenoorontsteking, werd een retrospectieve cohort studie uitgevoerd bij kinderen 
geboren met en zonder meconiumhoudend vruchtwater (Hoofdstuk 5.2). Op 2 tot 4 jarige 
leeftijd bleken beide groepen niet te verschillen in de frequentie van OME, vastgesteld 
met behulp van tympanometrie, noch in frequentie van gediagnosticeerde OM gedurende 
de eersle levensjaren. Op grond van beide studies naar geboortekenmerken en OM wordt 
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geconcludeerd dat de onderzochte geboortekenmerken niet kunnen voorspellen welke 
kinderen een verhoogd risico hebben op recidiverende OME. 
In Hoofdstuk 6 worden de resultaten beschreven van het onderzoek naar de 
gecombineerde rol van het immuunsysteem en de buis van Eustachius functie in de 
ontwikkeling van recidiverende dubbelzijdige OME. Univariate analysen van 
verschillende immunologische factoren (IgA, IgGl, IgG2, IgG3, IgG4, MBL, FcyRIIa-
H/R131 -genotype) en buis van Eustachius functietest ('forced response test') toonden 
geen associatie aan met recidiverende dubbelzijdige OME. Multivariate analysen lieten 
echter zien, dat kinderen met zowel een buis van Eustachius sluitingsdruk > TS5"" 
percentiel én IgG2 of IgA concentraties < 50,", percentiel van het cohort, meer kans 
hadden op het ontwikkelen van recidiverende OME dan de andere kinderen uil dit cohort. 
Tevens toonden de multivariate analysen aan dat kinderen met lagere serum MBL 
concentraties meer kans hadden op het ontwikkelen van recidiverende OME. Op grond 
van deze resultaten wordt gesuggereerd dat de ontwikkeling van dubbelzijdige 
recidiverende OME wordt beïnvloed door een combinatie van een verminderde 
immunologische afweer reactie én het disfunctioneren van de buis van Eustachius. 
In de algemene discussie (Hoofdstuk 7) worden de sterke en zwakke punten van het 
onderzoek besproken. Het onderzoek is sterk omdat het prospectief is en tegelijk 
immunologische parameters en de functie van de buis van Eustachius bestudeert. Zwakke 
punten van het onderhavige onderzoek zijn o.a. de kleine onderzoekspopulatie en de 
mogelijke misclassificatie van de aandoening. Het proefschrift eindigt met aanbevelingen 
voor verder onderzoek. Verder onderzoek blijkt nodig omdat dit proefschrift nog geen 
afdoende instrumenten voor de praktijk heeft opgeleverd, waarmee kinderen met een 
verhoogde kans op het recidiveren van OME geïdentificeerd kunnen worden. 
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STELUNGEN 
behorende bij het proefschrift 
Recurrence °Ç ofrfts Media uwfh Effusion in youns children 
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3 juni 2004 
1. Een essentiële voorwaarde voor de toepassing van de buis van Eustachius 
functietest als instrument voor diagnostiek en prognostiek van OME is dat 
deze test uitgevoerd kan worden op een intact trommelvlies. 
2. Kinderen geboren met meconiumhoudend vruchtwater hebben geen 
verhoogd risico op middenoorontsteking. 
3. Prognostisch onderzoek naar recidiverende OME vereist een 
multidisciplinaire aanpak. 
4. Het bestrijden van (recidiverende) OME met behulp van vaccinatie tegen 
één type ziekteverwekker geeft tegelijk kans aan andere ziekteverwekkers. 
Het netto resultaat is moeilijk voorspelbaar. 
5. Een ziekenhuis met een korte wachtlijst voor een chirurgische interventie 
die onderwerp is van onderzoek dat wordt uitgevoerd in een naburig 
ziekenhuis bedreigt de inclusie van onderzoekspersonen. 
6. In milieugezondheidkundig onderzoek kan de waakhond een dubbele rol 
spelen bij de bescherming van de mens tegen exogene bedreigingen. 
7. Het onderdeel 'statistische analyses' in medisch wetenschappelijke 
artikelen vereist het zoeken naar de balans tussen een formulering die 
enerzijds voldoende informatie bevat voor statistici om de kwaliteit van de 
analyses te beoordelen en anderzijds toch begrijpelijk is voor clinici. 
8. Wie het principe 'wie betaalt, bepaalt' ook voor de wetenschap omarmt, 
begraaft tegelijkertijd het principe van de academische vrijheid [Prof. Dr. 
Chr. F.G. Lorenz]. 
9. Het voltooien van een proefschrift lijkt op een marathon: het einddoel staat 
vast én in de laatste fase wordt het doorzettingsvermogen door 
vermoeidheid op de proef gesteld. 
10.De prevalentie van werkloze promovendi is hoger dan die van werkeloze 
promovendi. 


